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INTRODUCTION
Section 2 of this chapter has been published as L. Engelke, G. Winter, S. Hook, and J. En-
gert, Recent insights into cutaneous immunization: How to vaccinate via the skin, Vaccine
33(37) (2015) 4663-74. This article was written by myself.
1 Objectives and outline of this thesis
The aim of this thesis is to evaluate selected active intradermal delivery techniques and
their potential for cutaneous vaccination. This work focuses in particular on needle-free
powder injection and skin microporation using microneedles (MNs) or laser microporation
for intradermal antigen delivery. This thesis shall provide an insight into the challenges
and opportunities in the development of needle-free vaccination routes via the skin. Fur-
thermore it aims to highlight the great potential of the cutaneous route of vaccination to
serve as an alternative to conventional immunization by intramuscular (i.m.) injection.
Different aspects of the development of needle-free vaccination techniques are addressed
experimentally and discussed in relation to historical and most recent research. In partic-
ular, the intradermal deposition, reproducibility and efficiency of delivery, the induction of
an immune reponse, the ease of administration, the simplicity of design and the associated
cost-efficiency of development and large scale manufacturing are addressed.
In chapter II a novel design of a hand-held, needle-free powder injector is studied for cuta-
neous vaccination using a sugar-based microparticle vaccine. In the course of this study, a
highly concentrated vaccine using ovalbumin (OVA) as model antigen has been developed
using a two-step manufacturing process combining collapse lyophilization and cryogenic
milling. The model vaccine properties and long-term storage stability are assessed. More-
over, the loading of the powder injector is characterized by studying the vaccine adhesion
onto the device membrane using different oily adhesives. These oily adhesives allow not
only for a fixation of the vaccine powder, but can also serve as adjuvant upon intradermal
delivery. Therefore, the oily adjuvant is brought in contact with the concentrated vac-
cine to assess the long-term stability. Finally, the immune response by needle-free powder
injection is evaluated in vivo using the novel injector device.
Chapter III focuses on the intradermal delivery of micro- and nanoparticles using solid
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microneedles (MNs). Compared to the complex engineering required for the development of
the powder injector, solid MNs are easy and cost-efficient to manufacture in large scale and
commercially available in various configurations. In this chapter the intradermal delivery
of micro- and nanoparticles ranging from 0.1 µm to 7.0 µm using two different types of
solid MNs is characterized. Thereby, the influence of the particle size as well as the MN tip
geometry and application sequence on the intradermal penetration depth and quantitative
deposition is studied.
Furthermore, in chapter IV the intradermal delivery of macromolecules and particles from
water-soluble films upon fractional laser microporation is evaluated. In comparison to
solid MNs, the skin barrier is breached using a fractional erbium:yttrium aluminum garnet
(Er:YAG) laser poration device. The intra- and transdermal delivery of fluorescently-
labeled dextrane as well as micro- and nanoparticles of 5.0 µm and 0.5 µm from polyvinyl
alcohol (PVA)-based film patches is studied over 24 hours upon skin laser microporation.
The different intradermal delivery techniques presented in this thesis allow for a compari-
son of the utilized approaches with respect to simplicity of design and intradermal delivery
efficiency. Research beyond this thesis can be benchmarked against the results and obser-
vations presented here. This thesis not only provides a profound overview of needle-free
cutaneous vaccination approaches, but also identifies critical aspects and requirements of
intradermal vaccine delivery.
2
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2 Recent insights into cutaneous immunization: how
to vaccinate via the skin
2.1 Introduction
The skin has been used to induce protective immunity against highly infectious diseases
since the very first recorded vaccinations against smallpox in 1796 [1, 2]. Jenners break-
through eventually lead to the eradication of smallpox by mass vaccination programs, where
vaccines were initially administered by subcutaneous (s.c.) inoculation with a lancet and
later performed using needle-free jet injectors and bifurcated needles for intradermal (i.d.)
vaccine delivery [1, 3, 4]. Furthermore, bacille Calmette-Guérin (BCG) vaccines have been
administered intradermally since the early 1920s to prevent tuberculosis [5–7].
Although the skin has been known for centuries to be an attractive site for immuniza-
tion, recent developments in needle-free systems have renewed the interest in cutaneous
vaccination, here defined as the induction of an immune response upon topical, intrader-
mal, or intraepidermal delivery of a vaccine [8]. This route of immunization, sometimes
also referred to as skin vaccination or transcutaneous immunization, takes advantage of
the unique immunological features of the skin immune system [9–11]. The two uppermost
skin layers, the epidermis and the dermis, have a high density of immunocompetent cells
such as Langerhans cells (LCs) and dermal dendritic cells (dDCs) (Fig. I.1) [12]. These
antigen-presenting cells (APCs) play an important role in developing adaptive immunity
through the processing and presenting of antigen [13, 14]. Delivering a vaccine to the
skin has been shown to elicit similar or even higher immune responses compared to i.m.
injection, even in some cases using lower vaccine doses [15–22]. This could be of special
significance for pandemics, when vaccine supply is limited and dose reduction is neces-
sary. By evoking humoral, cellular and, in some cases, mucosal immune responses [23–25],
cutaneous vaccination holds the potential to expand the range of applications beyond con-
ventional prophylactic immunization into therapeutic vaccination for cancer and human
immunodeficiency virus (HIV) infections [26, 27].
The demand for a safe, pain-free and simple alternative to i.d. and i.m. needle injection
has led to the development of alternative techniques to deliver vaccines to the skin. Intra-
dermal vaccination, usually performed with needle and syringe (N&S), can be regarded as
the first approach of cutaneous vaccination. However today, the variety of strategies has
been expanded, including conventional i.d. injection, but also needle-free vaccine delivery
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Figure I.1: Professional antigen presenting cells of the superficial skin. Three subsets of
professional antigen presenting cells have been identified within the two topmost layers
of the skin. Whereas a high density of Langerhans cells (LCs) can be found within the
epidermis, CD1+ and CD14+ dermal dendritic cells (dDCs) reside in the underlying dermis.
techniques, stratum corneum (SC)-disruptive approaches, and passive targeting strate-
gies [28]. The simplest techniques involve the passive diffusion of protein or DNA vaccines
into intact skin or skin pretreated by tape stripping or abrasion of the SC [29–34]. Active
vaccination approaches deliver the antigen directly to immunocompetent cells either by
needle-free jet and powder injection or by creating microchannels or transient cavities in
the upper skin layers [35–37]. Such active microporation techniques include the use of
microneedles, thermal microporation, radiofrequency ablation, and laser poration, as well
as electroporation and sonoporation. Here we will review the latest advances in the field of
needle-free cutaneous vaccination with special consideration being given to DNA or RNA
vaccines and the use of adjuvants for cutaneous vaccination.
4
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2.2 Vaccination via the skin
2.2.1 Antigen presentation
The aim of vaccination is to activate the acquired immune system to induce long-lasting
protection against specific pathogens [38]. Upon encountering a pathogen APCs mature
and migrate towards draining lymph nodes [13]. By up-regulating antigen-loaded ma-
jor histocompatibility complexes (MHCs) class I and II as well as co-stimulatory surface
molecules, mature APCs initiate the proliferation and differentiation of näıve T cells into
effector and memory T cells [13, 39]. Typically, exogenous antigens are presented via
(MHC-II complexes to CD4+ T cells, comprising T helper cells (Th cells) and regulatory
T cells (Tregs), whereas CD8+ T cells (cytotoxic T cells, CTL) interact with cytosol-derived
endogenous antigens loaded onto MHC-I [40, 41]. However this segregation of antigen pre-
sentation is not complete as distinct subsets of APCs are able to cross-present exogenous
antigens via MHC-I to prime CD8+ T cells [42, 43]. This cross-priming is expected to play
an essential role for eliciting immune responses against tumor or virus-infected cells [42].
In addition to the MHC-restricted presentation of proteins and peptides, APCs are able to
process and present non-protein antigens, such as lipids, glycolipids and lipopeptides [44].
Surface molecules of the CD1 family are loaded with lipid antigens via endocytotic path-
ways [45], subsequently priming natural killer T cells (NKTs), which respond by secreting
large amounts of Th1 and Th2 cytokines and influencing dendritic cell (DC) matura-
tion [46, 47]. LCs have been found to express large amounts of the group 1 family of CD
molecule CD1a and moderate amounts of CD1c [48, 49]. However, all identified molecules
of group one and two of the CD1 family have been found on dDCs [49, 50]. CD1d is the
only molecule of the CD1 family that has also been detected in mice [51].
2.2.2 Acquired Immune Responses
CD8+ T cells that differentiate and proliferate upon MHC-I interaction into CTLs [41, 52]
are able to lyse transformed or infected cells through the production of granzymes and
perforin [53]. CD4+ T helper cells play a role in modulating a variety of immune responses.
This includes cellular, humoral, regulatory and inflammatory responses [54]. B cells may
be activated in either a T cell dependent or independent manner [55]. Upon activation
näıve B cells differentiate into antibody secreting plasma cells and memory B cells [56].
Four different subsets of T helper cells are known to reside in the skin Th1, Th2, Th17
and Th22 [51]. Promoted by IL-12, non-polarized CD4+ T cells differentiate into Th1
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cells, typically secreting interferon gamma (IFN-γ) and IL-2 [57]. The polarization to-
wards the Th2 subset is enhanced by IL-4 and these cells secrete IL-4, IL-5, IL-10 and
IL-13 [57]. While IFN-γ promotes a switch towards IgG2a in mice and stimulates cellular
immune responses, IL-4 induces the synthesis of IgG1 and IgE [58]. IL-23 induces the
proliferation of Th17 cells that secrete IL-17 and often IL-22 [59, 60]. The Th22 subset,
which has been identified recently, can be characterized by the secretion of IL-22 and in
the absence of IL-17 or IFN-γ [61, 62]. Healthy skin harbors approximately 8 % mainly
Th1-biased effector memory T cells as well as a substantial numbers of central memory
and regulatory T cells [63].
2.2.3 Dendritic cell subsets
While the dendritic cell network in the skin differs between mice and human, some simi-
larities exist. The main dendritic cell subsets that have been identified in mice and human
skin are the epidermal LCs and dDCs. In both species LCs form a continuous network
throughout epidermal keratinocytes and can be characterized by their expression of the
lectin receptor langerin (CD207) [51, 64]. In mice, the dDC population constitutes of der-
mal resident DCs, namely CD103+ DCs and CD11b+ DCs, as well as migratory LCs [65].
Langerin-negative CD11b+ DCs represent the main dermal dendritic cell subset, (approxi-
mately 70 % of DC) residing in the dermal skin layer [66]. Langerin-positive CD103+ DCs
are found below the epidermal-dermal junction [67]. In addition to these two dermal res-
ident DCs, a third dDC subset has been identified, expressing MHC-II and CD11c, but
no CD11b, CD103 or langerin on the cell surface [66, 68]. However, the phenotype of this
DC subset has not yet been fully identified [64]. It has been reported that CD11b+ DCs
play the main role in initiating CD4+ T cell responses, although all dDCs were able to
present viral antigens [69]. Furthermore, CD11b+ DCs were critical promoters of the local
proliferation of effector and regulatory T cells [70]. As regards Th1/Th2 differentiation,
CD103+ DCs induced IgG2a/c and IgG2b responses, whereas LCs provided an IgG1-based
humoral immune response [71]. Interestingly CD103+ DCs are the only DC subset reported
to be capable of cross-priming CD8+ T cells [69].
In human skin, three additional langerin-negative subsets of DCs have been identified, re-
ferred to as CD1a+, CD14+ and CD141hi DCs [72–74]. Several studies have highlighted
the potential of the different DCs subsets in influencing the direction of the immune re-
sponse with the CD14+ DC subset being shown to preferentially induce a Th1-biased
response [14, 75] and to promote the secretion of large amounts of different immunoglob-
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Figure I.2: T cell differentiation upon activation by CD14+ dermal dendritic cells (dDCs)
or Langerhans cells (LCs) and cross-presentation of CD141hi dDCs. After antigen process-
ing, dDCs and LCs migrate toward draining lymph nodes, presenting the antigen via the
major histocompatibility complexes I and II (MHC-I, MHC-II). By interaction with the
T cell receptor (TCR), CD4+ and CD8+ T cells are activated. CD14+ dDCs promote the
differentiation of CD4+ T cells into follicular T helper cells (Tfh) and T helper 1 (Th1)
cells that secrete large amounts of IL-2, IFN-γ and TNF. Both T cell subsets stimulate the
differentiation and proliferation of antibody-secreting plasma cells, which elicit an IgG2a,
IgA, and IgM based immune response. On the other hand, LCs induce the differentiation of
CD4+ T cells into Th2 cells, indicated by the secretion of IL-4, IL-5, IL-10, and interleukin
(IL)-13, and boosting IgG1 and IgE secreting plasma cells. Moreover, CD8+ T cells differ-
entiate and proliferate upon interaction with LCs or CD141hi dDCs into IL-2 and IFN-γ
secreting cytotoxic T cells (CTLs) providing a cellular immunity. The differentiation of
the Th1 and Th2 subset is furthermore enhanced by IL-12 and IL-4, respectively.
ulins [14, 76]. The recently discovered CD141hi DC subset was shown to efficiently cross-
present exogeneous antigens to CD8+ T cells in the periphery [74].
The role of LCs is more complex with these abundant cells being reported to have a role
in maintaining tolerance in healthy skin but then being able to induce T cell activation in
response to infection [77]. In this case LCs showed a superior ability to initiate antiviral
immunity by priming CD8+ T cells and to induce Th17 responses [75, 78, 79].
Figure I.2 gives an overview of the predominant activation routes of the different human DC
subsets. Although functional homologues to mouse DCs could be identified, the existing
differences in the expression patterns of surface molecules on human and mouse DC affects
the transferability of in vitro and in vivo study results. Another issue impacting on the
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transferability of mouse data to humans is the difference in the skin between mice and
humans. Mouse skin is thinner and has more hair follicles [80]. Therefore, data from mice
must be interpreted with caution.
2.3 Adjuvants for cutaneous vaccination
The best studied adjuvants for cutaneous vaccination are derived from bacterial adenosine
diphosphate (ADP)-ribosylating exotoxins [29, 81–84]. Cholera toxin (CT), Escherischia
coli heat-labile toxin (LT), or subunits of these proteins have commonly been utilized to
elicit or enhance the response towards a vaccine given via the cutaneous route [29, 33, 81]. It
was shown that CT and LT applied onto intact mouse skin induce the production of toxin-
specific antibodies [81]. Moreover, CT-adjuvanted formulations induced superior immune
responses against diphtheria and tetanus toxoid [81, 82, 85]. It has not yet been clarified
how bacterial ADP-ribosylating toxins influence the type of immune reaction. However,
several studies report the induction of Th2-biased immunity [81, 86]. Additionally, CTL
proliferation has been observed, indicating activation of epidermal LCs [87].
The second group of adjuvants that were utilized cutaneously are specific ligands of toll-like
receptors (TLRs) [88]. These receptors play a major role in the detection of pathogens
and are therefore an ideal target for enhancing the immune reaction [89]. One of the most
important adjuvants of TLR ligands to date are the CpG oligodeoxynucleotides (ODN) [90].
Prokaryotic CpG motifs are less methylated and are therefore recognized by TLR9, a
receptor subtype of the TLR family [91–93]. CpG ODN induce the production of pro-
inflammatory cytokines such as IL-12 and IFN-α [89], promoting a Th1 biased immune
response upon vaccination [88, 94]. Furthermore, TLR9 agonists have been shown to be
able to convert an established Th2-based immune response upon DNA vaccination into a
Th1-directed response [95].
Other TLR ligands, such as imiquimod (TLR7 ligand) or polyinosinic:polycytidylic acid
(poly I:C) (TLR3 ligand) have also been investigated for cutaneous vaccination [96, 97].
Both adjuvants elicit the proliferation of CD8+ T cells, thereby indicating a cellular immune
response [96–98]. Moreover, poly I:C additionally provides a Th1/Th2-balanced humoral
immunity [97]. Imiquimod has until now mainly been studied with the focus on tumor
immunity [96, 99]. As a commercial product it is already in use as an immunomodulator
for the treatment of human papillomavirus (HPV) infections [100]. Although imiquimod
can be administered cutaneously alone it showed a superior activation of the immune
system when combined with anti-CD40 ligands or UV light [96, 99].
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As shown in table I.1, there is a wide variety of adjuvants that have been utilized in
cutaneous vaccination studies, also including alum [88, 101], Quillaja saponins [15], and
other chemical substances [102]. Additional investigations are necessary to further clarify
how the type of adjuvant used and the route of administration influence the type of immune
response generated.
In addition, the extent of skin irritation upon delivery to the skin using different adjuvants
needs to be evaluated, and a suitable experimental model to investigate immediate and
long-term skin reactions remains to be developed. One example highlighting this aspect is
alum as cutaneous vaccination adjuvant, which has been used for i.d. immunization against
hepatitis A before [103, 104]. Adverse reactions after i.d. injection have been reported,
such as long lasting skin papules and dermatitis [104]. Furthermore, it was shown that
aluminum hydroxide can lead to the development of persistent intradermal granulomas
when used for i.d. hyposensitization [105]. This implies that alum adjuvants might not be
suitable for vaccination strategies that involve an i.d. vaccine delivery.
2.4 Needle-free injection techniques for cutaneous vaccination
2.4.1 Jet injection
The very first approach of needle-free vaccination used jet injectors. In the 1950s multiple
use nozzle jet injectors (MUNJIs) were extensively used in mass immunization programs
and played a major role in the smallpox eradication [3]. However, increasing numbers of
hepatitis B infections as well as epidemiologic and animal-model studies provided growing
evidence that cross infections were linked to the utilization of MUNJIs, causing the ter-
mination of jet vaccination campaigns [28, 106]. The discovered safety issues finally led to
the development of disposable syringe jet injectors (DSJIs) and single-use disposable jet
injector (SUDJI) [28, 107].
Conventional jet injector systems actuate a piston using a spring or compressed gas [3].
By pressing the fluid through a nozzle with a diameter of 80 − 360 µm [3], a liquid jet is
generated that encounters the skin with a velocity between 100− 200 m/s [108]. The high
impaction force of the jet initiates a piercing of the skin surface including the underlying
tissue [109]. After reaching a critical depth, the liquid does not penetrate further into
the tissue but instead forms a liquid depot in the skin [110]. Under these conditions it is
possible to achieve either a mainly subcutaneous (s.c.), or intramuscular (i.m.) deposition
of the liquid [28]. However, due to inter-individual variations, jet injector systems might
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Table I.1: Overview of adjuvants, sorted by the extent of utilization, and their effects
on the immune response upon cutaneous vaccination compared to non-adjuvanted (w/o)
studies.
Adjuvant Cutaneous Antigen Type of Investigated Reference
vaccination immunity parameter
technique
w/o Intact skin OVA, TT, DT Th2a IgG1 ↑ [31,171,203]
Tape stripping OVA Th2a IgG1 ↑, IgE [32]
Microneedles DT Th2a IgG1/IgG2a ↑ [132]
Laser poration DT, bGal Th2a IgG1 ↑, IgE [149]
ADP-ribosylating toxins
Whole protein, subunits, Intact skin TT, LT, DT Th2a IgG1 ↑, IL-5 ↑ [81,86]
or recombinant subunits Warm waxing pDNA Th2a, Cellular IgG1 ↑, IL-4 ↑, [23,168]
of Cholera toxin (CT), CTL
E. coli heat-labile Nanoparticles pDNA, OVA Th1b INF-γ ↑ [83,84]
toxin (LT) Microneedles DT, Influenza Th1b IgG1/IgG2a ↓ [85,132]
Powder injection Influenza Th1b, Mucosal IgG2a ↑, IFN-γ ↑, [18,25]
IgA
TLR agonists
CpG (TLR9) Laser poration Phl p 5, bGal Th1b IgG2a ↑, IL-4 ↓ [149,153]
Electroporation SIINFEKL Cellular CTL [159]
Powder injection Influenza Th1b, Mucosal, IgG2a ↑, IFN-γ ↑, [25,88]
Cellular IgA, CTL
Imiquimod (TLR7) Intact skin SIINFEKL + Cellular CTL [96,99]
anti-CD40 mAb
(i.v.)/UVB
Poly (I:C) (TLR3) Microneedles OVA Th1c, Cellular IgG2c ↑, CTL [97,98]
Quillaja saponins
Quil-A Nanopatch Influenza n.d. IgG [15]
QS-21 Powder injection Influenza Mucosal IgA [18]
Alum Tape stripping bGal n.d. IgG [101]
Powder injection DT Th2b IgG1 ↑, IL-4 ↑ [88]
Other adjuvants
c-di-AMP Nanoparticles OVA n.d. OT-II cell [173]
proliferation ↑
Mannan-coated liposomes Hair plucking pDNA Th1b IFN-γ ↑ [34]
Deformable liposomes Hair plucking pDNA Mucosal IgA [175-177,188]
Poly[di(carboxylate- Microneedles HBsAg n.d. IgG [102]
phenoxy)phosphazene]
a Evaluated by IgG1/IgG2a ratio.
b Investigated parameter compared to non-adjuvanted (w/o) cutaneous vaccination.
c Investigated parameter compared to vaccination by injection.
w/o - Without adjuvant.
n.d. - No differentiation between humoral Th1/Th2, cellular, or mucosal immunity.
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fail to reach the target tissue and often induce local reactions (related to the penetration
depth) such as pain, bruising, and redness of the vaccination site [28, 110].
Novel approaches using a pulsed jet are expected to minimize these effects [111]. The re-
cently developed pulsed jet injector system employs a voltage-regulated piezoelectric trans-
ducer [112]. The activation leads to a fast expansion of the piezoelectric elements, simulta-
neously accelerating a piston which pushes the liquid through a nozzle of 50−100 µm [112].
In comparison to conventional jet injectors, the pulsed piezoelectrical technology can cre-
ate narrow liquid jets of very small volumes between 2 − 15 µL [112]. By controlling the
velocity and jet volume, it is possible to achieve penetration depths around 200 µm or to
target layers of the skin specifically [112, 113]. The pulsed microjet technology represents a
promising strategy to perform cutaneous vaccination, targeting the upper layers of the skin
and diminishing the risk of pain and bruising. However, high production and disposable
costs might remain major issues for the establishment of pulsed jet injectors as single-use
devices.
2.4.2 Powder injection
The principle of ballistic powder injection, often referred to as biolistics, was exploited for
vaccination for the first time in 1996 [114]. The immune response after cutaneous powder
injection of a DNA vaccine was investigated using the gene gun technology [114]. As
summarized by Kis et al., different kinds of particles and technologies have been utilized
to deliver dry particles into the epidermal layer of the skin [35]. The basic mechanism of
injection involves the fast expansion of helium gas to accelerate the particles towards the
skin [115, 116]. When the particles encounter the surface, high impaction forces result in
the penetration of the particles into the epidermal and dermal layer [117, 118]. A bench-top
device that uses a pressure-regulated helium gas supply has been developed [119]. With
this system, it was reported that a higher pressure resulted in deeper jet penetration,
whereas the particle distribution increased with the nozzle diameter [119].
Two types of particles have been commonly used for powder injection. With the gene gun,
or the closely related particle-mediated epidermal delivery (PMED) technology, 1 − 3 µm
DNA- or protein-coated gold particles are delivered into the skin. Sugar-based particles
with a lower density but larger size (between 20 − 70 µm) are used for epidermal powder
immunization (EPI) [114, 120]. Powder injection facilitates the administration of both
DNA or RNA vaccines and conventional protein vaccines in a dry, solid state [18, 121].
By targeting the epidermal and dermal layers of the skin, powder injection efficiently
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exploits the unique immunology of the skin. It induces comparable or higher antibody
titers compared to conventional vaccination and holds the potential to elicit cellular and
mucosal immune responses [25, 121–123]. Moreover, powder injection might represent
a convenient strategy for genetic immunization and holds great potential for a range of
applications, such as the treatment of type 1 diabetes [124]. Powder injection also allows for
the combination of different vaccine formulations. Deng et al. developed a delivery system
that comprises protein-loaded nanoparticles in microparticles (nano-in-micro) for ballistic
powder injection, a system that could also be exploited for genetic skin vaccination [125].
The increased stability of dry vaccine formulations delivered by pain-free powder injection
circumvents the storage issue of liquid vaccines. However, the analytical effort for vac-
cine characterization remains high. Moreover, helium gas as accelerator medium increases
the device production costs. Because of changing skin properties, the total amount of
intracutaneous powder deposition can vary, representing a major challenge for EPI.
2.5 Microporation technologies
2.5.1 Microneedles
Microporation technologies for the delivery of macromolecular drugs, biopharmaceuticals
and vaccines are developing rapidly [36, 126]. These technologies promote the formation
of micron-sized pores into the skin, transiently breaching the main protective barrier [36].
Four main types of microneedles have been developed: solid, coated, hollow, and dis-
solving microneedles [reviewed in [127–129]]. The most common technique for cutaneous
vaccination involves the direct coating of antigen onto solid microneedles [15–17]. How-
ever, dissolving microneedles have also been extensively investigated [130, 131]. The aim
of this technology as regards vaccination is to pierce the SC bringing the vaccine in con-
tact with cutaneous APCs [132]. By avoiding penetration into deeper dermal regions,
safe, minimally-invasive and pain-free immunization can be achieved [132]. The utiliza-
tion of mechanical applicators, such as the Macroflux® technology (Zosano, USA) or the
MicronJet® device (Nanopass technologies, Israel) minimizes confounding factors and al-
lows for a uniform administration [128]. Different microneedle technologies for vaccination
are widely investigated in research and clinical trials [16, 97, 133–135]. One system, cur-
rently attracting attention, is the Nanopatch Technology (Vaxxas, Australia), which is
under investigation with an undisclosed vaccine candidate and was given WHO funding
for a polio vaccination research project [136–138]. Comparative studies using microneedle
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arrays have demonstrated superiority over intradermal or intramuscular vaccination in a
number of applications [16, 17, 97]. Comparable or higher antibody titers and Th1/Th2
balanced immune responses were observed [16, 97, 139].
Microporation technologies, most notably microneedles, have become a popular tool for
cutaneous vaccination. Over the last decade, production costs of microneedles have been
minimized and the reproducibility of insertion has been improved by utilizing mechanical
applicators. However, achieving an even coating thickness on solid microneedles, defined
breaking points of dissolving microneedles, and, in general, the release of the antigen
from the microneedle system are critical parameters [140, 141]. Dissolving or decomposing
microneedles are particularly promising technologies if mechanical and physicochemical
stability of the biocompatible materials can be ensured.
2.5.2 Thermal microporation technologies
The application of short heat pulses is the basic principle that is shared by all thermal
microporation technologies [36]. The heat pulses are applied to locally restricted areas
of the superficial skin creating microchannels due to decomposition and vaporization of
the treated tissue [142]. The short duration ensures a negligible heat transfer that would
otherwise damage the surrounding tissue [36].
At present, three different strategies that utilize this technology have been developed. One
method developed by the now defunct Altea Technologies (USA) employed electrically
resistive filaments that were heated by a controlled voltage pulse [143, 144]. Another
approach, termed radio frequency ablation (RF), is the basis of the ViaDerm technology
(Transpharma Medical, Israel) [145, 146]. This technique uses an array of microelectrodes
to induce ionic vibrations within the surrounding skin cells [147]. Laser-based systems
represent the third strategy of thermal microporation. Originally developed for medical
surgery [148], these devices use infrared light at λ = 2.94 µm generated by an Erbium
doped yttrium aluminum garnet (Er:YAG) laser [149]. The absorption of the infrared light
induces vibrations within the water molecules leading to vaporization [148, 150]. Currently,
several laser poration systems are available, such as the P.L.E.A.S.E.® laser device (Precise
Laser Epidermal System, Pantec Biosolutions, Liechtenstein) or the Epiture Easytouch
system (Norwood Abbey, Australia) [36, 151].
Depending on the microporation systems being used and the conditions under which it
is used, micron-sized pores of 30 − 200 µm in diameter and 30 − 200 µm in depth are
created, facilitating vaccine delivery to cutaneous APCs [144, 151, 152]. Several reports
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have shown that cutaneous vaccination using laser poration elicits Th2-typed immune
responses [149, 153]. Interestingly, it was also observed that T cell polarization can be
changed by targeting different skin layers [149]. Moreover, nano- and microparticles can
be delivered into the dermis upon laser microporation, indicating the potential for combined
cutaneous delivery approaches [154].
Similarly to microneedles, ablative microporation technologies allow the selective targeting
of specific skin layers. However, the epidermal and dermal layer thicknesses differ with
and between individuals, representing a major challenge for the reproducibility of abla-
tive microporation. In addition, these systems are costly and less convenient due to the
requirement for an additional step applying antigen after microporation. These disadvan-
tages are shared by the time-consuming vaccination strategies that use electroporation or
sonoporation. The simultaneous application of vaccine is feasible for both systems but it
remains unclear how the antigen is affected by the electric current or the ultrasound used
to create the micropores.
2.6 Transdermal electroporation
The first investigations using transdermal electroporation (EP) for cutaneous vaccination
were conducted in 1999 by Misra et al. [155]. Derived from in vitro transfection experi-
ments of DNA into living cells [156, 157], this technique is used to temporarily disrupt the
organized structure of the skin. It was shown that electrical pulses create transient and
reversible pores, allowing for the permeation of a drug into the tissue [37, 158]. These local
transport regions (LTRs) are generated in the SC by exceeding a predetermined voltage
threshold between 50 − 100 V [158].
Different outcomes of the vaccination efficacy of transdermal EP have been reported. Hu-
moral immune responses to diphtheria toxoid (DT) were lower as compared to intrader-
mal injection, whereas higher antibody titres to myristylated peptide (MYR) were re-
ported [155]. Moreover, equivalent cellular responses were observed for EP and conven-
tional i.d. vaccination [159]. Most notably, Zhao et al. reported that electroporation alone
promoted the migration of LCs to regional lymph nodes [159]. This indicates the ability of
electroporation to serve as a physical adjuvant, an advantage that could be exploited for
combined cutaneous vaccination approaches.
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2.7 Sonoporation
During the last decade the application of ultrasound, referred to as sonoporation or sonophore-
sis, was identified as a promising technology for vaccination via the skin [160]. Similarly
to transdermal EP, ultrasound at a frequency of 20 kHz creates localized transient regions
changing the barrier properties of the skin [161]. Remarkably, the structural changes remain
for several hours without inducing severe skin damage [162]. The prolonged permeability
allows for the stepwise application of ultrasound and drugs or vaccines. Additionally, a
simultaneous application of the vaccine and sonoporation is feasible [163].
The potential of low-frequency ultrasound to induce an immune response in mice has been
investigated using tetanus toxoid as a model vaccine [160, 164]. It was shown that the
concentration of the chemical enhancer sodium lauryl sulfate (SDS), which is commonly
utilized for sonoporation, affects the vaccination outcome [164]. Whereas higher antibody
titers were detected using a 0.5 % (w/w) SDS solution during sonication, lower titres
were elicited when SDS was not used or when higher concentrations were used [164]. Fur-
thermore, the application of low-frequency ultrasound alone triggered the activation of
LCs [160]. Interestingly, even non-disruptive sonication conditions enhance the cytokine
production, which could also affect the immune response [165]. As with transdermal EP,
sonoporation can be used as a potential adjuvant for cutaneous vaccination.
2.8 Stratum corneum-disruptive approaches
The complete removal of the SC to circumvent its barrier capacity is one of the oldest
techniques to enhance transdermal drug delivery and can be achieved by tape stripping
or skin abrasion [166]. By directly applying a protein vaccine to the viable epidermis, a
Th2-type immune response is elicited [32]. Furthermore, skin abrasion was recently trialed
in humans and resulted in the development of a humoral and cellular immunity [167].
Transfollicular delivery of vaccines after hair plucking has been investigated as an alter-
native strategy of minimally-invasive vaccination. Several pretreatments, such hot or cold
waxing, and cyanoacrylate skin surface stripping (CSSS) can be used to create channels
in the skin or to induce the hair follicles into growth stage before the application of the
vaccine [23, 168]. This approach evokes both humoral and cellular immunity [23].
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2.9 Passive targeting strategies
The easiest way to perform cutaneous vaccination is to apply antigen to intact skin. Ef-
ficient immunization has been achieved using protein vaccines, although molecules larger
than five hundred daltons usually cannot pass the intact SC [169], which would be nec-
essary to directly deliver antigen to dermal APCs. However, Naito et al. reported that
ovalbumin applied without adjuvant for more than 16 hours elicited a humoral immune
response in mice [170]. Further exploiting this strategy of contact prolongation, hydrogel
patch formulations were recently investigated [171]. It was proposed that hydrogel-based
approaches facilitate the delivery of antigenic proteins between 45− 150 kDa [31]. The cu-
taneous delivery of vaccines through intact skin has been suggested to occur by three main
mechanisms: The generation of a concentration gradient, a widening of intracellular gaps
due to hydration, and transfollicular diffusion [31]. Several studies in mice and humans
confirmed the successful activation of LCs and the induction of antigen-specific Th2-biased
immune responses using hydrogel patches [31, 171, 172]. Moreover, it was demonstrated
that antigen-loaded nanoparticles were efficiently delivered via hair follicles in intact skin
and provide the ability to stimulate antigen-specific CD4+ and CD8+ T cells [173].
Although these approaches represent the least invasive method of cutaneous vaccination,
the induction of a protective immunity comparable to other techniques remains to be
proven. It could be expected that even minimally invasive approaches elicit stronger im-
mune responses compared to the passive diffusion strategies. However, there is also the
potential to combine passive and minimally invasive technologies.
Vesicular systems act as both chemical adjuvants and physical delivery systems for cuta-
neous vaccination. They form vehicles for the cutaneous delivery of protein and DNA
or RNA vaccines, facilitating passive diffusion into the intact or physically-pretreated
skin [174]. Various vesicular systems, reported to elicit immune responses to different
extents, have been investigated including charged liposomes [174], niosomes [175], trans-
fersomes [176], ethosomes [177], cubosomes [178] and fusogenic vesosomes, which contain
bilayer destabilizing agents [179].These vehicle systems represent a further alternative for
DNA- or RNA-based vaccination and can be easily combined with several other active
vaccine delivery technologies [174, 179].
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Table I.2: Overview of routes that have been investigated for genetic skin vaccination using
nucleic acid (NA) vaccines.
Cutaneous vaccination pNA encoded antigen Adjuvant Reference
technique
SC-disruptive and passive vaccine delivery techniques
SC removed Influenza + [34]
HBsAg − [189]
Warm waxing bGal, OVA + [23]
Bacillus anthracis antigen PA63, + [168]
HIV-1 gp160
Liposomes JEV E protein − [174]
HBsAg − [188]
Nanoparticles bGal + [83]
Microporation techniques
Microneedles Hepatitis C virus protein − [187]
Thermal poration rdAd vector expressing bGal − [24]
Powder injection Influenza +/− [122,184,185]
HBsAg − [121]
GAD65 − [124]
Rabies virus − [186]
Jet injection Influenza − [180]
bGal +/− [181]
Plasmodium falciparum − [182]
circumsporozoite protein
HIV-1 gp160, p17, p24, p37B, +/− [183,191,222,223]
rev, reverse transcriptase
2.10 Potential of genetic skin vaccination
Genetic vaccination using DNA or RNA is a novel approach of evoking protective immune
responses against infectious diseases. Cutaneous vaccination offers several strategies for
introducing antigen-encoding nucleic acid vaccines to cells. Jet injection [180–183], powder
injection delivering gold particles with the gene-gun, PMED or EPI technique[122, 184–
186], microneedles [187], sonoporation [162], cationic liposomes (termed lipoplexes) [174,
188], SC-disruptive approaches [189], and transfollicular delivery routes [23] have been
shown to facilitate cutaneous vaccination. Additionally, transdermal electroporation is
expected to efficiently enhance skin vaccination with nucleic acid vaccines [190, 191] as
electroporation also enhanced the immune response upon intramuscular DNA vaccina-
tion [192].
Considering techniques using needles, DNA tattooing is an intensively studied approach
for genetic skin vaccination [193]. It has been shown to facilitate the antigen expression
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in the dermal tissue and to evoke a humoral and cellular immunity [194–196]. By DNA
tattooing, non-professional immune cells provided a superior antigen expression compared
to skin APCs [197, 198]. This indicates that keratinocytes might play a major role for the
induction of an immune response upon cutaneous vaccination using nucleic acids. More-
over, cross-presentation supported by keratinocytes was found be an important route to
prime näıve CD8+ T cells [199, 200]. Regarding the tattooing technique, it remains to
be evaluated whether and to which extent the findings can be transferred to needle-free
genetic vaccination approaches.
Most of these approaches were originally developed for in vitro transfection of living cells
and have now been transferred to antigen delivery [156, 157]. For successful transfection
of skin cells it is essential to introduce the DNA or RNA to skin cell nuclei. This is a
major challenge as penetration through two barriers, the outer cell membrane and the
nuclear membrane, must be achieved. Active delivery approaches, transiently affecting the
integrity of living skin cells, could be expected to elicit a superior immunity compared
to passive delivery approaches. Further investigation is needed to determine the efficacy
of antigen-encoding nucleic acid vaccines compared to conventional immunization using
protein antigens, especially focusing on cutaneous delivery approaches. Table I.2 provides
an overview of different strategies of skin vaccination that have been exploited for DNA or
RNA vaccination.
2.11 Latest trends in cutaneous vaccination
Considering recent developments, microneedles have been particularly in the focus of stud-
ies for cutaneous vaccination. It appears that dissolving or biodegradable microneedles
are suitable for the delivery of conventional protein antigens as well as for the delivery
of amyloid-β in a therapeutic mouse model of Alzheimer's disease [97, 131, 201]. Other
advanced approaches use biodegradable solid or microparticle-containing tips whereby anti-
gen or antigen loaded nanoparticles are released upon dissolution and degradation of the
microneedle matrix [97, 98]. Vaccine-coated nanopatches and cubosome formulations ap-
plied after microneedle pretreatment have also been studied for cutaneous vaccination in
mice [15, 178]. In addition, laser microporation and micro- and nanoparticle delivery
technologies have been successfully utilized to elicit humoral responses to protein anti-
gens [149, 154, 202]. Other cutaneous delivery strategies, which are particularly attractive
for their ease of use, are hydrogel patches and the delivery via hair follicles [168, 203].
Hydrogels based on hyaluronic acid have been shown to elicit an immune response against
18
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protein antigens after application for 24 h [171, 172]. Moreover, liquid DNA vaccine for-
mulations and also nanoparticles have been delivered via hair follicles indicating the im-
portance of this route of cutaneous vaccination [23, 173].
In addition to the previously discussed needle-free vaccination techniques, which are still
mainly restricted to research, a variety of conventional and needle-free i.d. vaccination de-
vices are currently under investigation, in clinical trials or are already available on the mar-
ket [134, 204, 205]. One example having reached market authorization is the BD Soluvia
device (Becton-Dickinson, USA) [206], which is utilized for seasonal influenza vaccination
with the i.d. vaccines Intanza, IDflu, and Fluzone (Sanofi Pasteur, France) [206, 207].
Also, the microneedle-based MicronJet® system (Nanopass technologies, Israel) has been
cleared by the Food and Drug Administration (FDA) and was shown to provide an im-
proved immune response compared to i.d. Mantoux or i.m. injection [133, 134, 208].
Moreover, West Pharmaceutical Services (USA) have developed the syringe West intra-
dermal (ID) adapter, which improves the reproducibility of i.d. vaccine delivery by the
Mantoux technique [28]. Intradermal vaccines are developed in order to improve safety
and efficacy and for possible dose sparing effects [209]. While many studies report positive
results as regards immune responses, in some cases i.d. vaccination has been shown to
result in lower antibody titers compared to conventional i.m. vaccination [210].
Although several needle-free jet injector technologies have already been successfully used
for i.m., s.c., and also i.d. vaccination, latest-generation DSJIs are currently undergoing
clinical trials [211–213]. Only recently, the needle-free i.m. administration of the Afluria®
influenza vaccine using the PharmaJet Stratis® (PharmaJet, USA) has been approved by
the FDA, although the device itself is licensed since 2011 [214, 215]. However, other jet
injector devices have also received FDA clearance before and after, such as the Biojector®
2000, Lectrajet®, Avant Guardian 101, Mini-Ject, or the Injex system [216–220]. To best
of our knowledge, i.d. vaccines administered by needle-free jet injectors are investigated in
humans but remain to be licensed for combined use [212, 221–223].
2.12 Conclusion
Vaccination is the most important tool in public health care for combating infectious
diseases. However, storage issues for liquid vaccines, the use of syringes and the need for
professional assistance limits its convenience and acceptance. Nevertheless, vaccination by
conventional needle injection represents the state-of-the-art, is highly reliable and provides
good cost-benefit ratio.
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Figure I.3: Active vaccine delivery techniques and passive approaches for cutaneous vacci-
nation. The injection, microporation and LTR techniques are displayed in representative
dimensions relative to the epidermal layer of the skin. The dimensions of the devices were
exemplarily chosen using typical sizes of the presented systems. LTR - local transport
region; NPs - nanoparticles. Adapted from [107]
Cutaneous vaccination is an attractive alternative for conventional vaccination. Many dif-
ferent technologies for cutaneous vaccine delivery are under development each with its own
strengths and weaknesses. While the technologies impact on the skin to different extents,
the systems are in general non- or minimally invasive. Figure I.3 gives an overview of active
and passive techniques for cutaneous vaccination. Needle-free jet and powder injection and
microporation technologies overcome the SC using mechanical approaches, whereas elec-
troporation, sonoporation and passive vaccine delivery techniques employ physicochemical
strategies. The passive diffusion of antigen upon topical application is the easiest but also
most time-intensive route of vaccination, limiting its convenience. Finally, it may be that
not all vaccines are suitable for cutaneous vaccination and that it is necessary to evaluate
the safety and effectiveness on a case-by-case basis.
The innovative approaches to a vaccination via the skin discussed here are highly promising
and safe alternatives to conventional needle injection. The potential that new or differ-
ent types of immune responses can be stimulated by cutaneous vaccination as opposed
to conventional i.m. immunization is also intriguing. Although the production costs of
these new vaccines still exceed those of conventional vaccination, the cutaneous vaccine
delivery technologies have the potential to minimize vaccine doses and to bypass common
vaccination-related limitations.
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[191] D. Hallengärd, A. Br̊ave, M. Isaguliants, P. Blomberg, J. Enger, R. Stout, A. King,
B. Wahren, A combination of intradermal jet-injection and electroporation overcomes
in vivo dose restriction of DNA vaccines, Genet Vaccines Ther 10 (2012) 5.
37
I. Introduction
[192] M. Selby, C. Goldbeck, T. Pertile, R. Walsh, J. Ulmer, Enhancement of DNA vaccine
potency by electroporation in vivo, J Biotechnol 83 (2000) 147–152.
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II
NEEDLE-FREE POWDER INJECTION FOR
CUTANEOUS VACCINATION WITH A HIGHLY
CONCENTRATED OVALBUMIN MODEL
VACCINE
A detailed list of contributions is listed in section 5.
Further results associated to this project have been published as Engert, J. et al., A pi-
lot study using a novel pyrotechnically driven prototype applicator for epidermal powder
immunization in piglets. Int J Pharm 545(1-2) (2018) 215-228.
1 Introduction
Since decades, the idea of needle-free injections appears as a highly attractive approach for
parenteral drug and vaccine delivery, promising low invasiveness, reduced pain, improved
ease of administration, and avoiding the use of sharps. The first jet injector devices were
used for multiple injections during mass immunization programs, leading to high numbers
of cross-infections [1–3]. Later, disposable jet injectors (DSJIs or SUDJIs) were introduced
and, until today, various types of jet injectors were developed and licenced for i.m., s.c., or
i.d. injection [1, 4]. Despite the high number of DSJI systems developed, only a limited
number of devices is commercially used for drug or vaccine administration. Examples are
SumavelDosePro [5] and the tri- and quadrivalent Afluria® vaccines approved for the
use with PharmaJet® Stratis® [6]. More recently, Takeda Pharmaceuticals announced a
collaboration to bring their antibody candidate Entyvio® to the market for s.c. adminis-
tration using the needle-free injecton system PRIME [7]. Although in principle appealing,
jet injectors mostly remained high-cost developments without major advantage over con-
ventional injections using N&S.
In comparison to jet injectors, ballistic powder injection introduces an additional aspect
which underlines a potentially stronger benefit over conventional injections. The admin-
istration of dry formulations by powder injection not only exploits the aforementioned
advantages of needle-free injections, but also exhibits the potential to enhance the storage
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stability of the drug candidate. Developments of needle-free powder injectors facilitate
a deposition of various kinds of powders and loadings into the skin, such as 1 − 3 µm
DNA-coated gold microparticles [8–10], 1 − 5 µm polymer microspheres [11], or 20-53 µm
sugar-based microparticles loaded with protein antigens [12, 13]. Due to a superficial deliv-
ery limited to the skin tissue, needle-free powder injection provides the strongest potential
as tool for cutaneous vaccination. The reproducible breaching of the skin barrier to deliver
a vaccine into viable skin layers is the major challenge of powder injection and is highly
dependent on the skin condition [14]. The successfull i.d. delivery into the viable skin with
a high density of APCs allows for an effective induction of immune responses, dependent on
the main skin layer targeted. Whereas humoral and also cellular responses can be elicited
by epidermal LCs, dDCs in the underlying dermal layer mainly provide humoral responses.
However, the underlying immunological processes are complex and dependent on multiple
factors including the type of antigen, adjuvant, as well as the skin layer as discussed in
section 2.
In this study a novel type of powder injector, which differed from predecessor devices by
its type of particle acceleration, was used. The powder injector in this study contained a
pyrotechnically driven particle accelerator [15], whereas the classical gene gun and hand-
held PowderJect® device rely on a helium gas-triggered acceleration of particles [11, 16, 17].
The relatively large dimensions, complex preparation processes, and the use of expensive
helium gas have limited the success of these devices for cutaneous vaccination in the past.
The overall aim of this study was to evaluate the performance of the novel needle-free
powder injector to generate an immune response upon intradermal delivery of a powdered
vaccine.
In this work, three main objectives were addressed. First, based on low-dose vaccine
developments for powder injection [18], a highly concentrated vaccine formulation was
developed using OVA as model antigen (Section 3.1). The trehalose and mannitol-based
vaccine was manufactured by a two-step process combining collapse lyophilization and
cryogenic grinding, generating particles in a size range of 20-80 µm [19]. The properties
of the highly concentrated vaccine was compared to placebo and low-dose formulations,
which were tested for powder injection before [15, 18]. Furthermore, the stability of the
highly concentrated vaccine was evaluated in a long-term stability study over 12 months
(Section 3.2).
To facilitate the intradermal powder administration, the vaccine powder needs to be at-
tached to a titanium (Ti) membrane within the needle-free injection device. To ensure
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particle adhesion, the vaccine powder is homogeneously coated using an oily liquid for
fixation. This liquid may be composed of a mixture of oils with adjuvant properties [20].
Upon device actuation, the oily adjuvant is delivered simultaneously with the vaccine pow-
der into the skin [20]. For this study, a mixture of the oily components in relative ratios of
the Adjuvant System 03 (AS03®) was used. AS03 is an emulsion based on squalene, DL-
α-tocopherol, and polysorbate 80 and was licenced in 2008 for the use with the pandemic
influenza vaccine Pandemrix® [21].
The second objective of this study was focused on the characterization of the adhe-
sion/adjuvant oil properties. The strength of vaccine powder adhesion was evaluated for
different oily liquids and mixtures based on the oily components of AS03 (Section 3.3). The
oil-device membrane interaction was characterized by surface angle measurements and a
correlation between vaccine powder adhesion and adhesion oil properties was evaluated.
Additionally, the effect of the highly concentrated vaccine powder on the oil stability was
evaluated under UV/Vis exposure and thermal stress (Section 3.4).
The last section of this chapter focuses on the main objective of this study, the evaluation
of needle-free powder injection for cutaneous vaccination using a highly concentrated OVA
model vaccine (Section 3.5). The in vivo immunization study compared cutaneous immu-
nization using powder injection to conventional i.m. injection. Furthermore, the approach
of simultaneous adjuvant oil delivery using the AS03 oily mixture was studied in compari-
son to paraffin as oily adhesive without expected adjuvant activity despite its known effect
as oily depot in Freund’s adjuvant system [22].
This study reveals a high potential of needle-free powder injection for cutaneous vacci-
nation but also highlights issues and hurdles for the development of highly sophisticated
technologies for intradermal delivery.
2 Materials and Methods
2.1 Materials
Bovine serum albumin (BSA), 5α-cholestane, free and horseradish peroxidase (HRP)-
linked goat anti-porcine IgG antibody, Hydranal® dry methanol, OVA grade V and VII,
mouse anti-OVA antibody, polysorbate 80, porcine albumin, porcine IgG, squalane, squa-
lene, sterile Dulbecco’s phosphate-buffered saline (PBS), 3,3’,5,5’-tetramethylbenzidine
(TMB) substrate, TMB stop reagent, tert-methylbutylether (TMBE), D/L-α-tocopherol,
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Tween® 20 were obtained from Sigma Aldrich (Taufkirchen, Germany). Mannitol, highly
liquid paraffin, polyethylene glycol 400 and 600 (PEG 400, PEG 600), butylated hydrox-
yanisole (BHA), disodium carbonate, potassium chloride, sodium hydrogen carbonate, and
potassium dihydrogen phosphate were from Merck (Darmstadt, Germany). Trehalose di-
hydrate was from VWR Prolabo (Darmstadt, Germany). Adjuvant System 03 (AS03®)
adjuvant emulsion was derived from Pandemrix® vaccine (GlaxoSmithKline, Rixensart,
Belgium) and was kindly provided by the Bavarian State Ministry of Environment and
Public Health. Sodium dihydrogen phosphate dihydrate and disodium hydrogenphosphate
were purchased from AppliChem (Darmstadt, Germany) and sodium chloride was obtained
from Bernd Kraft (Duisburg, Germany). Anti-mouse detection antibody (λex 778 nm and
λem 795 nm) was purchased from LI-COR (Bad Homburg, Germany). NuPAGE
® 10 %
Bis-Tris protein gels (1.0 mm, 12 wells) and 2-(N-morpholino)ethanesulfonic acid (MES)
SDS running buffer were obtained from Life technologies (Carlsbad, USA). Sylgard 184
silicone elastomer kit was purchased from Dow Corning (Seneffe, Belgium).
2.2 Preparation of model vaccines and oily adjuvant
2.2.1 Vaccine preparation by collapse lyophilization and cryogenic milling
The model vaccine at 200 µg/mg was prepared by dissolving 2 parts OVA and 8 parts
trehalose dihydrate/mannitol in 1:1 (w/w) ratio in 10 mM PBS (pH 7.0, 50 mM ionic
strength), resulting in 15 % (w/w) solid content. Placebo solutions and compositions
with 25 µg/mg OVA content were prepared similarly. After filtration using a 0.22 µm
cellulose acetate (CA) membrane filter (VWR International, Darmstadt, Germany), 2 g
of the compounded solution was pipetted into type I transparent 10R glass vials (Mglas,
Münnerstadt, Germany), semi-stoppered with 20 mm Westar® RS lyophilization stoppers
(Westpharma, Exton, USA) and collapse lyophilized using an Epsilon 2-6D freeze dryer
(Christ, Osterode am Harz, Germany) using a cycle described before [19]. Subsequently,
lyophilisates were cryomilled in aliquots of 1.5 g using a MM301 CryoMill (Retsch Technol-
ogy, Haan, Germany). Upon pre-cooling using liquid nitrogen, the milling was performed
at 25 Hz for 15 s. The powder was partitioned by sieving into powder particles ranging in
size from 20 − 80 µm and aliquoted into 10R vials under a glovebox flushed with nitrogen
with a relative humidity below 10 %. The final model vaccine contained a dose of 0 µg,
25 µg, or 200 µg OVA per mg vaccine powder. For long-term storage stability analysis,
lyophilisates and cryomilled powder aliquots containing 200 µg/mg OVA were stored at
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2 − 8 °C, 25 °C and 40 °C for up to 12 months. The stability of the highly concentrated
lyophilizates and cryomilled powder was analyzed after 1, 3, 6, 9, and 12 months storage.
For vaccination studies, the OVA-loaded vaccine powder was manufactured under aseptic
conditions. The formulation compounding was performed under laminar air flow (LAF) and
compounded solution was lyophilized under clean room conditions using an Epsilon 2-12D
freeze dryer (Christ, Osterode am Harz, Germany). Equipment with direct product contact
was autoclaved for 121 °C at 2 bar for 15 min or depyrogenized using dry heat at 250 °C
for at least 30 min.
2.2.2 Preparation of liquid vaccine for injection
Approximately 10 mg OVA grade VII was dissolved in 10 mL sterile Dulbeccos PBS and
filtered through a 0.22 µm CA filter (VWR International, Darmstadt, Germany). The OVA
concentration was determined by UV/Vis spectroscopy (λ = 280 nm). Subsequently, the
solution was diluted to a concentration of 0.8 mg/mL OVA and mixed with an equal volume
of AS03 adjuvant emulsion in transparent 10R vials, resulting in a final OVA concentration
of 0.4 mg/mL. The liquid model vaccine emulsion was stored 2 − 8 °C overnight before
application in the in vivo immunization study described in section 2.6.1.
2.2.3 Preparation of oily adjuvant mixtures
The oily adjuvant for in vivo immunization study was prepared based on the mass ratios of
AS03, which delivers 10.69 mg squalene, 11.86 mg DL-α-tocopherol and 4.86 mg polysor-
bate 80 per dose. Furthermore, the adjuvant composition was altered to investigate the
oily adjuvant stability using mass ratios as shown in table II.1. Mixtures were prepared
by weighing the components into a transparent 10R glass vial and mixing under aseptic
conditions using a magnetic stirrer at ∼ 50 rpm. Oily mixture F1 was used for needle-free
powder injection in the in vivo immunization study described in section 2.6.1.
2.3 Analytical characterization of the model vaccine
2.3.1 Turbidity
The turbidity was analyzed upon reconstitution of lyophilisates and cryomilled powder as
described before using a Nephla turbidimeter (Hach Lange, Düsseldorf, Germany). Sam-
ples were reconstituted with highly purified water (hpw) to match the liquid composition
prior lyophilisation. Reconstituted samples were diluted 1:1, transferred into flat-bottom
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Table II.1: Compositions of oily adjuvant mixtures.
Formulation Squalene D/L-α-Tocopherol Polysorbate 80
[%] [%] [%]
F1 39.0 43.3 17.7
F1* 39.0 43.3 17.7
F2 69.5 21.6 8.9
F3 99.9 0.1 -
* stabilized with 0.02 % butylated hydroxyanisole (BHA)
glass cuvettes (Hach Lange, Düsseldorf, Germany) and allowed to stand for 6 h at room
temperature (RT) prior to analysis. The turbidity was determined by analyzing the scat-
tering signal of light at λ = 860 nm at an angle of 90 °and was presented in formazine
nephelometric units (FNU). The turbidity of each condition was determined as average of
three samples.
2.3.2 Subvisible particles by light obscuration
Subvisible particles were analyzed by light obscuration using a PAMAS SVSS-C40 (PA-
MAS, Rutesheim, Germany) upon reconstitution and dilution as described in section 2.3.1.
A volume of 0.4 mL was used to flush the system. Cumulative particle counts ≥ 1 µm,
≥ 5 µm, ≥ 10 µm, and ≥ 25 µm were calculated as the average of three consecutive mea-
surements of 0.3 mL sample using the PMA software (PAMAS, Rutesheim, Germany).
Each sample condition was analyzed in triplicates.
2.3.3 Size exclusion chromatography
Size exclusion-high performance liquid chromatography (SE-HPLC) was carried out using
a Dionex HPLC system equipped with a Dionex UVD170u UV/VIS-detector (Dionex, Id-
stein, Germany). A TSKgel G3000SWxl (Tosoh Bioscience, Stuttgart, Germany) was used
for separation with 50 mM PBS (pH 7.0, 150 mM sodium chloride) as mobile phase. The
samples were reconstituted as described in section 2.3.1. Three samples of each prepara-
tion step and condition were analyzed. The separation was accomplished at a flow rate of
0.5 mL/min and peak areas were evaluated using Chromeleon 6.60 (Dionex, Idstein, Ger-
many). An OVA standard curve using five dilutions was generated to evaluate the total
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protein recovery relative to the liquid formulation prior processing.
2.3.4 Western Blot analysis
For Western Blot analysis, lyophilizate and cryomilled powder samples were reconstituted
as described in section 2.3.1 and diluted to 0.2 mg/mL OVA. Subsequently, the samples
were mixed 1:1 with sample loading buffer (4 % SDS, 20 % glycerol, 0.001 % bromophenol
blue in 250 mM tris(hydroxymethyl)aminomethane (Tris) hydrochloride at pH 6.8) and
heated for 20 min at 90 °C. Separation by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) was performed loading 10 µL sample into a 10 % Bis-Tris
protein gel using MES SDS as running buffer. 5 µL MagicMark XP Western protein
standard was used as molecular weight standard in the range of 20 − 200 kDa.
After separation, blotting onto a nitrocellulose membrane (Hybond-ECL, Amersham Bio-
science, Freiburg, Germany) was performed at 100 mV for 1.5 h under cooling. Upon
blotting, OVA detection was performed stepwise under constant shaking at 100 rpm in
a horizontal shaker (VWR Ismaning, Germany). In detail, membranes were blocked
with 5 % BSA in 50 mM Tris-buffered saline containing 0.1 % Tween® 20 (TBS-T,
150 mM NaCl, pH 7.4) for 2 h at RT. After washing with TBS-T, membranes were in-
cubated overnight at 2 − 8 °C with mouse anti-OVA primary antibody diluted in TBS-T
containing 1 % BSA. Subsequently, membranes were washed and anti-mouse detection
antibody (λex 778 nm and λem 795 nm) in TBS-T containing 1 % BSA was added and in-
cubated for 2 h at RT. After washing, membranes were analyzed using a LI-COR Odyssey
scanner (LI-COR, Lincoln, USA).
2.3.5 Residual moisture analysis
The residual moisture content was determined by Karl-Fisher direct injection using a
737 KF coulometer (Metrohm, Filderstadt, Germany). Samples were prepared by weighing
20 − 30 mg lyophilizate or cryomilled powder into 2R vials under a glovebox flushed with
pressurized air at a relative humidity below 10 %. Vials were crimped and approximately
2 mL dry methanol was injected to the dry sample. The samples were placed into an
ultrasonic water bath (Sonorex TK52, Bandelin electronics, Berlin, Germany) for 10 min
extraction. The water content in mg per g methanol was determined by injecting 1 mL
sample into the coulometric titrator. Each sample was analyzed at least four times.
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2.3.6 Differential scanning calorimetry
The thermodynamic behavior of the vaccine lyophilizates and the cryomilled powder was
analyzed by differential scanning calorimetry (DSC) using a Mettler Toledo 821e system
(Gießen, Germany). Approximately 5−15 mg of dry sample was weighed into an aluminum
pan and subsequently cold-sealed under a glovebox flushed with nitrogen and a relative
humidity below 10 %. Sample analysis was performed in two cycles heating from -10 °C to
180 °C with a rate of 10 °C/min. Thermal events were evaluated using the StarE software
(Mettler Toledo, Gießen, Germany). The instrument was calibrated by heating indium
from 0 °C up to 150 °C at rate of 10°C/min. Data were evaluated using OriginPro 9.1.0G
(OriginLab, Northampton, Massachusetts, USA).
2.3.7 X-ray powder diffraction
Mannitol polymorphs in dry samples were analyzed using a XRD 3000 TT diffractome-
ter (Seifert, Ahrenberg, Germany) equipped with a copper anode (λ= 0.154 nm, 40 kV,
30 mA). Measurements were taken between 5 − 45 ° 2-Theta in intervals of 0.1 °2-Theta
with a duration of 4 s. Excipient modifications were qualitatively evaluated by comparison
of the obtained diffraction curves with literature [23, 24].
2.3.8 Scanning electron analysis
Scanning electron microscopy of model vaccine lyophilizates and cryomilled powder was
performed using a Joel JSM-6500F electron microscope (Ebersberg, Germany). Dry sam-
ples were attached to self-adhesive carbon tape (Bal-tec GmbH, Witten, Germany) and
carbon-sputtered using a MED 020 coating system (Bal-tec GmbH, Witten, Germany).
Images were taken at 5.0 kV operation voltage and a magnification of 500x.
2.3.9 Specific surface area analysis
The specific surface area (SSA) of the lyophilizates was determined by nitrogen-cooled
krypton gas adsorption using an Autosorb-1MP analyzer (Quantachrome, Odelzhausen,
Germany). After degassing of 100 − 150 mg sample under vacuum at RT, the krypton
adsorption was determined. Each sample was analyzed twice, measuring eleven points over
a p/p0 range of 0.05 − 0.3. SSAs were evaluated according to the multipoint Brunauer-
Emmert-Teller (BET) fitting method using the Autosorb-1 software.
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2.3.10 Helium pycnometry
The true density of model vaccine lyophilisates was determined by helium pycnometry
(AccuPyc 1330, Micrometrics, Aachen, Germany). Approximately 300 mg lyophilizate
sample was analyzed after ten preliminary cleaning cycles with analytical grade helium.
The true density was calculated as average of six consecutive measurements.
2.3.11 Endotoxin measurements
The endotoxin content of the liquid and reconstituted model vaccines was evaluated based
on kinetic chromogenic limulus amebocyte lysate (LAL) assay. Samples were analyzed
using an EndoSafe®-PTS portable test system using cartridges with a sensitivity of
0.005 EU/mL (Charles River Laboratories, LArbresle, France) according to the manufac-
turers instructions.
2.4 Vaccine powder adhesion study
2.4.1 Vaccine powder adhesion testing
The adhesion of model vaccine powder to Ti membranes using different liquid mixtures
was tested using a customized drop apparatus as described before [25]. The adhesion of
placebo and OVA-loaded vaccine powder at concentrations of 25 µm/mg and 200 µg/mg
were investigated using the oily mixtures shown in table II.1, squalane, squalene, highly
liquid paraffin, D/L-α-tocopherol, polysorbate 80, PEG400, and PEG600. An area of
20x10 cm2 on Ti membranes were covered with a thin film of liquid mixture using a cotton
swab. Approximately 3 mg model vaccine powder was sprinkled homogenously over the
surface and gently pressed onto the membrane. Excess powder was removed by gentle
tapping and the loaded membrane was fixed to the drop apparatus. The membrane carrier
was accelerated by free fall over 1 m distance using a weight of 382 g. The carrier was
dropped five times and the remaining model vaccine powder was measured by weighing.
Each condition was analyzed in triplicates.
2.4.2 Surface tension and contact angle measurements
The surface tension and contact angles of the oily mixtures as shown in table II.1, squalane,
squalene, highly liquid paraffin, D/L-α-tocopherol, and polysorbate 80 were analyzed using
a drop shape analyzer DSA25S (Küss, Hamburg, Germany). The surface tension was
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determined using the pendant drop configuration and the surface angle of a 2 µL sessile drop
was determined on Ti, hydrophilic glass, and hydrophobic polydimethylsiloxane (PDMS)
surfaces. The contact angle was determined 30 s after first contact with the solid surface.
The work of adhesion as well as polar and disperse interactions were calculated using water
and diiodomethane as hydrophilic and hydrophobic reference liquids. The PDMS surface
was prepared following the instructions of the Sylgard 184 silicon elastomer kit.
2.5 Adjuvant oil stability study
2.5.1 Long-term storage and stress test oil-vaccine
Dry vaccine powder containing 200 µg OVA/mg was prepared as described in section 2.2.1.
Squalene, D/L-α-tocopherol and polysorbate 80 were weighed into a type I clear 10R glass
vial and mixed, matching the compositions definde in table II.1. The inner surface of type
I clear 2R glass vials were covered with ∼ 10 mg of the oily mixture using a cotton swab.
Subsequently, ∼ 50 mg vaccine powder was distributed inside the vial in one half of the
sample set. The inner walls of the transparent 2R vials were completely covered with oily
adhesive alone or with oil+vaccine powder, respectively. All samples were prepared under
a glovebox flushed with nitrogen with a relative humidity below 10 %. Six samples were
prepared for every time point of a specific storage condition, with and without vaccine
powder. For the long-term stability investigations, the samples were stored for six months
at 2 − 8 °C, 25 °C and 40 °C. The stress test involved the exposure to and shielding from
UV light using aluminum foil for 7 d using a Suntest CPS (Heraeus, Original Hanau,
Germany). The UV/Vis stress conditions employed an irradiance of 550 W/m2 for 48.2 h
using light at 200-800 nm, resulting in an illuminance of 6 mio. lux h. During UV/Vis
exposure, a temperature of 35 °C was measured in the Suntest CPS system.
2.5.2 GC-MS analysis
Gas chromatography-mass spectrometry (GC-MS) analysis was performed in full-scan
mode using a Varian Saturn Ion Trap 2000 system equipped with a CP-3800 GC (Var-
ian, Darmstadt, Germany). The separation was achieved using a Varian VF-5ms column
(30 m x 0.25 mm x 0.25 mm) and helium as carrier gas at a flow rate of 1.4 ml/min.
Aliquots of 1 µL sample were injected at 250 °C and electron ionization was performed at
270 °C ion source temperature and 70 eV ionization energy.
For organic extraction of the sample oils, a solution containing 10 µg/mL 5α-cholestane as
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internal reference standard in TMBE was prepared. TMBE with 5α-cholestane was added
to the sample vials to dissolve the oily components. Upon mixing, the suspension was
transferred quantitatively into a tube containing water-free sodium sulfate and centrifuged
for 2 min at 14,000 rpm. The supernatant was diluted 1:2500 using TMBE containing
5α-cholestane and samples were analyzed by GC-MS analysis. Calibration curves of squa-
lene, squalan, and D/L-α-tocopherol were prepared in TMBE containing 5α-cholestane as
internal reference standard. The conditions tested included a five point calibration in the
range of ± 20 % of the highest and lowest expected concentration. The obtained calibra-
tion curves provided good precision and accuracy. Statistical analysis was performed using
OriginPro 9.1.0G (OriginLab, Northampton, Massachusetts, USA).
2.6 In vivo vaccination study in piglets
2.6.1 Immunization
Domestic cross-breed piglets between six and seven weeks old were assigned to four different
vaccination groups by weight II.2. Immunization was performed by needle-free powder
injection or i.m. injection (control). For powder injection, piglets were anesthetized for
10 − 15 min using 5 % isoflurane (Isoba® MAC 1.5 vol % Essex Tierarznei, Munich,
Germany) as inhalational anesthetic. During anesthesia, the vital functions of the pigs
were continuously monitored. The ventrolateral region between mammary ridge and the
lateral side of the body was cleaned with water and bristles were removed using a trimmer.
The application site was marked by tattooing and labeled using a black marker. Two verum
groups received a dose of 1 − 2 mg vaccine powder loaded with 200 µg OVA/mg vaccine
using highly liquid paraffin (B) or oily AS03 adjuvant (C) as adhesive. A dose of 1− 2 mg
vaccine powder without OVA model antigen, attached to the injection device using paraffin,
was applied by powder injection in the placebo group (A). The vaccine was administered
by powder injection on day 0 and 14 to opposite sites of the body. The positive control
group (D) received an i.m. injection of 0.5 mL liquid vaccine, described in section 2.2.2,
into opposite sites of the neck (trapezius muscle) on day 0 and 14. Serum samples for
all groups were collected before and 1 d, 14 d, 21 d, and 28 days after immunization.
The health status of the piglets was checked on a daily basis using a score system. The
experimental protocol was approved by the Government Office of Upper Bavaria, Munich,
Germany (authorization reference number 55.2.1.54 − 2532 − 87 − 12; 30. Aug. 2012).
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Table II.2: Overview of treatment groups in the in vivo immunization study.
Group Route of OVA dose Oil adhesive Adjuvant Immunization
administration time points
A Powder injection - Paraffin - days 0, 14
B Powder injection 200 µg Paraffin - days 0, 14
C Powder injection 200 µg AS03 + days 0, 14
D i.m. 200 µg AS03 + days 0, 14
2.6.2 Quantification of OVA-specific porcine IgG
The OVA-specific antibody titer in serum samples was determined using an direct enzyme-
linked immunosorbent assay (ELISA). In brief, 96-well, clear, flat-bottom microtiter plates
(Nunc Maxisorp, VWR, Germany) were coated overnight at 2 − 8 °C using 50 µL of
10 µg/mL OVA in 50 mM carbonate-bicarbonate coating buffer (pH 9.6). Microtiter plates
were washed between each subsequent step with 10 mM PBS containing 0.05 % (w/w)
Tween® 20 (PBS-T, pH 7.4, 150 mM NaCl) using a Hydroflex plate washer (Tecan,
Männedorf, Switzerland). Blocking was performed using 100 µL 5 % (m/v) BSA in PBS-T
and incubation for 1 h at RT. Serum samples were diluted 1:25 using 1 % (m/v) BSA in
PBS-T and a two-fold serial dilution was pipetted into every row of the microtiter plate,
resulting in 50 µL per well. Each sample was measured twice. A pooled sample of 28 d
sera of the i.m. control group (D) (1:200) served as positive control in two rows per mi-
crotiter plate. Samples were incubated for 1 h at RT and 50 µL HRP-linked anti-porcine
IgG secondary antibody (1:40,000) was added for 1 h at RT. Detection was performed
by enzymatic reaction using 50 µL TMB substrate solution at RT. Reaction was stopped
after 10 min by directly adding 50 µL TMB stop solution and absorbance was measured
at λ = 450 nm using a Fluostar plate reader (BMG labtech, Offenburg, Germany). The
OVA-specific antibody titer was determined as inflection point upon four parameter logistic
regression of each sample curve using Origin 8G (OriginLab, Northampton, Massachusetts,
USA). Statistical analysis of the antibody titer was performed using ANOVA on ranks
(Kruskal-Wallis, α = 0.05) using SigmaPlot 12.5 (Systat Software, San Jose, California,
USA).
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2.6.3 Quantification of total porcine IgG
Total serum immunoglobulin (Ig)G was determined by sandwich ELISA, which was de-
veloped for the in vivo study. Briefly, coating was performed by incubating 50 µL goat
anti-porcine IgG capture antibody (1:20,000) in 50 mM carbonate-bicarbonate coating
buffer (pH 9.6) overnight at 2 − 8 °C in 96-well, clear, flat-bottom microtiter plates. Be-
tween each following step, microtiter plates were washed with PBS-T (pH 7.4, 150 mM
NaCl) using a Hydroflex plate washer (Tecan, Männedorf, Switzerland). Blocking was per-
formed using 100 µL of 5 % (m/v) BSA in PBS-T, incubating for 1 h at RT. Serum samples
were diluted in 1 % (m/v) BSA in PBS-T. Each sample was analyzed in duplicates using
50 µL sample per well, incubating for 1 h at RT. Detection was performed as described
in section 2.6.2 using HRP-linked anti-porcine IgG (1:20,000) as secondary antibody and
TMB substrate. The porcine IgG concentration of each sample was calculated by means
of a standard curve that was measured separately for each microtiter plate. Dilutions of
porcine IgG and porcine albumin at 1:3.3 ratio in 10 mM PBS (pH 7.4), matching the IgG
content relative to total serum proteins [26], was used to generate the standard curve. The
total porcine IgG ELISA was developed by two-step chessboard titration (CBT) providing
a detection range of 1−100 nm/mL porcine IgG (R2 > 0.999). The developed ELISA pro-
vided low intra- and interassay variability with relative coefficient of variation (CV) < 5 %
except for the high concentration standard, which showed an interassay CV of 14 %. A
standard curve was included to each microtiter plate. Statistical analysis was performed
using SigmaPlot 12.5 applying a one-way ANOVA on ranks (Kruskal-Wallis, α = 0.05).
3 Results and Discussion
3.1 Development and characterization of a highly concentrated
model vaccine for needle-free intradermal powder injection
3.1.1 Preparation of low and highly concentrated OVA model vaccine
Previous studies have shown that the preparation of a low dose vaccine powder using
OVA as model antigen at a concentration of 25 µg/mg was feasible, resulting in a vaccine
powder with good stability and suitable properties for needle-free powder injection [18,
19]. Considering a maximum dose of 1 − 2 mg vaccine powder delivered by needle-free
intradermal injection, only 25 − 50 µg OVA would be delivered into the skin. Comparable
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doses have been used for cutaneous vaccination in mice [27, 28]. However, the relatively
low potency of OVA as model antigen likely requires a higher dosing in larger animals. To
facilitate a high dosing in the in vivo immunization study in piglets, a highly concentrated
vaccine powder at 200 µg/mg was developed and characterized in relation to low-dose
vaccine formulations.
The simultanous preparation of vaccine at 0 µg/mg, 25 µg/mg, and 200 µg/mg OVA in
one lyophilization cycle was possible and resulted in comparable cake appearance for all
formulations. Temperature probe monitoring revealed a completion of primary drying after
10 − 12 h for 25 µg/mg and 200 µg/mg OVA formulations, applying aggressive primary
drying conditions at +45 °C and 2 mbar as described before [18]. The initiation of secondary
drying after around 31 h at +45 °C and 0.03 mbar highlights the possibility to further
reduce the primary drying time and thereby improve cost and time efficiency for vaccine
manufacturing.
The second step of vaccine preparation for powder injection by cryogenic milling resulted in
a white vaccine powder with comparable appearance for all OVA concentrations. The vac-
cine powder as placebo formulation or 25 µg/mg and 200 µg/mg OVA-loaded formulation
exhibited similar macroscopic properties upon manufacturing.
3.1.2 Ovalbumin antigen stability
The OVA protein stability of model vaccines with concentrations of 25 µg/mg and 200 µg/mg
was evaluated by SE-HPLC. The relative amount of OVA monomer, dimer, and high molec-
ular weight (HMWS) and low molecular weight species (LMWS) during the processing was
evaluated for the low and highly concentrated vaccine formulations (Tab. II.3). The OVA
monomer recovery remained constant at approximately 91 % for the liquid formulations
and after lyophilization and cryogenic milling of 25 µg/mg and 200 µg/mg OVA formula-
tions. Furthermore, around 8.3 % dimer and 1 % HMWS were detected for model vaccine
lyophilizates and the cryomilled powder. Upon cryogenic milling the relative amount of
HMWS increased to 1.6 % and 1.1 % for the 25 µg/mg and 200 µg/mg OVA powder, re-
spectively. Compared to the liquid formulations with 0.9 % and vaccine lyophilizates with
1.4 % and 1.1 % HMWS, the increase was minimal and not considered to affect the vaccine
quality negatively. Also, no fragmentation, indicated by increased LMWS, was detected
by SE-HPLC analysis.
The results suggest that the protein remained stable during collapse lyophilization and
cryogenic milling. Neither increased processing-related aggregation, nor fragmentation
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Table II.3: Protein composition by SE-HPLC of OVA model vaccine at 25 µg/mg and
200 µg/mg prior and after processing by lyophilization and cryogenic milling.
Formulation Monomer Dimer HMWS LMWS
[%] [%] [%] [%]
25 µg/mg OVA
Liquid (Liq) 90.8 ± 0.2 8.3 ± 0.1 0.9 ± 0.1 n.d.
Lyophilizate (Lyo) 90.2 ± 0.1 8.4 ± 0.1 1.4 ± 0.1 n.d.
Cryomilled powder (Cryo) 90.4 ± 0.2 8.0 ± 0.1 1.6 ± 0.1 n.d.
200 µg/mg OVA
Liquid (Liq) 90.7 ± 0.0 8.4 ± 0.0 0.9 ± 0.1 n.d.
Lyophilizate (Lyo) 90.6 ± 0.0 8.5 ± 0.0 1.0 ± 0.0 n.d.
Cryomilled powder (Cryo) 90.6 ± 0.0 8.3 ± 0.0 1.1 ± 0.0 n.d.
was detected. The processing of highly concentrated OVA formulation at 200 µg/mg did
not affect the monomer content negatively.
3.1.3 Subvisible particles and turbidity analysis
The visual appearance and the subvisible particle content of the placebo and OVA-loaded
vaccine was characterized by turbidity and light obscuration analysis upon reconstitution
of lyophilizate and cryomilled powder samples (Fig. II.1). Generally low particle counts
of 1, 000 − 2, 000 particles ≥ 1 µm /mL were detected for all liquid formulations prior to
lyophilization independent of the OVA target content. The particle counts of the placebo
formulation remained low after collapse lyophilization but increased to 4,000 particles/mL
≥ 1 µm upon cryogenic milling. Moreover, OVA-loaded formulations showed largely
concentration- and also processing-dependent particle counts upon collapse lyophiliza-
tion and cryogenic milling. Comparable particle counts of 6,410 particles ≥ 1 µm/mL
and 7,069 particles ≥ 1 µm/mL were detected for vaccine lyophilizates at 25 µg/mg and
200 µg/mg, respectively. However, major differences in the particle counts of low and high
dose vaccine formulations were observed after subsequent cryogenic milling. While the
25 µg/mg cryomilled powder showed 13,602 particles≥ 1 µm/mL, particle counts increased
significantly for the 200 µg/mg vaccine powder with values around 160,000-170,000 parti-
cles/mL in separate batches.
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Figure II.1: Subvisible particle counts of placebo and model vaccine with an OVA content
of 25 µg/mg and 200 µg/mg prior (Liq) and after processing by collapse lyophilization
(Lyo) and cryogenic milling (Cryo). The subvisible particle counts ≥ 1 µm (A), ≥ 10 µm
(B), and ≥ 25 µm (C) per mg dry vaccine and per mL reconstituted formulation are shown.
Furthermore, the turbidity of the reconstituted samples is provided (D).
The observations found for particles ≥ 1 µm were also confirmed by cumulative counts of
larger particles ≥ 10 µm and ≥ 25 µm. While a low number of particles was detected for
all liquid formulations and lyophilizates with values below 40 particles ≥ 10 µm/mL and
less than 5 particles ≥ 25 µm/mL, cryogenic milling led to increased particle counts in the
presence of OVA model antigen. Formulations with high dose OVA of 200 µg/mg exhibited
notably higher particle count of around 4,000 particles ≥ 10 µm/mL and 200 particles
≥ 25 µm/mL where as the low dose OVA vaccine remained relatively low with counts of
around 200 particles/mL and 8 particles/mL ≥ 10 µm and ≥ 25 µm, respectively.
The turbidity of placebo and OVA loaded formulations showed values depending on the
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OVA concentration and the processing step. In general, the turbidity in increased with
increasing OVA content. Lowest values around 0.5− 1 FNU were detected for the placebo
formulation prior and after two-step processing. The OVA vaccine at 25 µg/mg showed
turbidity values between 1−3 FNU, which increased with each processing step. As observed
by subvisible particle analysis, most pronounced differences in turbidity were detected for
the highly concentrated OVA vaccine after cryogenic milling. The liquid formulation and
vaccine lyophilizates at 200 µg/mg OVA provided values between of 3.6 FNU and 4.8 FNU,
whereas the turbidity was increased by cryomilling to up to 25 FNU.
The results suggest that the OVA model antigen concentration represents the major pa-
rameter that influences the subvisible particle quality attribute of the model vaccine for
needle-free intradermal powder injection. The most pronounced increase in subvisible par-
ticle counts and also turbidity was detected for the highly concentrated OVA cryomilled
vaccine powder at 200 µg/mg. In some cases, even visible particles were observed after
reconstitution. Despite the relatively high subvisible particle counts of the 200 µg/mg vac-
cine powder, regulatory requirements for subvisible particulates would be met, allowing a
maximum of 6,000 particles ≥ 10 µm and 600 particles ≥ 25 µm per container for parenteral
formulations [29, 30]. Moreover, with respect to vaccination, particles in the submicron
range could further enhance immune responses and serve as adjuvant for vaccination [31].
The vaccine preparation as a liquid formulation and collapse-dried lyophilizates showed
comparable results for the subvisible particle content independent of the antigen concen-
tration in a range of 0 − 200 µg/mg OVA. The cryomilling process increased the particle
content in all formulations. Empty milling tests (graphs not shown) revealed that about
48,000 particles ≥ 1 µm were generated per milling beaker, which represents the worst
case scenario of foreign matter that could be introduced into the 1.5 g vaccine powder pre-
pared by cryomilling. This means the cryomilling process itself could increase the particle
counts ≥ 1 µm by ∼ 3, 500 particles per milliliter of reconstituted formulation. Similarly,
around 20 additional particles ≥ 10 µm and less than 1 particle ≥ 25 µm would be found
after cryogenic milling of vaccine lyophilizates. Considering the particle counts detected
for particles ≥ 1 µm, this value is well comparable to the difference in particle counts
found for the placebo formulation after cryogenic milling. At an OVA content of 25 µg/mg
particle counts were higher, indicating that the increase in counts was caused not only
by foreign but also protein particles. This observation was even more pronounced for the
highly concentrated vaccine at 200 µg/mg OVA where the largest part of increase in sub-
visible particle counts was most likely generated by proteinaceous matter. Although this
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indicates changes in the physicochemical properties of the OVA model antigen at higher
concentrations, it remains to be assessed if this affects the immunological potency of the
molecule for vaccination.
3.1.4 Lyophilizate and cryomilled powder characteristics
The properties of model vaccine after processing by collapse lyophilization and cryogenic
milling were evaluated by residual moisture, specific surface area and true density analysis.
The residual moisture content of the model vaccine lyophilizates and cryomilled powder
with varying OVA content was determined by Karl-Fischer titration. In general, low mois-
ture contents between 0.4− 0.6 % were found for lyophilizates loaded with 0− 200 µg/mg
OVA (Fig. II.2). Processing by cryogenic milling increased the residual moisture content
to 0.6 − 1.1 %. Comparing the different OVA concentrations revealed a concentration-
dependent non-linear decrease of the residual moisture content most pronounced for the
cryomilled vaccine powder. In general, higher OVA concentrations lowered the residual
moisture content of the vaccine.
The results show that the highly-concentrated OVA vaccine at 200 µg/mg provided a
slightly lower moisture content compared to the 25 µg/mg OVA model vaccine. However,
the differences observed were small and good comparability of the OVA-loaded vaccine
at 25 µg/mg and 200 µg/mg can be assumed. Although the residual moisture content in-
creased after cryomilling, it remained below 1 % for the antigen-loaded vaccine formulations
and provided suitable properties for following studies.
The SSA of the vaccine lyophilizates and the cryomilled powder was determined by mul-
tipoint BET analysis. Figure II.2 shows that an increasing antigen concentration lowers
the SSA of the lyophilizates and cryomilled powder. Within a range from 0 − 200 µg/mg
OVA, the SSA decreased non-linear with increasing OVA concentration from 0.45 m2/g to
0.25 m2/g for the vaccine lyophilizates. Cryogenic milling upon lyophilization increased
the SSA of all formulations to 1.7 − 2 m2/g. The OVA antigen concentration showed
a less pronounced effect on the SSA of the cryomilled powder compared to the vaccine
lyophilizates.
In general, lower SSAs, which are generally associated with larger pores, reduces the speed
of secondary drying leading higher residual moisture contents [32]. However, in this study,
the highly concentrated OVA vaccine at 200 µg/mg exhibited the lowest SSA value but
also the lowest residual moisture content. This observation was likely driven by two effects.
First, as aforementioned, the aggressive lyophilization cycle applied in this study provided
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Figure II.2: Residual moisture content (bars), specific surface area (circles), and true
density (diamond) of model vaccine lyophilizates (Lyo) and cryomilled powder (Cryo)
without antigen (placebo) and with 25 µg/mg and 200 µg/mg OVA.
long primary and secondary drying times at a high temperature of +45 °C, leading to
complete drying for all formulations. Secondly, it has been reported that a higher protein
content leads to faster drying due to lowering of the cake resistance and results in reduced
residual moisture contents. It can be therefore assumed that the increase OVA antigen
concentration had a superior influence on the final moisture content compared to the
lyophizate pore structure.
The true density of the OVA vaccine was assessed by helium pycnometry. The results show
that the true density of the lyophilizates decreases slightly with increasing OVA concen-
tration (Fig. II.2). Placebo vaccine lyophilizates provided a density of 1.58 g/cm3 whereas
OVA-loaded lyophilizates exhibited values of 1.55 g/cm3 and 1.50 g/cm3 at concentrations
of 25 µg/mg and 200 µg/mg, respectively. The results show that the OVA concentration
provided a notable impact on the residual moisture content and SSA of the lyophilizates
and cryomilled powder. However, lower SSA values were not obtained due to densification
of the lyophilizate formulation at higher OVA concentrations but these were most likely
derived from differences in freezing and drying behavior during lyophilization. On the
other hand, an inferior effect of the OVA content on the true density was observed.
Previous studies at 25 µg/mg OVA using a ternary mixture of trehalose, mannitol, and
dextrane with 15 % solid content have found comparable results of with values of ∼ 1.5 %
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Figure II.3: XRPD patterns of placebo and model vaccine lyophilizates with 25 µg/mg and
200 µg/mg OVA.
moisture content of the cryomilled powder, 0.3 m2/g and 1.5 m2/g SSA of lyophilizates
and cryomilled powder, and a true density of the cryomilled powder around 1.5 g/cm3 [18].
Comparing the true density measurements of the lyophilizates in this study and the cry-
omilled powder in the previous study indicates that cryogenic milling did not notably affect
the true density of the vaccine. More likely, the formulation composition and, to a lower
extent, the lyophilization process impact the final SSA and density of the product [18].
The results obtained in this study at a high concentration of 200 µg/mg OVA were well
comparable to the placebo and low dose formulations used in this setup but also compared
to the previous study referenced above.
3.1.5 Characterization of excipient modification
The crystallinity of mannitol was investigated by X-ray powder diffraction (XRPD) and
DSC. The qualitative investigation of mannitol polymorphs by XRPD revealed that δ-
mannitol was formed by collapse lyophilization independent of the OVA content in the
range of 0 µg/mg to 200 µg/mg (Fig. II.3). The δ-modification of mannitol was confirmed
by a peak at 9.7 °2-Theta in all formulations. The absence of a peak at 17.9 °2-Theta
indicates that no mannitol hydrate was formed during lyophilization. The profiles suggest
that trehalose remained in the amorphous state during drying. Furthermore, the XRPD
profile did not change upon cryogenic milling for all formulations.
DSC analysis of the OVA vaccine at different concentrations revealed a comparable melting
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Figure II.4: DSC thermograms (A) of placebo and 25 µg/mg and 200 µg/mg OVA-loaded
vaccine lyophilizates (Lyo) and cryomilled powder (Cryo) and peak enthalpies (B) of the
second mannitol melting endotherm around 150-155 °C in dependence of the OVA vaccine
concentration.
profile for all formulations. The detected endothermic events occured in comparable tem-
perature ranges between 100 − 160 °C (Fig. II.4). Within this range, vaccine lyophilizates
showed overlapping thermal events between 90-145 °C and a distinct melting endotherm
around 150 − 155 °C. The peak enthalpy at 150 − 155 °C thereby decreased non-linear
with increasing OVA antigen concentration. No differences in the DSC profiles were ob-
served between vaccine lyophilizates and the cryomilled powder of the respective OVA
concentration.
Previous studies have reported an endothermic peak around 166 °C that is associated
with the melting of different modifications of mannitol, including the δ-modification [24,
33]. The δ-mannitol polymorph is a thermodynamically instable modification at ambient
conditions, with a relatively high kinetic stability [24]. This modification remains stable
upon mechanical stress and long-term storage [24]. In fact, cryogenic milling of the vaccine
lyophilizates did not change the mannitol modification of the vaccine formulations. Besides
that, heating at rates below 10 K/min induces the transition of δ-mannitol into the β-
modification, which consequently contributes to the endothermic melting of this mannitol
polymorph [24, 33].
The literature value of mannitol melting was confirmed by analysis of the pure crystalline
excipient used in this study, which showed a melting endotherm around 166 °C (data not
shown). The combined analysis of crystalline mannitol in combination with crystalline tre-
halose revealed a shifting of the mannitol melting endotherm towards lower temperatures
by up to 5 °C (data not shown). These findings suggest that the melting peak of crystalline
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mannitol within the multi-component formulations used in this study ocurred at a tem-
perature below 166 °C. It can be assumed that the endothermic peak around 150− 155 °C
was derived from the melting of crystalline δ-mannitol within the sample. The drop of
peak enthalpy with increasing OVA concentration would indicate a decrease of crystalline
content in the vaccine lyophilizates and cryomilled powder with increasing antigen content.
However, the analysis of additional OVA concentrations would be required to confirm this
hypothesis.
In the formulation composition used in this study, mannitol acted as a bulking agent,
leading to a stable lyophilizate cake and cryomilled powder. It can be expected that the
presence of a crystalline mannitol modification increases the density of the final product.
With the generation of kinetically stable δ-mannitol by freeze-drying it was possible to
take advantage of a good storage stability and increased density compared to amorphous
mannitol. It has to be noted that a higher OVA antigen content most likely reduced the
relative amount of crystalline mannitol in the sample, consequently reducing the density
(Section 3.1.4). However, the high comparability of measured density values at all OVA
concentrations from 0 − 200 µg/mg reveal that despite a lower degree of crystallinity, the
highly concentrated OVA vaccine provided suitable properties for needle-free intradermal
powder injection.
3.2 Long-term stability of the highly concentrated vaccine
3.2.1 Ovalbumin antigen stability
The long-term stability of the highly concentrated vaccine at 200 µg/mg OVA was evalu-
ated over a period of 12 months, storing model vaccine lyophilizates and cryomilled powder
at 2 − 8 °C, 25 °C, and 40 °C. The antigen stability during the long-term stability study
was evaluated by SE-HPLC and Western blot analysis. SE-HPLC results showed con-
stantly high monomer contents around 90 % for the lyophilizate and cryomilled powder
over 12 months storage at up to 40 °C (Fig. II.5). Similarly, the dimer and high molecular
weight species (HMWS) content remained constant around 8 − 9 % and 1 %, respectively.
Also, no formation of LMWS was detected by SE-HPLC over time. The total protein
recovery decreased slightly over a storage period of 12 months but stayed above ∼ 90 %
for all storage conditions.
The antigenicity of the protein after vaccine processing and storage at different conditions
was assessed by Western blot analysis. The Western blots of the vaccine formulation at
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Figure II.5: Relative OVA monomer, dimer, and oligomer composition (bars, left Y-axis)
and total protein recovery (symbols, right Y-axis) of the highly concentrated 200 µg/mg
OVA vaccine lyophilizates and cryomilled powder at stability study initiation (T0) and
after 12 months storage at 2 − 8 °C, 25 °C, 40 °C.
200 µg/mg OVA prior and after processing by lyophilization and cryogenic milling showed
up to five bands associated with the OVA antigen (Fig. II.6). The most pronounced band
was detected around 40 kDa associated to OVA monomer. Moreover, a distinct dimer
band of approximately 80 kDa as well as a trimer band of around 120 kDa were observed
above the OVA monomer. In some cases, further bands at higher molecular weights were
seen, however these were no longer clearly distinguishable. Besides higher molecular weight
species, an additional band was detected directly below the OVA monomer band. This
lower band exhibited a slightly lower molecular weight and showed higher mobility during
electrophoretic separation by SDS-PAGE. The low band provided a molecular weight below
40 kDa and was considered a fragment of the OVA monomer with maintained antigenicity.
Over a storage period of 12 months, comparable patterns of relative OVA composition were
detected for stored lyophilizates and the cryomilled powder. The antigenicity of the protein
during processing and storage was maintained. A slight increase in band intensity of the
OVA low molecular weight fragment was observed, however relative to the monomer band
intensity, the observed change was negligible. Furthermore, no differences were detected
between cold, ambient, and accelerated storage conditions.
The results obtained by SE-HPLC and Western blot analysis show that the OVA antigen
remained stable during 12 months storage at up to 40 °C. Unlike previous studies, which
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Figure II.6: Western blots of model vaccine lyophilizates (A) and cryomilled powder (B)
at 200 µg/mg OVA during 12 months storage at 2−8 °C, 25 °C, 40 °C. The bands detected
by Western blot analysis correspond to the OVA monomer (a), dimer (b), oligomers (c, d),
and lower molecular weight species (e). The latter were not detected by SE-HPLC.
observed a loss of antigenicity of influenza vaccine-loaded cryomilled vaccine powder after
6 months storage at 40 °C [15], the model antigen OVA used in this study maintained the
antigenicity over storage time and exhibited a comparable monomer, dimer, and oligomer
composition at all times.
3.2.2 Subvisible particles and turbidity analysis
The physicochemical stability of the vaccine lyophilizates and cryomilled powder with
200 µg/mg OVA was studied by light obscuration and turbidity analysis. As discussed in
section 3.1.3, the subvisible particle counts of the model vaccine at initial testing remained
constant prior and after collapse lyophilization with counts below 50 particles ≥ 1 µm per
mg dry vaccine (Fig. II.7). Cryogenic milling of the vaccine lyophilizates increased the
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Figure II.7: Cumulative subvisible particle counts ≥ 1 µm and turbidity of reconstituted
highly concentrated 200 µg/mg OVA vaccine lyophilizates (A, C) and cryomilled powder
(B,D) over 12 months storage at 2 − 8 °C, 25 °C, 40 °C.
subvisible particle content significantly to about 1,300 particles ≥ 1 µm/mg.
The storage of the vaccine lyophilizates and cryomilled powder at 2 − 8 °C, 25 °C, and
40 °C over 12 months revealed constant particle counts for lyophilizates and a decrease
in subvisible particles ≥ 1 µm for the cryomilled powder (Fig. II.7). Over a period of 12
months, the cumulative counts of particles ≥ 1 µm did not change in stored model vaccine
lyophilizates independent of the stoarge condition. For the cryomilled powder, on the other
hand, a slight decrease of particle counts ≥ 1 µm to approximately 500-1,000 particles/mg
was detected. Thereby, higher counts were found for cold storage whereas the storage at
an accelerated temperature of 40 °C led to lower particle counts. The difference in particle
counts observed after 12 months, was derived from a software update of the analytical
instrument and was not considered to reflect a real change in particle counts for the model
vaccine.
The cumulative counts of particles ≥ 10 µm and ≥ 25 µm showed values below 2 parti-
cles/mg vaccine for all samples (data not shown). No clear trends could be detected for
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larger particles over a storage period of 12 months at different conditions. Considering the
distribution of subvisible particles, it can be concluded that the main fraction of particles
found in the model vaccine were smaller than 10 µm and only a minor amount of larger
particles would delivered into the skin upon needle-free powder injection. Per vaccine dose
of 1 − 2 mg cryomilled vaccine powder a maximum of 4,000 particles in the micron size
range would be delivered into the skin.
The analysis of the sample turbidity showed a comparable trend over time as observed for
the subvisible particle counts. Higher turbidity values were generally associated with a
higher count of particles ≥ 1 µm and a decrease of turbidity over 12 months storage was
observed.
The decrease of subvisible particle counts and turbidity could be explained by intermolec-
ular changes, e.g. particle or aggregate ripening, within the dry formulation. It can be
assumed that over time, larger protein aggregates were formed which could not be de-
tected by light obscuration due to fast sedimentation, or by protein stability analysis, e.g.
SE-HPLC. Stress testing at elevated temperatures accelerated structural changes within
the dry vaccine, leading to higher amounts of insoluble OVA aggregates and lower particle
counts and turbidity values. Although this hypothesis was supported by decreasing par-
ticle counts, no increase in soluble aggregates could be detected by SE-HPLC or Western
blot analysis (Section 3.2.1). However, a slight decrease in total protein recovery was ob-
served, indicating a loss of protein by formation of insoluble OVA antigen aggregates in
the cryomilled powder. However it has to be noted that due to the generally high pro-
tein concentration after reconstitution around 30 mg/mL, the loss in protein by insoluble
particle formation might not be clearly detectable.
Considering the low number of particles that would be delivered by needle-free intradermal
powder injection and the generally low loss of soluble OVA antigen over 12 months, it
can be assumed that the model vaccine powder provided good storage stability at up to
40 °C. In general, slighlty superior stability was found for the model lyophilizates, indicated
by negligible changes in physicochemical quality attributes compared to the cryomilled
powder. Nevertheless, the results show that the vaccine powder provided suitable long-
term stability and was suitable to be stored up to 3 months at 2 − 8 °C in preparation of
the in vivo immunization study.
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3.2.3 Residual moisture analysis
The residual moisture of the 200 µg/mg OVA vaccine lyophilizates and the cryomilled
powder was analyzed by Karl-Fischer titration. At initial testing, the highly concentrated
lyophilizates and cryomilled powder exhibited a moisture content of 0.5 % and 0.7 %,
respectively. At cold storage conditions at 2−8 °C, the residual moisture content remained
stable over 12 months storage for the lyophilizates and increased minimally to 0.8− 0.9 %
for the cryomilled powder. With increasing storage temperature, the moisture content
increased over storage time to up to 0.8 % for the vaccine lyophilizates and up to 1.6 %
for the cryomilled powder, both stored at 40 °C.
The results show that the storage at higher temperature led to increased residual moisture
levels. Thereby, the cryomilled powder showed higher differences to the initial testing as
compared to the vaccine lyophilizates. In general, the residual moisture remained below
1 % for up to 6 months and below 2 % for up to 12 months storage at all conditions. The
generally low moisture content indicate good long-term stability of the model vaccine in
its primary packaging over a storage period of 12 months at up to 40 °C.
Figure II.8: Residual moisture contents of highly concentrated 200 µg/mg OVA vaccine
lyophilizates (A) and cryomilled powder (B) during 12 months storage at 2 − 8 °C, 25 °C,
40 °C.
3.2.4 Characterization of excipient modification
The stability of the mannitol excipient modification in the highly concentrated OVA vaccine
lyophilizates and cryomilled powder was evaluated by XRPD and DSC analysis. The
XRPD patterns of the dry samples prior and after storage for 12 months at 2−8 °C, 25 °C,
and 40 °C reveal a stable δ-mannitol modification over the entire storage time (Fig. II.9).
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Figure II.9: XRPD patterns of the highly concentrated 200 µg/mg OVA vaccine
lyophilizates and cryomilled powder at stability study initiation (T0) and after 12 months
storage at 2 − 8 °C, 25 °C, 40 °C.
The profiles of the lyophilizates and the cryomilled powder did not change over time and
exhibited a peak at 9.7 °2-Theta in all samples. This peak indicates the presence of δ-
mannitol, while the absence of a peak at 17.2 °2-Theta shows that no mannitol hydrate
was present in any sample. A slight increase in peak height could indicate the increase of
crystalline mannitol in the sample, assuming similar sample masses for XRPD analysis.
The amount of crystalline mannitol was studied by DSC. All lyophilizate and cryomilled
powder samples exhibited a similar DSC profile as discussed in section 3.1.5. Overlaid en-
dothermic events were detected in a temperature range between 90 °C and approximately
150 °C (Fig. II.10A). Dependent on the sample type and storage condition the endother-
mic melting shifted towards lower temperatures. The highest melting temperatures were
detected at the initial testing time point with minimally lower temperatures for the cry-
omilled powder. Over storage time and with increasing storage temperatures, the melting
onset shifted towards lower temperatures as indicated in figure II.10).
It can be assumed that the shifting of the melting temperatures was associated with the
increase in residual moisture content. As discussed in section 3.2.3, vaccine lyophilizates
showed inferior changes compared to cryomilled vaccine powders, particularly when stored
at elevated temperatures.
The DSC profiles also reveal minimal changes in the peak enthalpy of the second, single
melting endotherm between around 140 − 150 °C. Compared to initial values, the melting
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Figure II.10: DSC thermograms (A) of the highly concentrated 200 µg/mg OVA vaccine
lyophilizates and cryomilled powder at stability study initiation (T0) and after 12 months
storage at 2−8 °C, 25 °C, 40 °C and respective peak enthalpies (B) of the second mannitol
melting endotherm.
enthalpy increased slightly after 12 months storage of the lyophilizates and the cryomilled
powder. This could indicate a formation of crystalline mannitol over time. Although
recrystallization can affect the OVA antigen stability, no pronounced changes in protein
stability were detected by SE-HPLC and Western blot analysis (Section 3.2.1). The results
show that the storage of highly concentrated vaccine lyophilizates and cryomilled powder
was possible for 12 months at up to 40 °C.
3.3 Characterization of the vaccine-oil-adhesion on hydrophilic
and hydrophobic surfaces
3.3.1 Vaccine-oil adhesion on the device membrane
The needle-free powder injection device used in this study was composed of two main
parts, a pharmaceutical and pyrotechnical part, which were assembled directly before ap-
plication [15]. While the pyrotechnical part provided the trigger to actuate the device,
the pharmaceutical part was in direct product contact. Within the pharmaceutical part, a
defined area of a Ti membrane was coated with oily adjuvant followed by vaccine powder.
Upon actuation of the device, a high energy pulse was transferred from the Ti membrane
to the vaccine power, accelerating the powder particles to up to 500 m/s [15]. The vaccine
powder, which was coated homogeneously onto the membrane, was accelerated as particle
cloud through an orifice of approximately 1 − 2 cm towards the skin surface.
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For the loading of the device with vaccine powder, two main requirements had to be
balanced to optimize the device performance. First, appropriate fixation of the vaccine
powder was required to ensure reproducible loading, adherence of powder in alignment
with the orifice and to provide sufficient transportation stability. On the other hand, the
mixture used for vaccine fixation also needed to exhibit suitable properties to release the
particles upon device actuation. Besides that, the fixation mixture had to be biocompatible
and possibly serve as adjuvant for the simultaneous delivery of vaccine powder together
with the fixation mixture [20].
The adhesion of the vaccine powder on the Ti membrane of the powder injection device was
studied with different OVA loadings and oily mixtures and pure components for fixation.
Approximately 0.1 − 0.5 mg oil was coated onto an area of 20 mm x 10 mm on the Ti
membrane followed by loading of the vaccine powder. Using this technique, approximately
0.8 − 2.5 mg vaccine powder could be attached to the Ti membrane. The relative powder
adhesion was determined as the measured powder loading after drop testing relative to the
initial vaccine powder loading Qm/m0 (%).
After completion of the drop test, the amount of vaccine powder that remained on the Ti
surface was notably reduced (Fig. II.11). Depending on the oily mixture or component
used for fixation, the adhesion of the vaccine powder lowered to varying extents. The oily
mixture F1, based on the relative composition of the oily components of the adjuvant AS03
(Tab. II.1), showed a relatively low reduction of attached powder with 45−65 % remaining
vaccine. Comparably high values around 60 − 70 % were found for the oily mixture F1*,
stabilized with BHA, as well as the pure components α-tocopherol and polysorbate 80.
Interestingly, although insufficient spreading of α-tocopherol on the Ti membrane was ob-
served, the oil provided suitable properties to retain the vaccine powder on the membrane
during drop tests. Oily mixture F2, with half-concentration α-tocopherol and polysor-
bate 80 relative to F1, showed reduced powder adhesion compared to oily mixture F1 with
about 25 − 50 % remaining vaccine after the drop test. Similarly, intermediate adhesion
was found using highly liquid paraffin for vaccine powder fixation. The lowest particle
retention on the Ti membrane was provided using the oily mixture F3 and the pure com-
ponents squalene, and squalane with a particle adhesion below or equal to ∼ 20 %. The
oily mixture F3 was composed of a low content of 0.1 % α-tocopherol and pure squalene,
in absence of additional polysorbate 80.
The OVA concentration of the model vaccine powder did not exhibit a clear effect on
the adhesion properties on the Ti membrane. The powder adhesion differed only slightly
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between the placebo and 25 µg/mg and 200 µg/mg OVA-loaded vaccine powder and no
clear trend could be detected. However, it has to be noted that the amount of vaccine
powder coated onto the membrane largely affected the percentage of remaining vaccine
powder. Generally, higher initial coating increased the relative loss upon drop testing. It
can be assumed that the embedding of particles in the oily liquid was superior with a
lower number of particles. For this reason large standard deviations could be observed in
some samples. Furthermore, it is worth noting that a partial dissolution of vaccine powder
in the components, e.g. polysorbate 80, could have affected the adhesion measurements
due to retention of dissolved vaccine. However, despite the mentioned limitations, clear
differences between the oily liquids could be detected.
The results show that the oily mixture F1 provided suitable properties for the fixation of the
highly concentrated model vaccine powder for the in vivo immunization study. Compared
to other mixtures and components, the drop tests revealed good reproducibility and a
relatively high attachment of the vaccine powder on the Ti device membrane. Using this
oily mixture, the pharmaceutical device part can be loaded and transported safely without
the loss or dislocation of the vaccine powder within the device. Using highly liquid paraffin
as non-adjuvant oil, lower vaccine powder adhesion was detected compared to the oily
mixture F1. This indicates lower stability within the device during transportation and
highlights the need of gentle handling for the in vivo study.
3.3.2 Contact angle and work of adhesion of different oily mixtures
To evaluate the differences between the oily formulations and their ability to ensure particle
adhesion on the Ti membrane, the surface tension and contact angle of the oily liquids was
studied by pendant and sessile drop analysis. Comparable surface tensions were found
for the oily mixtures F1 − F3 with values around 31 − 35 mN/m (Tab. II.4). The main
component of the oily mixtures, squalene, showed a surface tension of 34.1 mN/m, whereas
the saturated equivalent, squalane, provided a slightly lower value of 28.4 mN/m. On the
other hand, α-tocopherol and polysorbate 80 provided slightly higher surface tensions of
36.6 mN/m and 35.2 mN/m, respectively.
Besides the surface tension, the contact angles of the oily mixtures on the Ti device mem-
brane were studied in comparison to hydrophilic glass and hydrophobic PDMS reference
surfaces. Figure II.11 shows that the contact angles of the oily mixtures were relatively
small on the Ti membrane and close to the values detected for the glass surface. Larger
contact angles were detected on the PDMS surface. This indicates that the Ti membrane
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Figure II.11: Relative powder adhesion at different OVA concentrations on the Ti mem-
brane using different adhesion oils and mixtures (A) and the calculated work of adhesion
and measured contact angle of the oily liquids on a hydrophilic glass surface, the Ti mem-
brane, and hydrophobic PDMS (B).
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provided hydrophilic surface properties rather than hydrophobic interactions. Small con-
tact angles indicate high interaction of the oily liquids with the Ti membrane, which could
lead to superior spreading of the liquid and would thus be beneficial for vaccine powder
adhesion.
Whereas relatively low contact angles of the oily liquids on the Ti membrane of 11.5° and
14.7° were detected for mixture F1 and highly liquid paraffin, slightly higher values in the
range of 15°−20° were found for the oily mixtures F1*, F2, F3, squalene, and squalane
(Fig. II.11). α-Tocopherol and polysorbate 80, which already provided the highest surface
tension, also revealed the largest contact angles on the Ti surface.
Based on the surface tension and contact angle of the oily liquids, the work of adhesion Wls
was calculated using the Young-Dupré equation (Eq. II.1), where σl is the surface tension
of the liquid and Θ is the contact angle of a sessile drop on the solid surface [34].
Wls = σl(1 + cosΘ) (II.1)
The work of adhesion Wls represents the work required to separate a drop from a clean,
solid surface and was evaluated based on the surface tension and contact angle of the oily
liquids (Eq. II.1) [35]. Considering this equation, the work of adhesion Wls reaches the
maximum interaction value at a contact angle of 0° and its lowest value at 180°. The work
of adhesion thereby constitutes of polar and disperse interactions of the liquid with the
solid surface.
For the oily liquids tested in this study, the work of adhesion was generally well comparable
for all mixtures and pure components. No clear differences could be detected. The oily
mixture F1 showed the highest work of adhesion with a value of 82 mN/m. The mixture
provided a relatively strong interaction exhibiting an intermediate surface tension and low
contact angle on the Ti membrane. On the other hand, paraffin showed a slightly lower
work of adhesion around 70 mN/m. Calculations of disperse and polar interactions using
the Owen-Wendt-Rabel-Kaelble equation (Eq. II.2) revealed a predominant disperse type
of interaction for all oily liquids tested (data not shown) [36–38].
σl(1 + cosΘ)
2
=
√
σpl ∗ σ
p
s +
√
σdl ∗ σds (II.2)
The comparison of the presented results with the vaccine powder adhesion revealed no
clear trend in relation to the surface tension, contact angle, or work of adhesion of the oily
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Figure II.12: Relative powder adhesion upon drop testing plotted against the viscosity of
different adhesion liquids and mixtures in logarithmic scale.
liquids. For the pure components, minimally superior vaccine adhesion was detected for the
oily liquids with higher surface tension, e.g. α-tocopherol and polysorbate 80. However,
paraffin with the lowest surface tension provided superior particle adhesion compared to
squalene or oily mixture F3.
It has to be noted that the powder adhesion as well as the contact angle measurements
depend on multiple parameters. The investigation of the oily liquids mainly focused on the
interaction with the Ti membrane. However, for powder adhesion, the interaction of the oily
mixtures and the vaccine needs to be considered similarly. Besides that, the contact angle
measurements were strongly influenced by measurement time, lower limit of detection,
surface tension, and the viscosity of the liquid sample. The Pelofsky equation reveals a
correlation of surface tension with molecular mass and viscosity of a liquid (Eq. II.3), where
A′ is equal to σl at infinite viscosity, C is a non-dimensional constant, M the molecular
weight (g/mol), κ the thermal conductivity (cal/s cm2), R the gas constant (1.986 cal/mol
K), and η the dynamic viscosity of the liquid (cPs) [39].
σl = A
′ exp
(
C
R
Mκ
η
)
(II.3)
The equation underlines the interconnection of multiple parameters in surface tension
and surface interaction measurements. As byproduct of this study, a correlation between
the powder adhesion and the oily liquid viscosity was found (Fig. II.12). Literature-based
viscosity values were plotted relative to the powder adhesion, revealing the following rela-
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Table II.4: Overview of the relative powder adhesion as average of all measurements per-
formed for each oily liquid and the respective liquid surface tension (σl) measured by
pendant drop analysis and viscosity values as provided by the supplier. The theoretical
viscosity of the oily mixtures F1 − F3 was calculated relative to the composition provided
in Table II.1.
Formulation Adhesion average Surface tension Viscosity
Qm/m0 σl ηLit
[%] [mN/m] [cPs]
F1 54.7 33.9 1900
F1* 68.3 32.1 1900
F2 34.6 35.1 955
F3 12.9 30.6 15
Squalene 22.5 34.1 15
Squalane 14.7 28.4 29
D/L-α-Tocopherol 63.7 36.6 4200
Polysorbate 80 71.3 35.2 425
Paraffin 27.5 26.0 52.5
PEG 400 41.6 36.6 118
PEG 600 54.8 n.d. 277.5
tionship (R2=0.83):
Qm/m0 ∼ ln
(
η
η0
)
(II.4)
The viscosity of the oily mixtures was calculated based on the relative composition of
the pure components (Tab. II.4). Besides viscosity, further factors are likely affecting the
vaccine powder adhesion. Within this study, all oily liquids showed comparable surface
tension and contact angles on the Ti surface. However, it can assumed that these parame-
ters would also influence the adhesion strength. Further studies are needed to support the
presented finding.
Considering the in vivo immunization study, the contact angle measurements and the work
of adhesion reveal suitable properties for the loading of the needle-free powder injector us-
ing mixture F1 as oily adhesive. Based on the oily components of the AS03 adjuvant,
the simultaneous delivery of the oily mixture together with the vaccine powder should
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potentiate the immune response upon i.d. delivery. Notably, the low amount of oil below
0.5 mg, which can be coated onto the Ti device membrane, will likely limit the adjuvan-
tation. The effect of the adjuvant oil therefore requires close evaluation during the in vivo
immunization study.
3.4 Stability of the oily adjuvants in contact with model vaccine
3.4.1 Calibration curve and recovery test
The main objective of this part of the study was to evaluate the oil stability when stored
in direct contact with the highly concentrated vaccine and to ensure suitable stability for
the in vivo immunization study. For this purpose, the relative composition of the oily
adjuvant components of AS03 was varied according to table II.1 to evaluate the influence
on the oil stability relative to the target composition F1. Higher doses of tocopherol have
been reported to lower the stability of unsaturated triglycerides [40], an effect which could
also be expected with squalene, one unsaturated component of AS03. For this reason, oily
mixtures with lower α-tocopherol contents compared to the target composition F1 were
included in this study (F2, F3).
It has to be mentioned that α-tocopherol in AS03 emulsions is considered as essential
adjuvant for vaccination, with lower α-tocopherol contents being linked to reduced adjuvant
potency [41]. Consequently, composition F1 and to unknown extent F2 could be expected
to act as synergistic adhesion and adjuvant mixture of squalene and α-tocopherol.
The addition of polysorbate 80 was required to ensure a spreading of the oily liquid on
the Ti membrane. Preliminary tests have shown that the addition of α-tocopherol to
squalene, in absence of polysorbate 80, notably reduced the spreading of the liquid on the
Ti device membrane. To ensure a homogeneous loading of the vaccine powder onto the Ti
membrane, the addition of polysorbate 80 was required despite the known oxidation-related
destabilizing effect of polysorbate. No polysorbate 80 was required for the spreading of the
oily mixture F3 with only 0.1 % α-tocopherol as antioxidant additive in the oily mixture.
To assess the effect of antioxidants on the oil stability, one mixture containing 0.02 % BHA
as stabilizing antioxidant (F1*) has been included in this setup. In case high amounts
of tocopherol would accelerate the oil degradation, additional stabilization using alterna-
tive antioxidants such as BHA could improve the overall mixture stability. Furthermore,
squalane was included in this study to represent the saturated alternative to its’ unsatu-
rated chemical equivalent squalene.
78
3 Results and Discussion
The stability of the oily liquids as provided in table II.1 as well as squalane was studied by
GC-MS analysis. Either the oily liquid alone or coated with vaccine powder was exposed
to UV/Vis light or thermal stress. The recovery of the oily main components squalene,
squalane, and α-tocopherol was determined upon ether extraction by GC-MS relative to
5α-cholestane as internal standard.
Calibration curves of all components tested were prepared within a concentration range
20 % below the lowest and above the highest expected concentration. For all components
calibration curves with good accuracy and precision were obtained (R2 > 0.99).
Furthermore, a recovery study was performed to evaluate the suitability of the method
to assess the oil stability. For this purpose, samples at the target oil content and ±20 %
were prepared, with and without vaccine powder. Ether extraction was performed and the
samples were analyzed by GC-MS. Squalene showed good recovery between 86−100 % for
all oily mixtures. Squalane provided second highest recovery values between 78 − 101 %.
In general, recovery rates between 80−120 % were considered acceptable for the analytical
approach. The recovery evaluation shows that the vaccine powder did not notably affect the
extraction and quantification of squalene or squalane within the utilized sample preparation
conditions.
Beside these oils, the recovery of α-tocopherol was highly dependent on the oil composition
and sample preparation. For the oily mixtures F1, F1*, and F2, the α-tocopherol recovery
was between 63− 121 %. Compared to the squalene and squalane recovery the analysis of
α-tocopherol provided lower precision. Moreover, exceptionally poor recovery was obtained
for the oily mixture F3 with only 0.1 % tocopherol content. Whereas 63 − 92 % recovery
was found for oil samples alone, an average of only 0.3 % was achieved for the sample
preparation with vaccine powder. It can be assumed that the low amount of α-tocopherol
adsorbed to the vaccine powder and could not be fully extracted for quantification. The
evaluation of the oil stability was therefore limited to squalene and squalane analysis and
the quantification of α-tocopherol for F1, F1*, and F2 only.
3.4.2 UV/Vis stress test of the oily adjuvant
The UV/Vis stress test was performed to evaluate the stability of different oil compositions
and oil components and to assess the impact of the highly concentrated protein-loaded vac-
cine powder on the oil stability. UV/Vis light exposure significantly reduced the squalene
recovery in F1-F3 compared to the samples shielded from light, which only underwent
minimal thermal stress (Fig. II.13). Notably, no significant differences between light expo-
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Figure II.13: Recovery of squalene/squalane (A) and α-tocopherol (B) from different oily
liquids without or in direct contact with protein-loaded vaccine powder after UV/Vis light
exposure or shielded from light (Two sample t-test, α = 0.05, n=6, * p < 0.05, ** p < 0.01,
*** p < 0.001).
sure and shielding was detected for squalane-containing samples. This indicates a superior
stability of squalene over its’ unsaturated chemical equivalent, squalene, even in presence
of an antioxidant.
On the other hand, a trend of decreasing squalene recoveries upon UV/Vis exposure were
associated with lower contents of α-tocopherol. A significantly lower recovery of ∼ 50 %
was detected for the mixture F3 containing only 0.1 % tocopherol. The results suggest
that higher tocopherol contents improved the stability and recovery of squalene under
UV/Vis light. Light exposure led to the degradation of α-tocopherol, as confirmed by very
low recoveries around 10 % remaining tocopherol in the mixtures F1* and F1*. For oily
mixture F2, the α-tocopherol content was below the limit of quantification after UV/Vis
exposure. It can be therefore expected that squalene is stabilized by α-tocopherol under
UV/Vis light and the oil stability improves with increasing α-tocopherol content.
Besides the influence of the oil composition on the oil stability, the results show that the
vaccine powder contact did not influence the oil stability negatively (Fig. II.13). In fact,
upon UV/Vis exposure, the squalene recovery was significantly higher for the formulations
F1* and F3 when in direct contact with the protein-loaded vaccine powder. An expla-
nation for these findings could be a shielding effect that the vaccine powder provided,
consequently influencing the oily liquid stability. The white color of the powder absorbs
distinct wavelengths of the visible light, could thus affecting the light inferference with
the oily components. For the samples shielded from UV/Vis light, no effect of the vac-
cine powder on the squalene, squalane, or tocopherol recovery was detected. Therefore it
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can be concluded that the increased squalene recovery in samples after UV/Vis light was
not attributed to an enhanced extraction efficiency but due to the stabilizing effect of the
protein-loaded vaccine powder itself.
3.4.3 Long-term and thermal stability of the oily adjuvant
The long-term oil stability was evaluated after 3 and 6 months storage at 2 − 8 °C, 25 °C,
and 40 °C. Figure II.14 shows the squalene, squalane, and α-tocopherol recoveries of the
different oily mixtures stored without or in direct contact with the highly concentrated
vaccine. The recovery of squalene and α-tocopherol in all oil mixtures remained relatively
stable for up to six months storage at 2 − 8 °C. With increasing storage temperature, the
squalene recovery decreased notably for all oily mixtures as well as pure squalane. Simi-
lar observations could be made for the recovery values of α-tocopherol under accelerated
storage condition.
Following 3 months storage at 40 °C, about 80 − 90 % squalene/squalane was recovered
from the sample. On the other hand, the tocopherol recovery was dependent on the oil
composition, showing lower recovery values around 55 % after 3 months for mixture F2.
Interestingly, the oily mixture F1* stabilized with 0.02 % BHA showed higher squalene
recoveries after 3 months compared to the original composition F1 for all storage conditions.
After 6 months storage, differences in the squalene and α-tocopherol recovery of the mix-
tures F1-F3 could be noticed. A slight trend of decreasing stability associated with lower
concentrations of α-tocopherol was observed. Generally, a reduction in squalene recovery
was also associated with a loss in α-tocopherol. The most pronounced difference was de-
tected for the oily mixture F3 that provided a notably lower squalene recovery around 40 %
after 6 months storage at 40 °C without vaccine powder. On the other hand, the recovery
was significantly increased when the same oil mixture was stored in direct contact with the
protein-loaded vaccine powder.
Generally, it was noticed that the storage stability of the oily mixtures and components
increased in contact with vaccine powder. Higher squalene, squalane, and α-tocopherol
recoveries were detected for a striking majority of the samples. For several conditions,
statistically significant higher recoveries were found. This indicates that the vaccine powder
most likely exhibits a stabilizing effect on the oily mixtures under UV/Vis exposure as well
as thermal stress.
It can be summarized that higher contents of α-tocopherol and the presence of protein-
loaded vaccine powder improved the stability of the oily adjuvant mixture. The results
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Figure II.14: Recovery of squalene/squalane (A) and α-tocopherol (B) from different oily
liquids stored without (light grey) or in direct contact with highly concentrated protein-
loaded vaccine powder (dark grey) for 3 and 6 months at 2 − 8 °C, 25 °C, and 40 °C (Two
sample t-test, α = 0.05, n=6, * p < 0.05, ** p < 0.01, *** p < 0.001).
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also indicate a beneficial effect of BHA as additional antioxidant, however further studies
to fully evaluate a possible effect including other antioxidants remain to be conducted.
Besides that, the loading and storage of the oily adjuvant mixture F1 and the vaccine
powder is feasible. A storage for up to 3 months at 2 − 8 °C can be readily supported
from the oil stability perspective. However, further investigations are needed to assess the
vaccine powder and antigen stability during storage in contact with the oily mixture.
For the in vivo immunization study the oily mixture F1, based on the oily components of
squalene-based AS03, was used as oily adhesive with adjuvant properties. Notably, other
oily components with suitable adhesion properties could be used for the vaccine powder
loading onto the device. Squalane could represent a suitable alternative to its’ unsaturated
equivalent, squalene, providing adjuvant potency and enhanced chemical stability due to
the fully saturated structure.
3.5 In vivo immunization study with a highly concentrated vac-
cine administered by powder injection
3.5.1 Evaluation of vaccine properties for needle-free powder injection
Highly concentrated OVA vaccine was prepared under aseptic conditions using endotoxin-
low excipients. All preparation processes that required open product handling were per-
formed under LAF. One exception was vaccine powder sieving and aliquotation, which was
performed under dry nitrogen atmosphere to avoid moisture uptake by the vaccine powder.
The cryomilled vaccine for in vivo immunization with a concentration of 200 µg/mg OVA
as well as the OVA-AS03 emulsion were prepared using OVA grade VII as model vaccine
with high purity and low endotoxin content.
The highly concentrated OVA model vaccine used for immunizaton was characterized us-
ing selected methods (Tab. II.5). No changes in lyophilizate characteristics were detected
considering the residual moisture, SSA, XRPD profile or DSC curves (data not shown).
A higher monomer content and reduced oligomer contents were detected for the OVA
grade VII vaccine compared to the lower grade OVA (Tab. II.5). Similar to the obser-
vations in section 3.1.2, cryomilling induced the formation of a small amount of HMWS.
Furthermore, slightly increased subvisible particle counts, but comparable turbidities com-
pared to the results discussed in section 3.1.3 were detected.
The endotoxin content of the highly concentrated OVA vaccine powder was analyzed us-
ing a chromogenic LAL assay. Low values of 31.6 EU/mg vaccine, 35.9 EU/mg, and
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Table II.5: Results of SE-HPLC, subvisible particles, residual moisture, and SSA analysis of
the placebo and highly concentrated model vaccine used in the in vivo study, prepared with
of target content of 200 µg/mg OVA grade VII. Subvisible particle and turbidity analysis
was restricted to lyophilizates only due to material restrictions. (n.a.= not analyzed, n.d.=
not detected)
Analysis Placebo 200 µg/mg OVA
(Lyo) (Lyo) (Cryo)
SE-HPLC
Monomer [%] - 96.5 ± 0.0 96.3 ± 0.1
Dimer [%] - 3.4 ± 0.0 3.5 ± 0.0
HMWS [%] - n.d. 0.2 ± 0.0
LMWS [%] - n.d. n.d.
Subvisible particles
Particles ≥ 1 µm/mL 1, 448 9, 997 n.a.
Particles ≥ 10 µm/mL 6 10 n.a.
Particles ≥ 25 µm/mL 1 2 n.a.
Turbidity [FNU] 2.9 1.7 n.a.
Residual moisture [%] 0.6 ± 0.0 0.4 ± 0.0 n.a.
SSA [m2/g] 0.41 0.19 n.a.
63.1 EU/mg were found for the liquid 200 µg/mg OVA formulation prior processing and
after lyophilization and cryomilling, respectively. The results suggest a cryomilling-related
increase of endotoxins in the vaccine. However, it remains unclear whether this increase
was induced by sample preparation variability or processing-dependent introduction of en-
dotoxins. Considering an applied dose of 1 mg vaccine powder per needle-free injection, the
endotoxin levels of the highly concentrated vaccine were within Pharmacopoeial require-
ments for influenza vaccine (split virion) allowing a maximum of 100 EU per dose [42, 43].
In comparison, 732 EU endotoxins per mg OVA were detected for the model antigen grade
V. No detectable amounts of endotoxins have been found in the liquid placebo formula-
tion prior lyophilization and cryogenic milling. It can be therefore assumed that the final
endotoxin content of the placebo vaccine powder was within Pharmacopoeial limits.
To sum up, the placebo and the highly concentrated vaccine with a concentration of
200 µg/mg OVA provided suitable properties and quality for intradermal administration
84
3 Results and Discussion
using the needle-free powder injection device.
3.5.2 Compatibility of the liquid ovalbumin-AS03 emulsion vaccine
Besides the model vaccine for needle-free powder injection, the compatibility of the OVA
liquid vaccine with the AS03 emulsion was tested. The adjuvant AS03 is a liquid emulsion
with a milky-white appearance and was used for i.m. vaccination in 1:1 dilution with
the Pandemrix® influenza vaccine. For the vaccination of an adult, usually 2.5 mL of
subunit vaccine is mixed with 2.5 mL adjuvant emulsion, providing an absolute adjuvant
dose of 10.69 mg squalene, 11.86 mg α-tocopherol, and 4.86 mg polysorbate 80 [21]. This
procedure was adapted to study the compatibility with OVA.
The visual and microscopic inspection of the antigen-adjuvant mixtures gave no signs of
reduced quality of the vaccine emulsion (data not shown). Furthermore, the hydrodynamic
diameter measured by dynamic light scattering (DLS) was comparable for AS03 emulsion
diluted with PBS and 0.8 mg/mL OVA with values of around 164 nm (PDI= 0.09) and
165 nm (PDI=0.09), respectively. Although the analysis of the OVA-AS03 emulsion was
not feasible by SDS-PAGE and Coomassie blue staining due to emulsion-related blurring of
bands, Western blot analysis revealed a profile comparable to OVA standard as discussed
in section 3.2 (data not shown).
The liquid OVA vaccine for i.m. injection with a concentration of 0.8 mg/mL provided
and endotoxin content of 107 EU/mL and 79.1 EU/mL for the immunization on day 0 and
14, respectively. Considering the subsequent 1:1 dilution with presumably endotoxin-free
AS03 adjuvant emulsion and the administration of 0.5 mL, the endotoxin levels were below
the Pharmacopoeial limits [42, 43].
The liquid vaccine for i.m. injection in the positive control group C exhibited suitable
properties and quality for the use in the in vivo study.
3.5.3 Characterization of the powder injection site
The in vivo immunization study evaluating vaccination by needle-free powder injection was
performed in piglets. Due to the device dimensions and the employed approach of particle
administration, this study would not have been feasible with smaller animal species, e.g.
mice. Furthermore, it has been reported that pig skin represents a well suitable model
for human skin [44–46]. Since pig skin reportedly exhibits a thicker SC [44] compared to
humans, piglets with a maximum age of seven weeks at the time of study initiation were
included to maximize similarity to human skin.
85
II. Needle-free powder immunization with a highly concentrated model vaccine
Table II.6: Theoretical penetration depths of model polystyrene (PS) particles and (FITC)-
loaded vaccine powder, calculated by equations II.5-II.7 based on a model used by Kendall
et al. [14]. The particle velocities and in vivo penetration depths, as well as the PS
particle density and diameter were taken from [15]. Experimental penetration depths were
obtained using PS particles and FITC-loaded vaccine powder with particle radii of 21 µm
and 10-40 µm, respectively.
Particle type ρp rp vi vi,ve dp,calc dp,in vivo
[g/cm3] [µm] [m/s] [m/s] [µm] [µm]
PS particles 1.1 10 516 294 23 − 38 n.d.
21 518 395 47 − 81 50 − 120
30 521 433 70 − 121 n.d.
FITC-loaded 1.55 10 526 354 33 − 55 n.d.
powder 25 526 449 82 − 142 20 − 120
40 526 476 131 − 229 n.d.
In a preliminary study, which was actively supported by myself, the particle penetration
into pig skin was assessed in vivo [15]. Histological images of skin sections upon needle-free
powder injection of 40 µm polystyrene (PS) model particles or model vaccine loaded with
fluorescein isothiocyanate (FITC) revealed an intradermal deposition below the SC in the
epidermal and upper dermal layer.
A theoretical evaluation of the penetration depth (dp) by the model used by Kendall et
al. matched well with the experimentally obtained data (Tab. II.6) [10, 14]. Assuming
a successful breaching of the SC, the velocity of the particles at the border to the viable
epidermis (vi,ve) was calculated using eq. II.5. Based on the obtained particle velocity, the
penetration depth into the viable epidermis (dve) and absolute penetration depth (dt) was
calculated (eq. II.6 and eq. II.7).
vi,ve =
√(
v2i +
6σsc
ρsc
)
e
−3ρsctsc
4ρprp − 6σsc
ρsc
(II.5)
dve =
4ρprp
3ρve
[
ln
(
ρvev
2
i,ve
6σve
+ 1
)]
(II.6)
dt = tsc + dve (II.7)
86
3 Results and Discussion
The calculations were performed assuming a ballistic yield stress of the SC (σsc) of 170 MPa
as reported at ambient temperatures [14], a density (ρsc) of 1500 kg/m
3 [47] and a thickness
(tsc) of 10.9 µm [14, 48]. The properties of the viable epidermis were 2.2 MPa and 10 MPa
as lower and upper limits of the yield stress of the viable epidermis (σve) [14, 49, 50] and
1150 kg/m3 for the tissue density (ρve) [47]. The density (ρp) and radii (rp) of the PS
particles as well as the particle impact velocities (vi) were from [15]. For the model vaccine
powder, the density discussed in section 3.1.4 and the nominal particle size described in
2.2.1 were used for calculations.
The calculations show that the particle penetration depth increases with increasing particle
density, radius, and velocity. Although it has been reported that the particle acceleration
and velocity decrease with increasing density and radius for a different type of needle-
free powder injector [51–53], no similar relationship was observed for the device used in
this study (Tab. II.6) [15]. Nonetheless, the previously used theoretical prediction of the
penetration depth [14], is expected to hold for this study.
During penetration of the SC, the particle velocity decreases. This effect is most pro-
nounced with decreasing particle size and density. If the velocity is sufficiently high, the
particle penetrates into the viable epidermis, which exhibits lower mechanical strength
compared to the SC. For the PS particles, penetration depths between 50 − 120 µm were
observed, which is close to the theoretically predicted value of 47 − 81 µm (Tab. II.6).
The relatively high distribution of penetration depth may potentially originate from high
particle payloads [50].
For the FITC-loaded vaccine powder with particle sizes in the range of 20−80 µm, compara-
ble penetration depths between 20 − 120 µm were observed in vivo (Tab. II.6). Assuming
full integrity upon particle impaction and penetration into the skin tissue, penetration
depths between 33 − 223 µm were predicted. Whereas lower penetration was expected for
smaller particles, a larger diameter of 80 µm could potentially facilitate a penetration as
deep as 223 µm. However, it remains unclear whether the sugar-based vaccine particles
remain intact upon contact with the skin. More likely, the size of the particle decreases by
breakage upon impaction and partial dissolution during tissue penetration, consequently
lowering the effective particle velocity and leading to lower penetration depths.
As discussed in the previous paragraphs, the microscopic penetration of particles into
the SC agrees well with theoretical predictions and is thus reasonably well understood.
Considering potential medical applications, a macroscopic assessment of the administration
side is also of major relevance and will be addressed in the following.
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Figure II.15: Exemplary photographs of the powder injection site of study group A on
day 0 directly after vaccine administration and 5 min, 1 d, and 7 d post administration.
Furthermore, administration site of the booster powder injection on day 14 on the same
study animal. Images used in [15]
Four different groups were studied in the the in vivo immunization study including three
groups using needle-free powder injection for intradermal vaccine delivery (Tab. II.2, p. 54).
For the needle-free powder injection, two main aspects were assessed: The impact of the
adjuvant adhesive and the antigen loading. Placebo vaccine powder and paraffin without
known adjuvant activity, administered by needle-free powder injection, served as negative
control (A). Two verum groups used 200 µg/mg OVA vaccine powder coated onto the device
using paraffin (B) or oily mixture F1 with the relative composition of the oily ingredients
of AS03 (C). The outcome of the powder injection groups was compared to a positive
control (D) using an i.m. injection of a OVA AS03-adjuvanted liquid vaccine.
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Figure II.16: Exemplary photographs of the powder injection site of study group A on
day 0 directly after vaccine administration and 5 min, 1 d, and 7 d post administration.
Furthermore, administration site of the booster powder injection on day 14 on the same
study animal. (Images used in [15])
The macroscopic evaluation of the application sites gave no signs of severe tissue damage
after needle-free powder injection (Figs. II.15, II.16, II.17). The pig skin prior injection
had a pink, healthy appearance. Directly after powder administration, a thin powder layer
was observed on the skin surface, maintaining normal skin appearance. Within 5 min,
the administration site developed diffuse purpura and a dot-shaped central lesion for some
animals. These minor bleedings were mainly observed in the superficial skin below the
skin surface. The intensity of purpura was not related to specific groups but occurred to
variable degree. Notably, powder injection on day 14 affected the skin to a lesser extent.
Histological evaluation showed no signs of severe or permanent tissue damage at the end
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Figure II.17: Exemplary photographs of the powder injection site of study group B on
day 0 directly after vaccine administration and 5 min, 1 d, and 7 d post administration.
Furthermore, administration site of the booster powder injection on day 14 on the same
study animal. (Images used in [15])
of the 28 days study.
The observations suggest a successful intradermal delivery of the vaccine powder for all
powder injection groups. However, it has to be mentioned that a distinct, unknown amount
of vaccine was not deposited in the skin but remained on the surface. Notably, confirmatory
studies revealed that only a limited number of particles was found to penetrate into the
tissue whereas the larger amount of ∼ 75 % remained on the excised pig skin surface [15].
To maximize the chances of intradermal uptake of residual vaccine formulation after skin
surface disruption by powder injection, a patch was used to cover the administration sites
for a couple of hours. In literature, alternative options to increase the intradermal de-
livery involve the mechanical weakening of the skin barrier by elevated temperatures and
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humidities [14], or by skin microporation [54].
The intracutaneous bleedings, which were visible one day after powder injection, disap-
peared completely within 7 days. This indicates a fast healing of the tissue damage in-
duced by powder injection. It has been discussed that certain tissue disruption can serve
as physical adjuvant supporting the induction of immune responses [55]. Therefore, the
initial tissue damage was considered preferential for this study.
3.5.4 Immune responses upon immunization
At specific time points upon immunization, the immune response was evaluated by quan-
tification of the OVA-specific IgG antibody titer in pig serum using a direct ELISA. The
evaluation of the antibody titer revealed the lack of immune responses in all powder in-
jection groups (A, B, C) (Fig. II.18). Both powder injection verum groups (B, C) showed
titers comparable to the negative control (A) over the entire study duration. On the other
hand, the positive control (D) exhibited increasing OVA-specific antibody titer during the
study. Slightly higher values were detected for the positive control after day 14. Following
21 and 28 days after the first i.m. injection of OVA-AS03 vaccine, significantly higher
specific antibody titers compared to the powder injection groups were detected.
Besides the antigen-specific antibody titer, the total IgG content of the pig sera was quanti-
fied using a self-developed sandwich-ELISA. No differences were detected between all time
points of testing or the study groups (Fig. II.19). Due to the lack of difference in total IgG
despite the observed changes in OVA-specific titer, this assay was not considered further
for the evaluation of the immune response upon intradermal powder or i.m. immunization.
The results of the OVA-specific antibody titer show that no immune response was elicited
by intradermal, needle-free powder injection using the highly concentrated OVA vaccine.
Despite the high antigen content of 200 µg/mg OVA, it can be assumed that the dose de-
livered into the tissue was not sufficient to initiate an immunologic cascade within 28 days.
Considering a total delivery of 25 % as stated before [15], only 50 µg OVA reached the
dermal tissue. For the relatively weak antigen OVA, this dose was insufficient to generate
a humoral IgG-based immunity.
Besides the actual antigen dose delivered into the skin, the adjuvant dose likely played an
important role to enhance the immune response. Compared to the conventional dose of
AS03 discussed in section 3.5.2, only 0.4 − 1.8 % of this dose was delivered together with
the vaccine considering 0.1 − 0.5 mg adjuvant oil loading and 100 % delivery efficiency.
Most likely, the adjuvant dose applied by powder injection was not sufficient to enhance
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Figure II.18: OVA-specific antibody titer quantified by direct ELISA after 0, 1, 14, 21, and
28 days after immunization. Vaccine was administered on day 0 and day 14 by needle-free
powder injection or i.m. injection for the different study groups as provided in table II.2.
(One-way ANOVA on ranks, Kruskal-Wallis, α = 0.05, n=7, *** p < 0.001).
Figure II.19: Total amount of IgG in porcine serum quantified by Sandwich-ELISA 0, 1, 14,
21, and 28 days after immunization, administered on day 0 and 14 by needle-free powder
injection or i.m. injection (Tab. II.2) (One-way ANOVA, α = 0.05, n=7).
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the immune response, which is supported by the results obtained using an influenza vaccine
in the same study setup [15].
On the other hand, the full dose of both, 200 µg OVA plus AS03 adjuvant, was administered
by i.m. injection and led to a significant immune response. Notably, even higher titers
have been detected using stronger antigens, e.g. influenza [15, 56]. Retrospectively, with
the current knowledge, an additional control group covering the i.m. injection of the full
or 25 % of the dose OVA antigen in absence of adjuvant would have been beneficial to
assess the potency of the cutaneous vaccination approach by needle-free powder injection.
Moreover, a third vaccination by powder injection and the analysis of antibody titers at
additional timepoints after 28 days should be considered in future studies.
4 Conclusion
This study shows that the combination of collapse lyophilization and cryogenic grinding
allows for the manufacturing of a highly concentrated 200 µg/mg OVA-loaded, vaccine
powder suitable for needle-free powder injection. The vaccine powder obtained by this
approach provides an antigen dose per mg vaccine up to 13 times higher than a conventional
dose of 15 µg antigen used for influenza vaccination [57–59]. Compared to the pandemic
vaccine Pandemrix® the dose is even 53 times higher [21].
Despite the lack of antigen-specific immune responses upon intradermal delivery of the
highly concentrated OVA vaccine, protective immune responses can be expected upon in-
tradermal powder injection using antigens with higher potency. Considering a cutaneous
delivery efficiency of 25 %, an influenza vaccine powder with a loading of 60 µg/mg would
be required to achieve an intradermal deposition of a conventional influenza antigen dose.
Furthermore, a loading of only 15 µg/mg would be required when the vaccine is adminis-
tered in combination with a potent adjuvant system.
With the current device design, the AS03 adjuvant dose delivered was too low to potentiate
the immune response. The particle fixation through the adjuvant is an attractive approach,
however the common dose of 27.41 mg oily AS03 components [21] exceeds the existing
device capacity by far. The use of alternative adjuvants suitable for cutaneous vaccination
as discussed in section 2.3, incorporated into the vaccine powder, could be beneficial for
the approach of intradermal needle-free powder immunization.
The highly concentrated vaccine provided good stability without loss of antigenicity or
pronounced changes in vaccine quality within 12 months of storage at up to 40 °C. However,
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other studies using influenza antigens have shown reduced stability of low-dose vaccine at
elevated storage temperatures [15]. Therefore, the stability of the vaccine powder needs
separate assessment for each type and concentration of vaccine antigen used.
The loading of the vaccine powder onto the device membrane is feasible using a mixture
of the oily components of the AS03 adjuvant system. The oily mixture provides suitable
spreading on the Ti membrane, good powder adhesion for storage and transportation,
and also allowed for a full release of the vaccine powder upon device actuation. Notably,
other oils and oily mixtures can be used for vaccine powder fixation. Liquids with good
spreading behavior and high viscosity are expected to optimize the particle adhesion while
maintaining a good release from the device. Notably, the liquids used for this purpose
are required to maintain the sugar-based vaccine integrity, rendering hydrophobic oils and
liquids the preferred choice for particle adhesion.
The vaccine powder-oil compatibility is a critical factor for the loading and storage of the
device before use. In this study, the stability of the oil was investigated and revealed a
tendency of increased oil stability when stored in direct contact with the vaccine powder.
The vaccine stability in direct oil contact was not focus of this study and should be address
ed in a different work.
All in all, the results of this study show that the immunization using needle-free powder
injection is feasible, but requires precise optimizations. The manufacturing process allows
for the preparation of vaccines at variable concentrations up to 200 µg/mg and the load-
ing, storage, and transport of the device with oil-fixed vaccine powder provides notable
stability. Cutaneous vaccination by needle-free powder injection is an attractive approach
since it allows for an easy, quick, and pain-free administration of vaccine. The deposition
of antigen in the skin tissue, rich of APCs, has been shown to successfully elicit protective
immunity [60–62]. Compared to conventional i.m. injection, cutaneous vaccination can
facilitate a dose reduction of up to 60 % [62]. The high flexibility of needle-free powder in-
jection with regard to the loaded vaccine is a major advantage. The applied powder may be
readily loaded with other potent vaccine and antigens, e.g. DNA or RNA, virus-like parti-
cles, inactivated or attenuated vaccine candidates. After solving the main disadvantages of
high production costs and overcoming safety-related licensing hurdles, the powder injection
device has a promising potential to become an alternative to conventional vaccination.
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COMPARING INTRADERMAL MICRO- AND
NANOPARTICLE DELIVERY BY DIFFERENT
MICRONEEDLE TREATMENTS
1 Introduction
Since the mid 1990s MNs have been extensively studied for their potential to enhance
the transdermal delivery of small molecules and macromolecular drugs [1, 2]. The elegant
concept of breaching the SC, the main barrier of the skin, using small needles that are
minimally invasive, pain-free, and easy to produce, made them a popular tool in trans-
dermal delivery research [1]. The transport of a variety of different molecules into and
through the skin could be improved by microneedling. Particularly macromolecules, e.g.
proteins or oligonucleotides, but also certain particulate formulations benefit from the skin
barrier disruption, which is a prerequisite to facilitate transdermal drug delivery for these
molecules [3–5]. Although proven successful in principle, the use of conventional MN arrays
is still mainly restricted to research due to low dosing or insufficient delivery efficiency [6, 7].
For this reason, the focus of MN research has shifted in recent years from a systemic de-
livery towards the delivery of highly potent, low dose molecules with local targets in the
skin tissue, particularly vaccines [8].
Nowadays, the skin is recognized as highly immunologic organ with a high density of
LCs and dDCs residing in the viable skin tissue [9]. When a critical amount of antigen
reaches the tissue, the skin-resident APCs initiate an immunologic cascade that can result
in protective immunity. Furthermore, skin keratinocytes have a key function in innate
immunological processing and can promote antigen-specific immunity [10]. Targeting of the
epidermal and dermal layer for cutaneous vaccination has been proven successful in many
studies and is particularly interesting for potential dose reductions and development of new
treatment options [11]. Besides other passive and active techniques targeting the skin for
vaccine delivery, skin microporation and particularly MNs have proven their potential to
challenge the state-of-the-art administration of vaccines by s.c. or i.m. injection [12, 13].
Various types of MNs have been used for the i.d. delivery of antigens into the skin,
including solid, coated, hollow, and degradable MNs [6, 14]. While solid MNs are mainly
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used to breach the mechanical barrier of the skin and provide access to the viable tissue,
other types of MNs, namely coated, hollow, or biodegradable MNs, can facilitate a direct,
one-step delivery of antigens in the skin. Each MN type provides certain advantages
and disadvantages over others and has been tested to varying extent in clinical trials [6,
14–16]. Hollow MN devices with needle lengths of up to 1500 µm provide a high and
reproducible dosing, however still require the use of liquid vaccine formulations with limited
storage stability [6, 7, 14, 16]. Polymeric MNs are conveniently applied as dissolving,
swelling, or biodegradable MN patch and exhibit good delivery efficiency but are commonly
manufactured by micromolding based on centrifugation, which is difficult to scale-up [14,
17]. Moreover, reduced mechanical stability represents a major challenge for a broader
application of polymeric MN arrays [1]. Coated MNs based on silica or metal exhibit
good mechanical stability but the amount of drug or antigen that can be coated onto and
released from the MN tips is limited [1, 8]. Solid MNs provide the advantage of an easy and
cost-effective manufacturing, good mechanical stability, easy handling and compatibility
with different semi-automated MN insertion devices [6]. The two-step ’poke with patch’
approach, using microneedles to breach the skin barrier followed by the application of a
drug-loaded solution or patch, allows to study the i.d. delivery of a variety of different
molecules, vehicles, and formulations [18]. This flexibility makes them a convenient tool
for the initial testing of new i.d. vaccines and adjuvants, e.g. particulate formulations.
Different materials, tip geometries, and application modes have been developed to breach
the skin barrier with solid MNs followed by administration of the molecule or vehicle of
interest [18]. Most common materials for the manufacturing of solid MNs include silicon,
metals (e.g. stainless steel, titanium), ceramics, silica glass, and non-degradable polymers
(e.g. photolithographic epoxy, polycarbonate, poly(methyl methacrylate) (PMMA)) [1, 6].
Silicon MNs prepared by etching allow to produce high-precision, specifically tailored MNs
with various shapes [6]. On the other hand, MN arrays from metals can be produced by
different techniques including etching and laser-cutting, each leading to a different type of
MN. The manufacturing of ceramic and polymeric MNs usually involves the micromolding
technique [1, 19]. Today, different types of solid MNs, mainly from stainless-steel, are com-
mercially available and widely applied for cosmetic treatments. Particularly handheld roller
or stamp devices can be easily purchased from various suppliers, e.g. the Dermaroller®,
Dermapen, 3Ms solid microneedle system (sMTS), and others [20]. Only recently, a draft
guidance has been published by the FDA to regulate the increasing number of requests
for the licensing of microneedling devices. However, specific quality standards related to
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Good Manufacturing Practice (GMP) remain to be defined [20, 21].
Cutaneous vaccination using particulate vaccine formulations has attracted increasing at-
tention in recent years due to the growing knowledge about skin immunology and the
adjuvant potential of particles [5]. Particle delivery to intact skin via the transfollicular
route has been studied and characterized in several studies. The phase of hair follicle
growth and the structure of the infundibulum have been identified to influence the depo-
sition of particles in the skin. It has been found that drugs and particles are exclusively
delivered to open (active) follicles [22, 23]. About 74 % of all follicles are open under
normal conditions, while the orifice of inactive follicles is closed by sebum and shed cor-
neocytes [24]. By peeling and hair plucking, follicles can be opened and made accessible
for drug delivery [24]. Different types of particles with sizes between 3.5 nm and up to
6 µm have been successfully delivered to intact skin via hair follices [25–30]. Thereby, the
deposition of particles was found to be superior compared to free dye and could be signif-
icantly improved if massage was applied to mimick hair follicle movement [25, 26, 28, 31].
Particles with a size of approximately 650 nm reached maximum penetration depths upon
massage into the skin [27].
Although particles can be delivered into deeper parts of the skin targeting the follicular
infundibulum, the penetration past the follicle into the epidermal and dermal layer re-
mains limited. Based on previous studies, it is generally assumed that particles larger
than ∼10 nm do not pass superficial skin layers [32], which also surround the follicular
infundibulum. This consequently limits the uptake and processing by skin-resident APCs
required for vaccination. Furthermore, the area of the skin, which is accessible via hair
follicles, is highly restricted with densities between 0.09 % on the volar forearm and up
to 1.28 % on the forehead [23]. Both factors, particle size and follicular density, limit
the delivery of active drugs and vehicles and highlight the need for active administration
techniques that increase the efficiency and reproducibility of delivery.
One technique to circumvent the limited access to the viable skin tissue via hair follicles
is the i.d. delivery of film fragments by punching using MNs. The aim of this approach,
tested in the course of this thesis, is to deliver micron-sized fragments from 50 − 500 µm
thin polymer films into the epidermal and dermal layer of the skin using MN rollers with
needle lengths of 500 µm and 1000 µm. These films can be loaded with vaccine antigens,
adjuvants, micro-, or nanoparticles. In a preliminary proof-of-principle study, thin polymer
films with varying excipient compositions were prepared using pure film forming polymers
or blends of polyvinyl alcohol (PVA), chitosan, methacrylic acid derivatives, or cellulose
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derivatives of varying type and size, e.g. carboxymethyl cellulose (CMC), hydroxyethyl
cellulose (HEC), methyl hydroxyethyl cellulose (MHEC), hydroxypropyl methyl cellulose
(HPMC) [33]. These films were prepared using an automated film casting technique and
different post-drying treatments, e.g. cross-linking or freeze-thaw curing, and characterized
covering a range of mechanical strengths, flexibility, and brittleness [33]. Although the
piercing of the polymer films was successfully proven, further studies are needed to assess
the feasibility of i.d. delivery of particle-like film fragments using MNs with defined shapes
and geometries.
The study presented in this chapter aims to characterize the delivery of particles into MN-
treated skin by massage comparable to transfollicular delivery. The penetration behavior
of particles was studied dependent on the particle size and the MN type. Two commer-
cially available MN devices with different MN tip geometries and application modes were
compared for their efficiency to assist the delivery of particulate formulations into the skin.
A conventional MN array with out-of-plane, flat stain-less steel MNs and a MN roller with
cone-shaped MNs were used to deliver particles in the micro- and nanometer range into
the viable skin tissue. The MN array was pressed flat onto the skin, whereas the MN
roller was applied by rolling a handheld device with MNs on a rotating drum over the skin
surface (Fig. III.1). Both application modes were used as a pretreatment to breach the SC
and access the viable skin tissue. In addition, model particles were delivered to the skin
by reversing the application sequence using the MN roller as massage tool in the second
application step.
Due to skin elasticity, certain closure of pores after MN treatment can be expected, leaving
narrow channels for the delivery of particles [34]. Therefore, model particles were applied
by massage in order to maximize the deposition in the skin. Fluorescent silica particles were
used to determine the maximum penetration depth into the skin by fluorescence microscopy
depending on the particle size and MN treatment. Additionally, the i.d. deposition of
fluorescent poly(lactic-co-glycolic acid) (PLGA) particles was quantified upon extraction
from the skin. The i.d. deposition was evaluated in relation to the particle size as well as
the MN shape and application mode. The findings of this study will broaden the knowledge
about the administration of particles within a size range of 0.1−7 µm into MN-treated skin
and help interpreting existing research on the i.d. delivery of micro- and nanoparticles after
MN treatment. Moreover, this study demonstrates the need to select optimum conditions
for future studies using MN and particles for i.d. drug or vaccine delivery.
104
2 Materials and Methods
2 Materials and Methods
2.1 Chemicals
Silica particles with diameters of 7.0 µm, 1.3 µm, 0.6 µm, and 0.1 µm were purchased from
Microparticles GmbH (Berlin, Germany). Green fluorescent PLGA particles with diame-
ters of 1.2 µm, 0.5 µm, and 0.1 µm were obtained from Phosphorex (Degradex®, Hopkinton,
Massachusetts, USA). Poly(allylamine) hydrochloride (PAH) (15 kDa), FITC (isomer I),
and polystyrene sulfonate (PSS) (70 kDa) were purchased from Sigma Aldrich (Steinheim,
Germany). Sodium chloride was obtained from Bernd Kraft (Duisburg, Germany). Dimethyl
sulfoxide (DMSO) was from Fisher Scientific (Leicestershire, United Kingdom) and dichloro-
methane was from Merck (Darmstadt Germany).
2.2 Fluorescent coating of silica particles
The preparation of fluorescently labeled PAH was adapted from Schneider et al. [35]. In
precise, 1 g PAH was dissolved in 20 mL 100 mM carbonate-bicarbonate buffer at a pH
of 9.4. Under vigorous stirring and exclusion from light, 1.5 mL of ∼8 mg/mL solution of
FITC in DMSO was added dropwise in 5 µL aliquots to the PAH solution over a period of
eight hours. The solution was stirred overnight under exclusion of light and dialyzed for 48 h
against highly purified water using a CelluSep T1 dialysis tubing (MWCO 3, 500, Orange
Scientific, Braine-l’Alleud, Belgium) to remove unbound FITC. After dialysis, the fluores-
cein isothiocyanate- labeled poly(allylamine) hydrochloride (FITC-PAH) was lyophilized
and stored at 4 °C or directly utilized for layer-by-layer coating.
Fluorescent silica particles were prepared according to the layer-by-layer (LbL) principle as
described before [36, 37]. Silica particle suspensions with particle sizes of 7.0 µm, 1.3 µm,
0.6 µm, and 0.1 µm were diluted to 2 % (w/v) using 0.5 M sodium chloride solution
at pH 6.5. For the coating process, FITC-PAH and PSS (MW 70,000) were adsorbed
to silica particles in four consecutive layers, starting with positively charged FITC-PAH
followed by negatively charged PSS. The layers were obtained by mixing equal volumes of
the particle suspension and 5 mg/mL polymer solution in 0.5 M sodium chloride, followed
by incubation for 3 h under stirring and exclusion from light. Subsequently, the particles
were washed three times by centrifugation at 13, 000 rpm for 10 min and resuspension
with 0.5 M sodium chloride solution to a concentration of 2 % (w/w). Sonication was
used to improve resuspension. Four polymer layers were adsorbed to the silica particles
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starting with positively charged FITC-PAH and ending with negatively charged PSS. After
LbL-coating, the particle suspensions were stored at 4 °C until further utilization.
2.3 Scanning electron microscopy
Scanning electron microscopy of the silica particles prior and after coating was performed
using a Joel JSM-6500F electron microscope (Ebersberg, Germany). The samples were
prepared by air drying of each particle suspension on self-adhesive carbon tape (Bal-tec
GmbH, Witten, Germany) and subsequent carbon sputtering under vacuum using a MED
020 coating system (Bal-tec GmbH, Witten, Germany). Images were taken at a magnifi-
cation of 5,000 for the 7.0 µm and 1.3 µmicroparticles and at 25,000 for the 0.6 µm and
0.1 µm nanoparticles, respectively.
2.4 Zeta-potential measurements
The surface charge of the particles was assessed using a Malvern Zetasizer Nano ZS
(Malvern Instruments, Worcestershire, United Kingdom). A volume of 500 µL of plain
and coated silica particle suspensions with sizes of 1.3 µm, 0.6 µm, and 0.1 µm at a con-
centration of 2 % (w/v) was pipetted into a folded capillary zeta-cell (Malvern Instruments,
Worcestershire, United Kingdom). Subsequently, highly purified water was carefully pipet-
ted on top of the sample until the cell was completely filled. After resting for 1 h to ensure
a stable equilibrium, the zeta-potential was analyzed at 25 °C. Silica microparticles with
a diameter of 7.0 µm were prepared similarly using 50 µL at a concentration of 5 % (w/v)
to achieve comparable measurement quality.
The mean zeta-potential was calculated from four different measurements at 25 °C, each
composed of three serial runs with 20 subruns. Malvern software 6.12 (Malvern Instru-
ments, Worcestershire, United Kingdom) was used for data acquisition and analysis.
2.5 Static light scattering measurements
The particle size and distribution of plain and coated silica particles were characterized by
laser diffractometry using a Partica-LA 950 (Horiba, Kyoto, Japan). Optimum laser trans-
mission intensities were obtained by spiking approximately 10− 20 µL particle suspension
into 0.5 M sodium chloride solution at pH 6.5. Moreover, 0.2 M sodium hydroxide and
0.1 M hydrochloric acid were spiked as needed to evaluate changes in the size distribution
pattern. Refractive indices of 1.42 for silica and 1.33 for water was used for evaluation by
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Table III.1: Overview of microneedle treatments and particle sizes for the evaluation of
particle penetration depths into excised pig skin.
Group Microneedle treatment Particle sizes Particle sizes
Silica PLGA
[µm] [µm]
A MN array 7.0 -
250 µm length 1.3 1.2
Before particle admininstration 0.6 0.5
0.1 0.1
B MN roller 7.0 -
200 µm length 1.3 1.2
Before particle administration 0.6 0.5
0.1 0.1
C MN roller 7.0 -
200 µm length 1.3 1.2
After particle administration 0.6 0.5
0.1 0.1
the system software. The particle size was provided as median size within one fraction of
the static light scattering (SLS) size distribution analysis.
2.6 Particle suspensions for intradermal administration
LbL-coated silica particles as described above were used for microscopic evaluation of the
i.d. penetration behavior upon MN treatment. For this purpose, particle suspensions
with a concentration of 2 % (w/v) in 0.5 M sodium chloride solution at a pH of 6.5 were
prepared. The quantitative i.d. particle deposition was analyzed using green fluorescent
PLGA particles (Degradex®, Phosphorex, Hopkinton, Massachusetts, USA). The PLGA
particles with diameters of 1.2 µm, 0.5 µm, and 0.1 µm were reconstituted as received with
half volume to obtain 2 % (w/v) suspensions.
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2.7 Microneedle treatment and particle administration
The particle administration was studied using excised pig skin from the ventrolateral region
of 5−7 week old piglets, provided by the Clinic for Swine (Faculty of Veterinary Medicine,
LMU Munich, Oberschleißheim, Germany). Full thickness pig skin samples were prepared
using a scalpel and stored at −80 °C for a maximum of three months. For particle ad-
ministration, skin samples of at least 3x3 cm2 were prepared and hydrated for 5 min in
0.9 % sodium chloride solution. After removing excess moisture from the surface, the skin
samples were placed on a polystyrene foam support in order to avoid breakage or bend-
ing of the MNs. Three different MN application modes were used to study the particle
penetration behavior (Tab. III.1).
For the treatment groups A and B, a MN pretreatment of the skin samples was performed.
The pretreatment procedure of group A involved a MN array (AdminPatch® 300, Ad-
minMed, Sunnyvale, USA) with 752 flat, hollow 250 µm MNs, which was applied to the
skin surface using a 2 kg weight for 3 min (Fig. III.1). Subsequently, the MN array was
turned 90 degrees and the application procedure was repeated, resulting in a microporated
area of 0.8 cm2. For group B, a MN roller (Dermaroller HC902, Dermaroller GmbH,
Wolfenbüttel, Germany) with 162 cone-shaped 200 µm MNs was used. The microneedling
procedure was performed as per manufacturers description by rolling ’back and forth’ four
times, each time turning at an angle of 45 degrees (Tab. III.1). Subsequently, partially
microporated skin in the corners was covered with Leukoflex tape (BSN Medical, Ham-
burg, Germany), leaving a 2x2 cm2 area for subsequent particle administration. After skin
pretreatment in group A and B, the liquid particle suspension was topically applied and
manually massaged into the skin for 3 min in a circular movement.
The particle administration in treatment group C was performed by reversing the appli-
cation sequence. After placing the skin samples on the polystyrene foam support, an area
of 2x2 cm2 was prepared by covering the residual tissue with Leukoflex tape. Within the
free skin area, the particle suspension was topically applied and followed by performing the
microneedling procedure as described above using the MN roller. The MN roller procedure
was repeated ten times to mimic the massage effect as compared to the other treatment
groups. For all groups, a suspension volume equivalent to 2 mg/cm2 was applied. After
administration, excess formulation was gently removed using a cotton wipe and tap water,
avoiding further pressure on the skin surface. Subsequent analysis was peformed using a
1x1 cm2 sample of the central region of the treated skin sample. Each test was performed
in triplicates.
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Figure III.1: Photographs and microscopic images of the commercially available MN array
(A) and MN roller (B) used in this study. The MN array with 752 flat, 250 µm long, out-
of-plane MN was applied twice in two different directions (C). The MN roller was applied
by rolling a drum comprising 18 rows of nine 200 µm long MN over the skin surface at four
different directions (D). For the MN roller, a central region of 2x2 cm2 was used to study
the particle penetration.
2.8 Laser scanning microscopy
Processed skin samples were embedded into tissue freezing medium (FSC 22® Clear, Le-
ica Biosystems, Wetzlar, Germany) and stored overnight at −80 °C. Skin cross-sections of
10−20 µm were prepared at −18 °C using a Microm HM560 microtome (ThermoScientific,
Massachusetts, USA). The artifical introduction of particles into deeper skin layers was
avoided by orienting the microtome blade parallel to the normal of the skin surface. Skin
cross-sections from equally distributed locations of the entire skin sample area were pre-
pared and collected for imaging. The cross-sections were mounted onto microscope slides
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(SuperFrost® Plus, VWR, Leuven, Belgium) and analyzed without further staining.
The skin sections were mounted upside down on a Zeiss 510 LSM confocal laser scanning
microscope (Carl-Zeiss AG, Oberkochen, Germany) and were imaged with identical set-
tings for all groups using a EC Plan-Neofluar10x/0.3 air objective. At least 29 positions
per particle size and MN treatment group were analyzed for the penetration depth. A
position was defined as region of particle deposition and accumulation in the skin that was
generated by one MN penetration. The penetration depth was measured as the maximum
distance between the lowest visible particle deposition and the microporated skin surface
using Fiji image analysis software [38]. The penetration depths were evaluated using one-
way ANOVA statistical analysis by SigmaPlot 12.5 (Systat Software, San Jose, California,
USA).
2.9 Extraction of PLGA particles from skin
The i.d. particle deposition was determined upon extraction from horizontal skin sections.
The sections were prepared by placing the skin samples on a pre-cooled stainless steel
plate with the SC facing the plate surface. After embedding into tissue freezing medium
and overnight freezing at −80 °C, horizontal skin sections of 30 µm were prepared using a
Microm HM560 microtome (ThermoScientific, Massachusetts, USA). In total 25 sections
were collected in 1.5 mL tubes reaching a maximum skin depth of 750 µm. Up to four skin
sections were collected per sample tube. Green fluorescent PLGA particles were extracted
by adding 200 µL dichloromethane into each sample tube followed by 20 min incubation at
60 °C during which PLGA and fluorescent dye was dissolved. The samples were centrifuged
for 2 min at 13, 000 rpm to remove skin residuals and the supernatant was transferred into
black sample tubes. The content of green fluorescent PLGA particles was quantified by
fluorescence spectroscopy.
2.10 Quantification of PLGA particles by fluorescence spectroscopy
The concentration of green fluorescent PLGA particles in the skin extract was quantified
using a Cary Eclipse fluorescence spectrophotometer (Agilent, Santa Clara, CA, USA) at
excitation and emission wavelengths of 460 nm and 500 nm, respectively. A standard
curve was generated for each separate particle size by drying 100 µL of 2 % (m/v) par-
ticle suspension under vacuum and exclusion from light. Upon reconstitution in 200 µL
dichloromethane, diluted standard solutions were analyzed by fluorescence spectroscopy
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and correlated to the equivalent particle concentration. The experiment was performed in
triplicates for each particle size. The curves showed linear ranges of 25 − 500 ng/mL for
1.2 µm particles, 25 − 750 ng/mL for 0.5 µm particles, and 100 − 3000 ng/mL for 0.1 µm
PLGA particles with regression factors of above 0.99 for each analysis.
3 Results and Discussion
3.1 Characterization of LbL-coated particles
The LbL technique is a well-known method for the preparation of coated particles or
capsules and has been exploited for numerous applications in research [35, 37, 39–43].
The approach benefits from a high universality and the compatibility with various parti-
cle materials, e.g. melamine-formaldehyde, polystyrene, silica, as well as different coating
polymers, e.g. PSS, PAH, or poly acrylic acid (PAA). Initially performed by charge-derived
adsorption, the LbL technique has been further developed exploiting other molecular in-
teractions [39].
In this study, charge-based LbL-assembly of silica micro- and nanoparticles was performed
to successively coat four layers of positively charged FITC-PAH and negatively charged
PSS, facilitating the imaging by fluorescence laser scanning microscopy (LSM). To en-
sure a good stability of the particles after LbL-coating, the microscopic appearance, zeta-
potential, and static light scattering of the particles prior and after coating was studied.
Figure III.2 shows scanning electron microscopy (SEM) images of plain and LbL-coated
silica micro- and nanoparticles with a diameter of 7.0 µm, 1.3 µm, 0.6 µm, and 0.1 µm.
Generally, the surface morphology of the particles was smooth and homogeneous for all par-
ticle sizes before and after LbL-coating. At higher magnification, an uneven surface became
visible on 0.6 µm nanoparticles before and after coating. Plain silica particles arranged
in hexagonal superstructure, which has been reported for mesoporous silica structures be-
fore and appeared to be most pronounced for nanoparticles (Fig. III.2 C.1, D.1). After
LbL-coating, the ordered superstructure disappeared (Fig. III.2 C.2, D.2), indicating a
change of surface charge and particle interaction due to FITC-PAH and PSS coating. The
comparison of surface morphology and particle appearance by SEM showed not signs of
irreversible particle aggregation due to the coating process.
The particle size and size distribution of the silica particles prior and after LbL-coating
was studied by SLS. Plain and LbL-coated microparticles of 7.0 µm and 1.3 µm showed
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Figure III.2: Scanning electron microscopy images of silica particles prior (left column,
index 1) and after (right column, index 2) coating with positively charged FITC-PAH and
negatively charged PSS. Silica particle with sizes of 7.0 µm (A), 1.3 µm (B), 0.6 µm (C),
and 0.1 µm (D) were used in this study. Scale bar 1 µm, Magnification 5,000x (A, B) and
25,000x (C, D).
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Figure III.3: Particle size distribution determined by static light scattering prior (solid line)
and after LbL-coating (dashed line). LbL-coated silica nanoparticles showed reversible
aggregation, which was improved at pH ∼11 (*, dotted line).
monomodal size distributions (Fig. III.3 A, B). Equivalent sizes before and after LbL-
coating were measured, indicating that the LbL-coating did not affect the mean size of
the microparticles (Tab. III.2). Plain silica nanoparticles with a diameter of 0.6 µm
exhibited a single peak, which broadened and shifted towards larger sizes after LbL-
coating (Fig. III.3 C). At higher pH around 11, by addition of sodium hydroxide, the
shifting could be reversed towards smaller particle sizes. Plain and LbL-coated 0.1 µm
nanoparticles exhibited a bimodal distribution during SLS analysis. The two particle size
fractions detected for plain silica particles showed a mean diameter around 0.1 µm, in-
dicative for single particles, and 22 µm, suggesting aggregate formation, respectively. In
the same dispersion medium, the LbL-coated 0.1 µm nanoparticles exhibited a bimodal
distribution with fractions around 0.2 µm and 3.1 µm. The increase of the pH to ∼11
induced a shifting of the larger size fraction of LbL-coated nanoparticles towards the peak
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Table III.2: Particle size determined by static light scattering (SLS) and zeta-potential of
plain and LbL-coated silica particles with nominal sizes of 7.0 µm, 1.3 µm, 0.6 µm, and
0.1 µm. The nanoparticle size with nominal diameters of 0.6 µm and 0.1 µm was derived
from the particle fraction detected by SLS with lowest particle size (*). The size of the
LbL-coated nanoparticles was derived from measurements at pH ∼11 (Fig. III.3).
Mean particle size Zeta- potential
Nominal Plain silica LbL-coated Size ratio Plain silica LbL-coated
[µm] [µm] (LbL/Plain) [mV] [mV]
7.0 µm 6.17 ± 0.003 5.93 ± 0.011 0.96 −27.3 ± 2.3 3.2 ± 0.4
1.3 µm 1.51 ± 0.020 1.59 ± 0.008 1.06 −64.6 ± 0.5 −30.5 ± 0.3
0.6 µm 0.36 ± 0.004 0.47 ± 0.009 * 1.29 −29.0 ± 0.5 −26.3 ± 0.3
0.1 µm 0.12 ± 0.000 * 0.22 ± 0.001 * 1.79 −18.7 ± 0.6 −22.6 ± 0.3
at 0.2 µm diameter (Fig. III.3 D). The pH-induced shifting of larger size fractions towards
smaller particle sizes indicates a reversible association of the LbL-coated nanoparticles of
0.6 µm and 0.1 µm. Notably, a comparable pH-dependent shifting of size fractions was
also observed for plain silica nanoparticles of 0.1 µm (data not shown).
Measurements of the single nanoparticle diameter by SLS deviated slightly from the nom-
inal diameter provided by the manufacturer (Tab. III.2). Moreover, after LbL-coating
the diameter increased by approximately 0.1 µm. Notably, particle size measurements
of plain silica nanoparticles by dynamic light scattering (DLS) provided results in agree-
ment with the nominal value of 0.6 µm and 0.1 µm (data not shown). However, poor
measurement quality was observed for larger particle sizes as well as LbL-coated nanopar-
ticles. It can be assumed that SLS-related limitations in measuring particle sizes below
0.5 µm caused a deviation of SLS-measurement results from the actual particle diameter.
Moreover, LbL-coating could induce a change of refractive indices of the particles, thus
affecting SLS-measurement accuracy. On the other hand, the larger particle size fraction
of the LbL-coated 0.1 µm nanoparticles showed a diameter almost ten times smaller than
the larger size fraction of the plain silica particles. With a diameter around 3.1 µm, the
LbL-coated particle aggregates might have interfered with size measurements by DLS.
Therefore, despite its analytical limitations in submicron size measurements, SLS was se-
lected as main technique to assess the particle size and the reversibility of particle aggregate
formation.
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The zeta-potential prior and after coating was measured to further characterize the parti-
cle interaction in suspension. Plain silica particles exhibited a size-independent negative
zeta-potential between −20 mV for 1.3 µm particles and −65 mV for 0.1 µm nanoparticles
(Fig. III.2). After LbL-coating, the zeta-potential leveled around −25 mV for all particles
except the 7.0 µm microparticles. The largest silica particles exhibited a neutral to slightly
positive zeta-potential. Although the neutral surface charge could be indicative for aggre-
gation, this was not observed by SEM or SLS analysis. It can be speculated that the low
surface to volume ratio of the larger microparticles prevented notable particle aggregation.
Generally, a comparable zeta-potential was achieved by LbL-coating of particles within a
size range of 1.3 µm to 0.1 µm. A good peak homogeneity was observed during measure-
ments of the coated particles, indicating a homogeneous charge distribution generated by
LbL-coating, which was superior to plain silica particles.
The LbL-coating procedure allowed for a preparation of fluorescent particles of 7.0 µm,
1.3 µm, 0.6 µm, and 0.1 µm with suitable properties to study the i.d. delivery upon
MN treatment. The particles were easily detectable by fluorescence LSM using imaging
parameters with low background fluorescence of the skin tissue. Analysis by SEM and
SLS showed no signs of aggregation of microparticles ≥ 1.3 µm. Moreover, aggregation of
LbL-coated nanoparticles ≤ 0.6 µm was shown to be reversible. It can be assumed that the
application by massage provides sufficient energy to disrupt reversibly associated particles.
Size measurements showed an increase in particle diameter, which was most pronounced at
lower particle sizes (Tab. III.2). However, as the SLS measurements come with analytical
limitations, it can be assumed that the single particle diameter prior and after LbL-coating
was comparable for all particle sizes as seen by SEM imaging. We conclude that the particle
size increase by LbL-coating was negligible and a direct comparison of the i.d. deposition
can be done using the nominal particle diameter between 7.0 µm and 0.1 µm. Moreover, a
similar approach has been used before to study the selective i.d. transfollicular delivery [27].
3.2 Particle penetration depths
The penetration depths of green fluorescent LbL-coated silica particles into excised MN-
treated pig skin were determined by LSM. The particles were administered into the skin
using different types of MNs and application modes. A conventional array of flat MNs
(group A) or a handheld roller with cone-shaped MNs (group B) was applied as skin pre-
treatment followed by i.d. particle administration by massage for 3 min. Alternatively, the
MN roller was used in reverse order after topical particle application (group C). Typically,
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MNs have been used to disrupt the skin barrier, creating microchannels and facilitating the
subsequent delivery of particulate formulations to the viable skin tissue [44, 45]. However,
here, a reverse order of application was additionally studied to assess the possibility to
reach deeper skin layers and to evaluate the delivery efficiency compared to conventional
skin pretreatment.
The particle penetration depth was determined based on LSM images of skin cross-sections
from different locations distributed over a total area of 1x1 cm2 after i.d. particle adminis-
tration. Figure III.4 shows four representative images of skin cross-sections prepared from
treatment group C. MN-generated micropores and the deposition of particles with sizes
of 7.0 µm, 1.3 µm, 0.6 µm, and 0.1 µm were visible upon topical administration of the
particle suspension on intact skin followed by MN roller treatment. For the determination
of penetration depths, each position of particle deposition was marked and the penetration
depth was evaluated as maximum distance between skin surface and the deepest visible
particle per MN-generated micropore. At least 29 positions of different microchannels in
the skin were measured for each particle and MN treatment group.
Figure III.5 provides an overview of measured deposition depths in relation to the applied
particle size and MN treatment. The mean particle penetration depth as well as depth
distributions were comparable for all particle sizes when MNs were applied as skin pre-
treatment (group A+B). Compared to the MN pretreatment, broader depth distributions
were obtained for the i.d. particle delivery by microneedling (group C). The reverse order
application resulted in comparable mean deposition depths for particles of 7.0 µm, 1.3 µm,
and 0.6 µm. However, significantly deeper penetration and wider depth distribution in
the skin tissue was achieved for the smallest particle size of 0.1 µm. In general, maximum
penetration depths per microchannel ranged from about 50 µm to 450 µm for all particle
sizes and treatment groups.
The statistical evaluation of the particle penetration depth in relation to the applied MN
treatment revealed a tendency of superior deposition depths for the MN roller compared to
the MN array (Fig. III.5). No difference was detected between the application of the MN
roller prior or after particle administration. The MN roller reached an average penetration
depth of 166 µm compared to 131 µm for the MN array. The maximum depths that could
be reached were up to 450 µm and 300 µm using the MN roller and array, respectively.
Considering the skin structure, the results suggest that all treatment conditions can pro-
vide a deposition of particles in the epidermal layer and upper dermis (Fig. III.6). Thus, a
particle delivery in the viable tissue, in close vicinity to skin-resident APC for immunologi-
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Figure III.4: Laser scanning images of vertical skin sections of treatment group C. Four dif-
ferent particle sizes (green) were used: 7.0 µm (A), 1.3 µm (B), 0.6 µm (C), and 0.1 µm (D).
The images are representative for other treatment groups. Scale bar 200 µm, Magnification
10x.
cal processing could be achieved. While the median penetration depth was around 120 µm
for the MN array pretreatment (group A), both application modes using the MN roller
resulted in higher median values around 150 µm (group B+C).
Considering the differences in particle penetration by different MN treatments, the mea-
sured depths did not correlate with the needle length, which was 200 µm for the MN roller
compared to a needle length of 250 µm for the array. This indicates that the tip geometry
had a stronger influence on the penetration of particles into the skin than the needle length
itself. Furthermore, the application modes of the MN array and roller differ significantly.
The MN array is pressed onto the skin surface, whereas the MN insertion and retraction
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Figure III.5: Penetration depths of LbL-coated silica particles into excised pig skin after
different microneedle treatments. Lbl-coated silica micro- and nanoparticles with a diame-
ter of 7.0 µm, 1.3 µm, 0.6 µm, and 0.1 µm were massaged for 3 min into the skin upon MN
array (group A) or MN roller (group B) pretreatment or reverse order of application using
the MN roller (group C). Box plots represent the 25th and 75th quartiles, median and
standard deviation (whiskers) derived from penetration depth measurements of separate
microchannels (symbols). First statistical analysis was performed comparing the pene-
tration depths of different particle sizes within one treatment group. Second statistical
analysis was performed upon pooling the penetration depths within each treatment group
using a one-way ANOVA (Tukey multiple comparisons, α = 0.05, *** p < 0.001), revealing
significant differences in the penetration depth between skin treatment using the MN array
(group A) and the MN roller (group B+C).
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Figure III.6: Histogram of measured particle penetration depths upon MN skin pretreat-
ment using a MN array (group A) or roller (group B), or in reverse order of application
using the MN roller (group C). The median (dotted line) and mean (dashed line) penetra-
tion depth of particles is shown for each respective treatment group. All measured particle
penetration depths were considered for this graph, independent of the particle size applied.
using the MN roller occurs at different angles. Due to the rolling process and cone-type
shape of the MNs, the MN roller likely induced a more efficient disruption of the skin
barrier compared to the small, well-defined microchannels created by the MN array. The
results suggest that for such small differences in needle length, the needle tip geometry and
the application mode govern the performance of the microneedling process and the related
particle penetration.
3.3 Quantitative intradermal particle delivery
The quantitative deposition of PLGA micro- and nanoparticles with sizes of 1.2 µm, 0.5 µm,
and 0.1 µm in the skin tissue was determined by extraction and quantification by fluores-
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cence spectroscopy. Horizontal skin sections were prepared and collected after particle
administration on intact skin (control) or after application by MN treatment as described
above (group A, B, C). Green fluorescent PLGA particles, that penetrated into the skin
tissue, were dissolved and the total particle content was determined in the extract.
Figure III.7 provides the total and relative amount of PLGA particles deposited per cm2
skin tissue. In all treatment groups, a superior deposition of nanoparticles with a size
of 0.5 µm was observed compared to the smaller nano- and larger microparticles. Up
to 14 µg/cm2 of 0.5 µm nanoparticles were delivered into the skin, whereas a maximum
deposition of 5 µg/cm2 and 3.5 µg/cm2 was achieved applying 0.1 µm and 1.2 µm particles,
respectively.
This finding is in agreement with previous studies that identified a particle diameter of
∼650 nm as optimum particle size to penetrate into intact skin via the transfollicular
route [27, 46]. However, compared to the delivery to intact skin via hair follicles, in the
present study, breaching of the skin barrier by microneedling improved the absolute i.d.
deposition by factor ten. Although no clear effect of the particle size on the penetra-
tion depth was detected (Section 3.2), the deposited amount of particles revealed a clear
dependency of the applied particle size on the quantitative i.d. deposition.
Interestingly, a slightly higher deposition of 0.1 µm nanoparticles was detected using the
MN roller in reverse order compared to the MN array pretreatment. On the other hand,
the particle deposition was marginally increased for 1.2 µm microparticles in combination
with the MN array pretreatment in comparison to reverse order microneedling. Although
the observed effect is minor, it could indicate that manual massage affects the i.d. delivery
of larger particles to higher extent compared to nanoparticles around 0.1 µm. On the
other hand, increasing particle sizes ≥ 1.2 µm appeared to hinder the simultaneous barrier
disruption and particle transport into the skin by reverse order microneedling as performed
in treatment group C. The reverse application of the MN roller might be particularly
beneficial for suspensions of nanoparticles smaller than 0.1 µm and for solutions. However,
it has to be noted that nanocarriers have been previously found to provide superior delivery
compared to free molecules [31, 44, 47]. This suggests the existence of an optimum size for
the efficient delivery of particles and macromolecules into the skin tissue.
A compromise between efficient i.d. delivery and uptake by skin-resident APCs has to be
established to successfully facilitate cutaneous vaccination. Mechanical stimuli allow for
the delivery of particles of up to 6 µm into deeper parts of follicles [25–30], however, no
particle uptake from the follicles into deeper skin tissue has been detected [48]. Moreover,
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Figure III.7: Total intradermal delivery of PLGA particles with diameters of 1.2 µm (light
gray), 0.5 µm (white), and 0.1 µm (dark gray). The particles were administered by
massage on intact skin or after pretreatment using a MN array (group A) or MN roller
(group B). Furthermore, particles were delivered by reversed sequence of application using
the MN roller to massage particles into the skin (group C). (Data of 1.2 µm and 0.5 µm
(groups A-C) were acquired by Lisa M. Völk during her Bachelor’s thesis [50].)
after reaching the viable tissue, particles in the submicron range are preferably taken up
by DCs, inducing a size-dependent type of immunity [49].
The comparison of the different treatment groups revealed that the lowest deposition of
PLGA particles was detected in intact skin. The highest i.d. delivery for all particle sizes
was achieved applying the MN roller pretreatment followed by particle administration by
massage (group B). Skin pretreatment using the MN roller facilitated a deposition up to
three times higher compared to the MN array pretreatment (group A) and reverse order
application of the roller (group C). The MN array and the reverse order application of
the MN roller provided particle deposition in comparable range for each respective particle
size (Fig. III.7).
Similar to the penetration depth (discussed in section 3.2), the quantitative i.d. particle
deposition was largely influenced by the MN tip geometry, application mode, and treatment
sequence. Besides the efficient barrier disruption using the MN roller in treatment groups
B+C, the particle administration was mainly dependent on the massage effect, whereas
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the number of pores only played an inferior role. Previous studies have shown that about
125 micropores are generated by ten passes of a MN roller with 192 needles [51]. Notably,
the MN roller used in this study provided only 162 MNs and was applied in eight passes for
the MN pretreatment, likely resulting in less than 125 micropores. Neither ten repetitions
of this microneedling sequence as performed in group C, nor the 752 MNs of the MN array
resulted in a particle deposition comparable to the roller pretreatment. Interestingly, the
reverse order treatment using the MN roller induced a particle deposition comparable to
the MN array pretreatment (group A). This suggests that the relatively low skin barrier
disruption induced by the flat MN array was compensated by efficient manual massage
compared to the high disruption using the repeated application of the MN roller with an
inferior massage effect.
Results suggest that the MN type is the key factor influencing the skin tissue disruption,
whereas massage and the applied particle size additionally determine the associated i.d.
particle delivery. Furthermore, a strong interplay between the application of MNs and the
skin has been observed. When comparing the efficiency of different MN types to breach
the skin surface, the mechanical properties of the skin tissue have to be considered. Several
studies have reported the contraction of MN-generated micropores after their formation
due to skin elasticity [14, 34, 51]. Besides micropore orifices, which turned out to be
significantly smaller than the applied MN width [51, 52], studies have also concluded that
only 10− 30 % of the nominal needle length enters the tissue [53]. It can be assumed that
the efficiency of MN insertion strongly depends on the applied MN length, usually being
more efficient with decreasing needle lengths. These observations are further supported
by research that successfully applied densely packed MN arrays with even smaller needle
lengths of 65 − 110 µm for cutaneous vaccination [54].
Furthermore, the MN device itself as well as the skin treatment site determine the extent
of MN penetration into the tissue [52, 55]. Dependent on the skin condition, application
force and time, MN density, and repetitions, the skin tissue disruption occurs to vari-
able extent [53]. Reportedly, higher insertion forces are required with increasing needle
lengths [53]. The needle length of the MN array and the roller used in this study were in
comparable range, therefore comparable insertion forces could be expected for both MN
types. The force applied for insertion of the MN array was about 20 N. Similar forces are
reportedly achieved by manual pressing by human volunteers [56]. Additionally, forces of
∼20 N were found to be sufficient for the insertion of MN arrays with needle lengths of
up to 900 µm [56]. The relatively long application time of the MN array for 3 min in this
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study allowed for a full penetration of the MN array into the skin tissue. Although no
application force was measured during the microneedling using the MN roller, successful
breaching of the skin barrier was proven by i.d. particle delivery. The results suggest that
full insertion of the MN types used in this study were achieved and major differences in
i.d. particle delivery were derived from variations in tip geometry, application mode and
sequence.
The study shows that a notable i.d. delivery of particles between 1.2 µm and 0.1 µm can
be achieved by only 3 min massage. The particles reached into the epidermal and dermal
layer of MN-treated skin, increasing the delivery efficiency compared to (transfollicular)
delivery to intact skin by factor ten. Moreover, this is the first time showing the possibility
to deliver a formulation into the skin by applying simultaneous skin barrier disruption
and particle delivery using a conventional solid MN roller. Compared to previous studies,
the time required for i.d. particle delivery could be reduced by active massage compared
to up to 48 h incubation [45, 57]. However, notably higher delivery efficiencies can be
achieved by longer incubation. Considering the effects of particle size, MN tip geometry,
length, and application mode, the development of MN devices requires the consideration
of treatment site-specific conditions to achieve an optimum i.d. delivery to specific layers
of the skin. The combination of repeated microneedling using a MN roller and manual
massage at optimum duration represents an option to further maximize the i.d. particle
delivery in future studies.
4 Conclusion
Cutaneous vaccine delivery is a promising alternative to conventional i.m. or s.c. injection
for vaccination. Cutaneous vaccination provides the option for dose reduction and may
potentially offer new treatments against cancer, Alzheimer’s disease, or infectious diseases
that are not yet preventable, e.g. malaria, ebola, or HIV. Although today i.d. liquid injec-
tions are the most widely used approach for cutaneous vaccination and studied in several
clinical trials, the requirement of a stable cold-chain represents a major challenge. There-
fore, the development of vaccine formulations with increased storage stability, suitable for
i.d. delivery needs to be further intensified.
This study provides insights into the qualitative and quantitative deposition of micro-
and nanoparticles in the context of different commercially available types of MNs. It was
shown that the penetration depth of particles with diameters below 7 µm is independent
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of the particle size. However, the quantitative amount deposited in the tissue was highly
dependent on the particle diameter with an optimum around 0.5 µm.
Besides the particle size, the MN tip geometry and application mode strongly influenced
the penetration behavior of the particles as well as the quantitative i.d. delivery. No
clear impact of the MN length and the number of micropores was identified. Cone-shaped
MNs applied using a roller device were superior in providing a high penetration depth
and also induced the highest particle deposition compared to a dense array of flat MNs.
Independent of the MN tip geometry, needle lengths between 200 − 250 µm were suitable
to facilitate a deposition of particles in the epidermal and dermal skin layer, which is
the preferred delivery depth for cutaneous vaccination. The deposition of nanoparticles
in close vicinity to epidermal and dermal APCs allows for the uptake and processing of
antigen-loaded particles. Nanoparticles delivered intradermally by this approach can serve
as suitable adjuvants for cutaneous vaccination. Microparticles, on the other hand, could
serve as antigen-releasing depot in the skin tissue.
To date, an easy to develop and cost-effective approach for cutaneous vaccination that
can truly compete with conventional vaccination is still missing. MNs are a promising
tool to fill this gap. This study provides valuable insights regarding the key factors that
affect the i.d. particle delivery upon microneedling, namely MN tip geometry, application
mode, particle size, and massage. These findings help interpreting existing research and
serve as starting point to select optimum MN treatment conditions. Although model
particle suspensions have been used in this study, other drug and vaccine delivery systems
can be easily combined with efficient MN treatment, e.g. virus-like-particle vaccines or
dry powder patches. Additionally, microneedling is an attractive tool to enhance active
delivery approaches, such as gene gun delivery [58].
The commercial availability of solid MNs makes them a useful and cost-efficient tool in re-
search, especially for early screens of new vaccines and formulations. Particularly particles
are a promising component in cutaneous vaccination due to their high potential to serve
as sustained release depot or vaccine adjuvant. This study contributes to the thorough
characterization of the mechanistics of particle application and MN treatment, which is of
key relevance for the design of future studies.
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[33] D. Hüwel, Characterization of polymer films for intradermal vaccine delivery, bthesis,
Ludwig-Maximilians-University Munich, 2015.
[34] Y. A. Gomaa, D. I. J. Morrow, M. J. Garland, R. F. Donnelly, L. K. El-Khordagui,
V. M. Meidan, Effects of microneedle length, density, insertion time and multiple
applications on human skin barrier function: Assessments by transepidermal water
loss, Toxicol In Vitro 24 (2010) 1971–1978.
[35] G. Schneider, G. Decher, N. Nerambourg, R. Praho, M. H. V. Werts, M. Blanchard-
Desce, Distance-dependent fluorescence quenching on gold nanoparticles ensheathed
with layer-by-layer assembled polyelectrolytes, Nano Lett 6 (2006) 530–536.
[36] C. S. Peyratout, L. Dahne, L. Dähne, Tailor-made polyelectrolyte microcapsules: from
multilayers to smart containers, Angew Chem Int Ed Engl 43 (2004) 3762–3783.
[37] W. Feng, X. Zhou, C. He, K. Qiu, W. Nie, L. Chen, H. Wang, X. Mo, Y. Zhang, Poly-
electrolyte multilayer functionalized mesoporous silica nanoparticles for pH-responsive
drug delivery: layer thickness-dependent release profiles and biocompatibility, J Mater
127
III. Intradermal micro- and nanoparticle delivery using microneedles
Chem B 1 (2013) 5886–5898.
[38] J. Schindelin, I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch,
S. Preibisch, C. Rueden, S. Saalfeld, B. Schmid, J.-Y. Tinevez, D. J. White, V. Harten-
stein, K. Eliceiri, P. Tomancak, A. Cardona, Fiji: an open-source platform for
biological-image analysis, Nat Meth 9 (2012) 676–682.
[39] J. J. Richardson, J. Cui, M. Bjornmalm, J. A. Braunger, H. Ejima, F. Caruso, Inno-
vation in layer-by-layer assembly, Chem Rev 116 (2016) 14828–14867.
[40] D. V. Volodkin, A. I. Petrov, M. Prevot, G. B. Sukhorukov, Matrix polyelectrolyte
microcapsules: new system for macromolecule encapsulation, Langmuir 20 (2004)
3398–3406.
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IV
APPLICATION OF WATER-SOLUBLE
POLYVINYL ALCOHOL-BASED FILM PATCHES
ON LASER MICROPORATED SKIN FACILITATES
INTRADERMAL MACROMOLECULE AND
NANOPARTICLE DELIVERY
This chapter has been published as L. Engelke, G. Winter, and J. Engert, Application
of water-soluble polyvinyl alcohol-based film patches on laser microporated skin facilitates
intradermal macromolecule and nanoparticle delivery, Eur J Pharm Biopharm 128 (2018)
119-130. I designed and conducted this study and wrote the manuscript by myself.
1 Introduction
During the past decades, the research and knowledge regarding the intradermal delivery of
biologics and particularly vaccines has significantly increased [1, 2]. Proteins, peptides, and
nucleic acids have been topically applied, including antigens for active vaccination, allergens
for the treatment of type I allergies, and antibodies for local or systemic delivery [3–
5]. However, the transdermal delivery of proteins into intact skin is known to be highly
restricted due to their size, instability, and mostly hydrophilic properties [6]. The efficient
and reproducible delivery of rather high-priced macromolecules into the skin therefore
represents a major challenge with regards to their broad application in topical delivery.
To investigate and exploit the benefits of topically applied proteins, today, various tech-
niques can be used which actively deliver drug formulations into the skin [7]. Fractional
ablative laser microporation is a particularly attractive approach for the active intra-
dermal delivery of molecules and provides the possibility to access specific layers of the
skin [8]. Pulsed infrared lasers are used to induce a thermal ablation of tissue in micron
sized columns with a diameter of 30 − 200 µm [9], mainly referred to as microthermal
zones (MTZs) [10] or microscopic ablation zones (MAZs) [11]. Carbon dioxide (CO2) and
Er:YAG lasers operating at wavelengths of 10.60 µm and 2.94 µm, respectively, are the two
most common types of lasers used for ablative skin laser treatment [12]. At these wave-
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lengths, water molecules show strong light absorption that induces vibrational excitation
and heating in very short time, leading to vaporization and the ablation of surrounding
tissue [13–15]. The thermal impact on the remaining tissue thereby depends on the sys-
tem and parameters applied, e.g. laser fluence, local beam power density, pulse duration,
and pore density [16]. Due to a higher absorption coefficient at ambient temperatures,
Er:YAG devices are associated with a more precise microablation and reduced residual
thermal damage (RTD), showing coagulation zones of 10− 40 µm compared to a thickness
of 100−150 µm for CO2 lasers [12, 16]. Severe side effects, including erythema, edema, and
postinflammatory hyperpigmentation, as well as overall healing times could be significantly
reduced using fractional lasers and particularly Er:YAG devices emitting very short pulses
of laser light [17]. ’Cold ablation’ is characterized by minimal RTD on the tissue and pro-
vides a micropore closure within two days, driven by natural re-epithelialization [8, 18, 19].
The reduced thermal damage goes along with inferior skin contraction, collagen shrinkage,
and tissue remodelling [20, 21], which are beneficial effects for the treatment of rhytides,
photodamaged skin, scars, and other skin conditions [22].
Today, fractional laser microporation is an inherent part in the portfolio of skin resurfacing
treatments and by that is well established as a safe dermatological method. Besides this,
recent studies have reported on the delivery of drug substances into laser microporated
skin, including small molecules [23–29], peptides [30, 31], macromolecules [32–36], nucleic
acids [37, 38], particles [39, 40], and cells [41]. Of special interest is the precise targeting
of specific skin layers for the intradermal delivery of immunogenic molecules. The skin has
long been recognized as an immunologic organ comprising a high density of APCs, namely
LCs in the epidermal and different subsets of dDCs in the dermal layer [42–44]. Moreover,
epidermal keratinocytes are involved in early inflammation processes and play a key role
in promoting adaptive immune responses when targeted by cutaneous vaccination [45, 46].
The high abundance of immunocompetent cells in the epidermis and dermis makes the
skin a particularly attractive site for vaccine delivery. By directly addressing LCs and
dDCs, it is possible to regulate the differentiation of CD4+ T helper cells (Ths) and
CD8+ cytotoxic T lymphocytes (CTLs) [43]. Moreover, such specific targeting has a direct
impact on the Th cell polarization [47, 48]. Without further adjuvantation, T cells tend
to differentiate along the Th2 pathway upon intradermal delivery of antigens. However,
a re-modelling towards Th1/Th2-balanced immune responses is possible using suitable
adjuvants [8, 49, 50]. The advantage of a precise targeting of different skin layers and
immune cells by fractional laser microporation has been exploited for cutaneous vaccination
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Table IV.1: Drug formulations and molecule types that have been tested for skin delivery in
connection with ablative fractional laser poration using CO2 (λ = 10.60 µm), Er:YAG (λ =
2.94 µm), or erbium:yttrium scandium gallium garnet (Er:YSGG) lasers (λ = 2.80 µm).
Type of molecule Reference
Solution
CO2 lasers Small molecules 5-Fluorouracil [23]; Vitamin C, magnesium ascorbyl phosphate [24];
Hydroquinone, Imiquimod, FITC [35]; Sulphorhodamine B,
methylene blue [64]
Macromolecules FITC-dextranes 4, 20, 40 kDa [35]; Texas red-OVA [64]
Er:YAG lasers Small molecules Methotrexate [11]; 5-Fluorouracil [23]; Vitamin C, magnesium
ascorbyl phosphate [24]; 5-Aminolevulinic acid [25,27];
Lidocaine [26]; Prednisone [28]; Diclofenac [29]; Imiquimod [31];
FITC [33]; Sulphorhodamine B [37]; Indomethacin, Nalbumphine [72]
Peptides Peptides (716 Da, 1429 Da, 2190 Da, 2354 Da) [30,31]
Macromolecules Lyzozyme [30]; FITC-dextranes 4, 20, 40, 70, 150 kDa [31]
FITC-dextranes 4, 19, 38, 77 kDa, FITC-insuline hexamer [33];
ATG (Thymoglobulin®), Basiliximab (Simulect®) [34];
hGH [36, 55]; Phl p 5 [49, 51]; OVA [51]; OVA, XCL1-OVA
Vaccibody [53]; HBsAg, conjugate vaccines (Menveo®, ActHIB®) [54];
Cyt c, FSH, FITC-BSA [55]; FITC-dextranes 4, 10, 20 kDa [71]
Nucleic acids Fluorescein-labeled oligonucleotides (15-mer, 25 mer),
plasmid DNA [37]; siRNA [38]
Er:YSGG lasers Small molecules Hydrocortisone [32]
Macromolecules γ-IFN [32]
Suspension
CO2 lasers Small molecules Triamcinolon acetonide [56]
Particles Quantum dots [35]
Er:YAG lasers Particles Ti2O nanoparticles, Al2O3 microparticles [39];
CaCO3 microcontainers containing Fe3O4 nanoparticles [40];
Triamcinolone acetonide-, nile red-, fluorescein-loaded microparticles [57]
Cells Adipose-derived stem cells (ADSC) [41]
Liposomes
CO2 lasers Small molecules Carboxyfluorescein [58]
Macromolecules FITC-OVA [58]
Semi-solid preparation
CO2 lasers Small molecules Diclofenac [29]; Methylaminolevulinic acid [59];
5-Fluorouracil [60]
Er:YAG lasers Small molecules Diclofenac [29]; Lidocaine [61]
Dry powder patch
CO2 lasers Small molecules Sulphorhodamine B [62,65]
Macromolecules OVA [62]; OVA, insuline, antibody [65]
Nucleic acids Vaccinia virus encoding OVA cDNA [62]
Cells BCG vaccine [62]
Er:YAG lasers Macromolecules OVA [52]
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and transcutaneous/epicutaneous allergen-specific immunotherapy (TCIT/EPIT) [51–54].
Table IV.1 highlights that a wide range of different molecules have been successfully deliv-
ered into laser-generated micropores using liquid formulations, e.g. solutions [23, 55], sus-
pensions [56, 57], or liposomes [58]. However, only few studies have been using formulations
easier to apply under real-life conditions, e.g. semi-solid or dry patch formulations [59–62].
Many proteins and especially vaccines have limited stability in the solubilized state, which
requires a cold chain and limits the shelf-life at ambient temperatures. On the other hand,
superior micropore filling has been observed for liquid formulations compared to semi-solid
preparations [63]. For these reasons, novel drug delivery systems should provide improved
storage stability and liquid-like micropore filling properties. Based on these demands,
powder-loaded patches, which are based on an array of laser-generated and drug powder-
loaded microchannels, have been developed and tested for immunotherapy [52, 64, 65]. The
present study introduces an alternative formulation strategy exploiting water-soluble dry
film patches as a drug delivery system. We aimed to solubilize hydrophilic polymer films
directly on laser microporated skin, taking advantage of an enhanced water transport from
the tissue through the porated skin into the film under occlusion. Occlusive backings, used
for fixation on the skin, prevent water loss and accelerated a dissolution of the polymer
films. The drug is then released upon dissolution of the film matrix, which allows the
molecule to diffuse through the micropores into the viable skin tissue.
Different polymer film formulations based on water-soluble PVA or blends of PVA with
carboxmethyl cellulose (CMC) or cross-linked carbomer as gelling agents were prepared
using the film casting technique. This easily scalable fabrication approach resulted in thin,
fast-releasing polymer films that could be loaded with a broad variety of molecules and
concentrations. To validate the feasibility of our approach, the release from the film patches
and the delivery of FITC, rhodamine B-labeled dextrane 70 kDa (RD70), and PS-particles
into laser microporated pig skin was tested using the P.L.E.A.S.E.® fractional laser po-
ration technology (Pantec Biosolutions, Ruggell, Liechtenstein). The P.L.E.A.S.E.® laser
system enables a safe and pain-free ablation of superficial skin layers and has been success-
fully tested for immunotherapy in research [49, 51–54].
This study presents a novel drug delivery platform based on PVA polymer films suitable for
the intradermal administration of macromolecules and nanoparticles upon fractional skin
laser microporation. The water-soluble polymer films provide the potential to enhance the
drug storage stability while preserving liquid-like diffusion properties upon administration.
Furthermore, the polymer film patch reduces the risk of infection by covering the impaired
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skin barrier during micropore closure.
2 Materials and Methods
2.1 Chemicals
FITC, OVA, polysorbate 20, polyvinyl alcohol (PVA, Mowiol® 4-88, MW ∼31 kDa),
rhodamine B-labeled dextrane 70 kDa (RD70, MW 70 kDa), sucrose, and trichloroacetic
acid (TCA) were purchased from Sigma-Aldrich (Taufkirchen, Germany). Red-fluorescent
PS-particles (ex 530 nm/em 607 nm) were purchased from microparticles GmbH (Berlin,
Germany). CMC (Tylopur® C30 G1) was obtained from Clariant (Wiesbaden, Germany).
Cross-linked carbomer (Carbopol® 974P) was obtained from BF Goodrich Chemical (Brus-
sels, Belgium). Trehalose and sodium dihydrogen phosphate were purchased from VWR
International (Leuven, Netherlands). Potassium carbonate and Tris were obtained from
Merck (Darmstadt, Germany). Propylene glycol was from BASF (Ludwigshafen, Ger-
many). Di-sodium hydrogen phosphate was purchased from Applichem (Darmstadt, Ger-
many). Sodium chloride was obtained from Bernd Kraft (Duisburg, Germany).
2.2 Liquid polymer film formulations
PVA was dissolved alone or together with CMC in 10 mM PBS (pH 7.0, 50 mM ionic
strength) at 80 °C in a water bath. Propylene glycol and polysorbate 20 were added to
the polymer solutions and mixed thoroughly. The PVA-carbomer blend formulation was
prepared as described above using water for dissolution and Tris for subsequent pH ad-
justment. After cooling down to RT, solutions of different model substances were added
to the polymer mixtures, using OVA, FITC, RD70, or red-fluorescent 5 µm or 0.5 µm
PS-particles as model substances and vehicles. The model substance was dissolved in
10 mM PBS or water containing sucrose and trehalose as protein stabilizers in a molar
ratio of 1/500 for each stabilizer. Different OVA loadings were obtained by adjusting the
amount of model substance and PVA (Tab. IV.2). Film formulations containing FITC
or RD70 were prepared similarly, providing molar concentrations equal to sim25 µg/mg
and sim100 µg/mg OVA-loaded films, respectively. Particle-loaded films were obtained
by adding an appropriate volume of 2.5% (w/v) particle suspension (as provided by the
manufacturer) to the polymer mixture with a target concentration of 100 µg particles/mg
dry film.
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Table IV.2: Composition of ovalbumin (OVA)-loaded polymer film formulations with target
concentrations from 25 µg to 100 µg OVA per mg dry film.
Polymer film formulation
Component [% (w/w)] PVA PVA-CMC PVA-Carbomer
Ovalbumin (OVA) 0.6 - 2.4 0.3 - 1.2 0.3 - 1.2
Trehalose/Sucrose (1:1) 3.4 - 13.4 2.4 - 9.7 2.3 - 9.2
Propylene glycol 5.0 8.7 8.7
Polysorbate 20 0.07 0.04 0.04
Carboxymethyl cellulose (CMC) - 4.4 -
Cross-linked carbomer - - 4.4
Polyvinyl alcohol (PVA) ad 100 ad 100 ad 100
Solid content 15.1 % (w/v) 23.6 % (w/v) 23.6 % (w/v)
Knife height 1000 µm 500 µm 500 µm
Casting speed 1.0 mm/s 1.0 mm/s 0.5 mm/s
2.3 Casting of the polymer films
The liquid film formulations were cast onto polytetrafluoroethylene (PTFE)-coated cards
(mtv messtechnik, Erftstadt, Germany) using an Erichsen Coatmaster 510 (Erichsen GmbH,
Hemer, Germany). The automated film applicator operated at a working speed of 1mm/s
for the PVA and PVA-CMC blend films or at 0.5 mm/s for the PVA-carbomer blend films.
PVA films were prepared using a 1000 µm casting knife whereas a 500 µm casting knife
was used for the PVA-CMC and PVA-carbomer blend films. The polymer films were dried
overnight at RT and cut into 15x15 mm2 samples. The film sample dimensions and weight
were determined prior to each experiment. The OVA loading was quantified upon recon-
stitution of the dry polymer films using a bicinchoninic acid (BCA) assay (Micro BCA
Protein Assay Kit, Thermo Scientific, Waltham, MA, USA). The FITC and RD70 con-
tents were determined by fluorescence spectroscopy upon dissolution in 100 mM Tris buffer
(pH 9.0, 150 mM ionic strength).
136
2 Materials and Methods
Figure IV.1: Schematic illustration of the customized flow-through diffusion chamber to
assess the release from polymer films.
2.4 Fluorescence spectroscopy
The model substances FITC and RD70 were quantified using a Cary Eclipse fluorescence
spectrophotometer (Agilent, Santa Clara, CA, USA) at excitation and emission wave-
lengths of 492 nm/ 518 nm and 555 nm/ 576 nm, respectively. Calibration resulted in
linear detection ranges between 1-400 ng/mL for FITC and 50-3,000 ng/mL for RD70 so-
lutions (both R2 = 0.999). The limit of detection was 1 ng/mL for FITC and 50 ng/mL
for RD70, respectively. Each value was determined as the average out of 5 consecutive
measurements. The fluorescence intensity of each sample was analyzed in triplicates.
2.5 Release from polymer films
The release of FITC as model substance from dry polymer films was tested in a customized
flow-through diffusion chamber (Fig. IV.1). In precise, the dry film patches were mounted
in the donor compartment with the polymer film facing the circular opening of a low-
volume receptor chamber. The receptor chamber provided a medium in- and outlet on
opposite sides, generating a laminar flow of the receptor medium. Nucleopore membrane
filters with a pore size of 12 µm (25 mm diameter, Whatman, GE Healthcare, Freiburg,
Germany) were used to separate donor and receptor compartments and Leukoflex® occlu-
sive tape (BSN Medical, Hamburg, Germany) was used for fixation of the polymer films.
At a flow-rate of 400 µL/h, Tris buffer (100 mM, pH 9.0, 150 mM ionic strength) was
pumped through the receptor chamber using a LA-160 syringe pump (Landgraf Laborsys-
teme, Langenhagen, Germany). At the chamber outlet, receptor medium was collected in
fractions after 30 min, every hour until 8 h, and after 10 h. The amount of FITC in each
fraction was quantified and compared to the total FITC content of each film sample. The
total FITC content was calculated from the theoretical loading determined by dissolution
of film samples in a defined volume. All experiments were performed in triplicates.
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2.6 Laser microporation treatment
Excised skin from both sides of the ventrolateral region between mammary ridge and the
lateral side of the body of 5 − 7 week old piglets was supplied by the Clinic for Swine
(Faculty of Veterinary Medicine, LMU Munich, Oberschleißheim, Germany). Skin samples
were cleaned with water and bristles were removed using a hair clipper. Full thickness
pig skin was prepared by removing excess subcutaneous tissue with a scalpel. The skin
samples were stored at −80 °C for no longer than one month. Before use, the pig skin
was thawed and approximately 3x3 cm2 skin samples were prepared. After equilibration in
0.9 % saline for 10 min, the skin surface was dried using a cotton wipe and positioned on
a flat surface. For laser microporation using the P.L.E.A.S.E.® fractional laser poration
system (Pantec Biosolutions, Ruggell, Liechtenstein), two pulses of 125 µs per pore with
a fluence of 17.8 J/cm2 were applied, creating a nominal pore depth of 71 µm on a total
treatment area of 14x14 mm2 and a pore density of 15 %. For cosmetic applications
typically 100 µm pore depth and 5 % pore density are targeted. The pore density in pores
per cm2 was determined by counting and the pore diameter was assessed by histological
imaging.
2.7 Transepidermal water loss measurement
The transepidermal water loss (TEWL) before and after laser microporation was quanti-
fied using a Tewameter® TM 300 (Courage + Khazaka electronic, Cologne, Germany).
The TEWL was determined in triplicates, each value being calculated as the mean of 5
consecutive stable measurements within equilibration for ∼5 min. Freshly excised pig skin
and pig skin stored at −80 °C for 1, 14, or 28 days were compared in this experiment. The
skin samples were hydrated for 10 min in 0.9 % saline and subsequently adjusted onto a
flat surface. Skin surface moisture was removed using a cotton wipe and the TEWL was
measured after 10 min resting at ambient conditions. Laser microporation was performed
as described above. After mounting onto Franz diffusion cells and equilibration for 30 min,
the TEWL of intact and laser microporated skin was measured as described above.
2.8 Skin penetration and permeation
RD70 or PS-particle loaded polymer film samples were attached to laser microporated or
intact skin using Leukoflex occlusive tape (BSN Medical, Hamburg, Germany). Subse-
quently, the skin samples were mounted in jacketed Franz diffusion cells with an orifice
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diameter of 15 mm (A = 1.77 cm2). The conjunction of donor and receptor compartment
was covered with parafilm to avoid leakage and fixated with a clamp. The receptor com-
partment (12 mL) was filled with 100 mM Tris buffer (pH 9.0, 150 mM ionic strength)
and the samples were incubated for 24 h at 32 °C. After 2, 4, 6, 12, and 24 h, 1 mL of the
receptor volume was withdrawn and replaced by fresh medium. The amount of RD70 in
the receptor medium was quantified by fluorescence spectroscopy. After 24 h incubation,
Franz cells were dismantled, excess formulation was removed from the skin surface and an
area of 1x1 cm of the treatment region was prepared for further analysis. All experiments
were performed in triplicates.
2.9 Histological analysis
Incubated skin samples were embedded in tissue freezing medium (Leica Biosystems, Wet-
zlar, Germany) and shock frozen in liquid nitrogen. Vertical skin sections with a thickness
of 10 µm were prepared using a Microm HM560 cryostat (Thermo Scientific, Waltham, MA,
USA). Histological samples were prepared using 4’,6-diamidino-2-phenylindole (DAPI)
mounting medium (Fluoroshield, Sigma-Aldrich, Taufkirchen, Germany). The skin cross-
sections were imaged upside down using a LSM 510 laser scanning microscope equipped
with a LD-Achroplan 40x/0.6 corr objective (both from Carl-Zeiss, Jena, Germany). The
settings were kept constant for each image. Image analysis was performed using Fiji image
analysis software [66].
2.10 Quantification of RD70 in skin
The amount of RD70 that penetrated into the skin was quantified upon extraction from
horizontal skin sections. In precise, incubated skin samples were fixed with the surface
down onto a pre-cooled plate, embedded in tissue freezing medium (Leica Biosystems,
Wetzlar, Germany), and frozen at −80 °C. Horizontal skin sections with a thickness of
20 µm were prepared by cryosectioning. Five slices were collected in a tube, adding up in a
total thickness of 100 µm for each extracted skin layer. RD70 was extracted from the skin
sections by incubation in 200 µL of 100 mM Tris buffer (pH 9.0, 150 mM ionic strength)
for 20 min at 60 °C. After cooling down to RT, proteins were removed from the extract
using TCA. For deproteinization, the extracted samples were centrifuged at 13,000 rpm for
2 min and 180 µL supernatant was transferred to a fresh tube. Subsequently, 30 µL of ice
cold 100 % TCA was added to the solution and the mixture was incubated for 5 min on ice.
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After centrifugation at 13,000 rpm for 2 min, 200 µL supernatant was quickly transferred
to a fresh tube and mixed with 30 µL ice cold 5 M potassium carbonate solution. The basic
pH of the extract was checked using pH paper. The RD70 content of the deproteinized
extract was analyzed by fluorescence spectroscopy. The experimental flux was calculated
based on the amount of RD70 detected in the skin tissue below 300 µm per cm2 and the
amount detected in the receptor compartment after 24 h.
3 Results
3.1 Film properties and release behavior
Transparent, water-soluble polymer films with an average thickness of 36 ± 14 µm for
pure PVA, 71 ± 12 µm for PVA-CMC, and 58 ± 13 µm for the PVA-carbomer blend were
prepared using the film casting technique followed by overnight drying at ambient tempera-
tures. Different hydrophilic model substances could be incorporated into the polymer films
by direct loading. The addition of varying amounts of model substance to the polymer
solution while adapting the PVA content allowed to adjust the target concentration per
area unit as preferred (Tab. IV.3).
Stable, homogeneous films were obtained with up to 389.4 ng/2 FITC or 268.6 µg/2 RD70
incorporated as model substances into the polymer films. Although polysaccharides can
increase the brittleness of dry polymer films [67], films loaded with RD70 provided suit-
able properties for the patch application. RD70 is a branched polysaccharide composed
of 1,6-alpha and 1,3-glycosidic linkages between glucose units, which is labeled with rho-
damine B fluorescent dye molecules via thioester links to free glucose hydroxyl groups.
The macromolecular model substance exhibited a molecular weight of 70 kDa and hy-
drophilic properties to simulate the behavior of protein antigens and other hydrophilic
macromolecules.
Besides small and macromolecular model substances, films with suitable properties were
obtained when PS-particles with a size of 5 µm or 0.5 µm were loaded as model vaccine
vehicles into the formulations. The content of model substance or vehicle could be adjusted
by varying film thickness and polymer content of the film formulation.
All films showed a high solubility and dissolved in large amounts of water within seconds.
To simulate the restricted access of the films to tissue fluids through laser-generated mi-
cropores, FITC-loaded films were attached to a customized diffusion chamber, separated
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Table IV.3: Film properties and maximum concentrations per mass or area unit that were
achieved by direct loading of the model substances fluorescein isothiocyanate (FITC) and
rhodamine B-labeled dextrane 70 kDa (RD70). (* used for skin penetration and permeation
experiments)
Film formulation Film Weight per FITC RD70
thickness 15x15 mm2 * content content
[µm] [mg] [ng/cm2] [µg/cm2]
PVA 36 ± 14 6.0 ± 0.5 242.5 ± 36.5 92.4 ± 18.6
PVA-CMC 71 ± 12 20.2 ± 0.2 389.4 ± 51.1 268.6 ± 79.6
PVA-Carbomer 58 ± 13 17.2 ± 0.2 203.5 ± 16.8 207.5 ± 7.7
from the receptor medium by a filter with a nominal pore size of 12 µm. Upon contact with
the receptor medium, which was passing below the filter at a low flow-rate, the hydrophilic
film polymer dissolved and led to a fast release of the model substance. The occlusive
tape that was used for fixation of the polymer films served as a tight, water-resistant seal
within the diffusion chamber entrapping the solubilized film formulation. Within six hours,
75− 100 % of the incorporated FITC was released from the films regardless of the investi-
gated polymer film formulation(Fig. IV.2). The comparison of low and high FITC loading
in pure PVA, PVA-CMC, and PVA-carbomer films revealed a tendency of inferior release
after 12 h for the high FITC content with a total release around 80 %. The incorporation
of lower amounts of FITC into the films resulted in an improved release behavior close
to 100 % total release. Considering the release kinetics of different film compositions, no
obvious differences between PVA, PVA-CMC, and PVA-carbomer films with comparable
FITC content were detected.
3.2 Transepidermal water transport and film dissolution
To evaluate the suitability of the utilized experimental setup to provide a good transferabil-
ity to in vivo skin conditions, different aspects of the Franz diffusion cell experiment were
examined. The pore formation process as well as the micropore dimensions are affected not
only by laser parameters but also by skin condition and the level of hydration [68]. Further-
more, the extent of skin barrier disruption and the storage-induced damage of excised skin
samples might affect the water transport through the tissue. To ensure a pore formation
comparable to in vivo conditions, the release of water from freshly excised and stored pig
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Figure IV.2: Cumulative release of the hydrophilic model substance FITC from PVA and
PVA-CMC/ PVA-carbomer blend films loaded with 50-100 ng (low) and 200-400 ng (high)
FITC per cm2 film. All film formulations provide a fast drug release within 6 h with
restricted water contact through 12 µm filter pores.
skin at the time of microporation was examined by TEWL measurements. Similarly, the
water transport through intact and laser microporated pig skin was characterized in the
Franz cell setup.
After hydration, the skin samples were prepared for laser treatment, which was performed
∼ 10 min after removal from saline solution. At this point in time, all skin samples
showed TEWL values between 4−15 g/m2/h regardless of the storage duration (Fig. IV.3).
Furthermore, comparable results were obtained for each sample when the untreated pig
skin was assembled in the Franz diffusion cell setup. Fresh pig skin and skin samples that
were stored for one day provided slightly higher TEWL values compared to skin samples
with a storage duration of 14 or 28 days at −80 °C. The lowest values were detected using
pig skin that was stored for 14 days. Fractional laser microporation using the previously
specified parameters led to a 4- to 5-fold increase in the water transport trough the skin.
The dissolution of the polymer films was studied macroscopically over an incubation period
of 24 h using untreated and laser microporated pig skin. It was observed that all polymer
film formulations dissolved within less than 6 h when attached on top of laser-generated
micropores. However, no or incomplete disintegration was detected when untreated skin
was used in the Franz cell setup. Figure IV.4 gives a representative overview of the film
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Figure IV.3: Water loss of excised pig skin after different treatments.
dissolution behavior in the Franz diffusion cell setup, showing PVA-CMC blend films di-
rectly after fixation to laser microporated skin and after 6 h incubation. The dissolution
of the films was macroscopically visible. Upon solubilization, air bubbles were formed due
to a small residual interspace between film patch and skin surface at the time of patch
application. The occlusive tape used for film fixation, facilitated the generation of a liquid
depot between skin surface and tape. After disintegration of the polymer matrix, the model
substance or particles were free to diffuse into the underlying tissue. Using untreated skin,
first signs of a beginning dissolution were detectable only after 24 h incubation. Upon
dismantling, shape and surface of these polymer films was predominantly intact but sticky
due to incomplete hydration.
3.3 Intradermal delivery of RD70 and PS-particles
The intradermal delivery of RD70 and PS-particles was evaluated qualitatively by laser
scanning fluorescence microscopy. After 24 h, excess solubilized film was removed from
the skin surface and vertical sections were prepared. Cell nuclei of the viable tissue were
stained with DAPI to enable the distinction between epidermal and dermal skin layer.
Microscopic imaging revealed an increasing deposition of RD70 in the epidermis and upper
dermis of micropores over 6, 12 and 24 hours (images not shown). After 24 h incubation, the
penetration of RD70 into the micropores was comparable for each polymer film formulation
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Figure IV.4: Dissolution behavior of representative polymer films observed during incuba-
tion in Franz diffusion cells using red-fluorescent RD70 as model substance. The images dis-
play an array of laser-generated micropores on excised pig skin (a), a single laser-generated
micropore (b), as well as RD70-loaded PVA-CMC blend films directly after mounting onto
Franz diffusion cells (c) and after 6 h incubation on laser microporated pig skin (d). Fur-
thermore, polymer films are shown after incubation for 24 h (e) and after disassembly from
Franz cells using untreated pig skin (f). (Magnification 200x, scale bar=100 µm)
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(Fig. IV.5a − c). The delivery of the PS-particles however, was dependent on the particle
size and the used polymer formulation. The application of nanoparticle-loaded films with
a size of 0.5 µm led to a deposition over the entire micropore surface (Fig. IV.5d − f),
whereas no particle delivery was observed for microparticles with a diameter of 5 µm
(Fig. IV.5g − i). Moreover, the nanoparticle delivery using PVA polymer films was found
superior over the deposition using PVA blend formulations. No substantial deposition of
RD70 or PS-particles was detected on intact skin.
The penetration of RD70 was quantified by fluorescence spectroscopy after extraction from
100 µm horizontal skin sections and sample deproteinization. The incubation of laser mi-
croporated skin with RD70-loaded polymer films facilitated a penetration of the macro-
molecule into the epidermal and dermal layer of the skin. For all tested film formulations,
an amount of 150−300 ng RD70 per cm2 was extracted per 100 µm horizontal skin section
up to a depth of 500 µm (Fig. IV.6). Furthermore, it was shown that RD70 permeated
through the skin during incubation on laser microporated skin. Although the amount
of RD70 in the Franz cell receptor compartment remained below the limit of detection
within 12 h incubation, the macromolecule was quantifiable in the receptor medium after
24 h incubation. PVA films provided a slightly higher RD70 delivery into and through ex-
cised pig skin compared to the PVA-CMC and PVA-carbomer blend formulations, which
both showed comparable RD70 penetration and permeation behavior. The calculated to-
tal amount of RD70 that was delivered into and through the skin over a microporated
area of 14x14 mm2 was highest for the pure PVA polymer film formulation with a total
amount of 4.8 µg (Tab. IV.4). In comparison, 3.4 µg and 3.0 µg were delivered into the skin
applying RD70 loaded PVA-CMC and PVA-carbomer films. Approximately 75 % of the
total amount was detected in deeper skin layers or permeated into the Franz cell receptor
compartment with values of 2.8 µg, 1.8 µg, and 1.7 µg for the pure PVA, PVA-CMC, and
PVA-carbomer film patches.
The experimentally determined flux upon 24 h provided relatively low values between
0.07−0.12 µg/cm2/h (Tab. IV.4). A slightly superior flux was detected for pure PVA films
compared to the PVA blend formulations, which provided comparable values. Based on
theoretical considerations the predicted flux was calculated based on the intuitive model
(Jint) and the proposed model (Jmodel) by Rzhevskiy et al. (Tab. IV.4) [69]. A pore
density of 273 pores/cm2 determined by counting and a pore diameter of 200 µm was used
for flux prediction. The molecular weight of 70 kDa of RD70 was used as provided by
the manufacturer. Furthermore, the RD70 concentration was determined based on the
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Figure IV.5: Fluorescence microscopy images of excised pig skin cross-sections after laser
microporation and incubation with PVA, PVA-CMC or PVA-carbomer blend films for
24 h on Franz cells. Intradermal deposition of RD70 (a-c), 0.5 µm PS-nanoparticles (d-f),
or 5 µm (g-i) PS-microparticles was shown by red fluoresce surrounding the micropore
tissue. Dashed lines frame the skin surface (upper, determined in transmission mode)
and the border between epidermal and dermal layer (lower). (Magnification 40x, scale
bar= 100 µm)
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Figure IV.6: Quantitative amount of RD70 per square centimeter extracted from 100 µm
horizontal skin sections and recovery of RD70 from the receptor compartment after 24 h
incubation of polymer films on laser microporated pig skin.
RD70 content per cm2 of each sample and the mean TEWL of 58.1 g/m2/h upon laser
microporation per cm2 within 24 h.
For the flux prediction using the intuitive model, a thickness of 1500 µm of the skin tissue
below the SC hs was used to represent full thickness skin. Moreover, a thickness equivalent
to the average film sample thickness (Tab. IV.3) was used as height hv above the SC. The
theoretical model by Rzhevskiy et al. predicted 4- to 10-times higher flux values compared
to the experimental flux. Higher deviations were observed for the CMC and carbomer
blend formulations. On the other hand, the intuitive model provided good estimates for
PVA-CMC and PVA-carbomer films but estimated a lower value for the pure PVA film.
The incubation of untreated pig skin with RD70-loaded PVA films did not result in a
substantial delivery into the skin. A total amount of 0.08 µg was recovered from intact
skin after 24 h incubation. This represents a delivery of approximately 0.08 % of the
total RD70 applied in a PVA film patch on intact skin. The model substance was mainly
detected in the first 100 µm horizontal layer of the skin, providing a deposition below
50 ng/cm2 (Fig. IV.6). Moreover, no RD70 could be quantified in the Franz cell receptor
compartment after 24 h incubation with a level below the limit of detection.
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Table IV.4: Total amount of RD70 delivered into the skin after 24 h, calculated as the sum
of substance that penetrated into and permeated through the skin and the experimental
and theoretically predicted RD70 flux per cm2 and hour. The predicted flux was calculated
based on the intuitive model (Jint) and the proposed model by Rzhevskiy et al. (Jmodel)
[69].
Film formulation Total RD70 delivery Jexp Jint Jmodel
[µg/cm2] [µg] [%] [µg/cm2/h] [µg/cm2/h] [µg/cm2/h]
PVA 3.6 ± 1.5 4.8 ± 1.7 2.3 ± 1.0 0.12 0.03 0.47
PVA-CMC 2.5 ± 0.4 3.4 ± 0.4 0.7 ± 0.1 0.08 0.08 1.06
PVA-Carbomer 2.2 ± 0.2 3.0 ± 0.4 0.7 ± 0.1 0.07 0.07 0.92
4 Discussion
4.1 Transepidermal water loss and film dissolution behavior
The TEWL of excised pig skin was determined under varying conditions to evaluate its
comparability to in vivo human skin. Furthermore, the influence of a short-term storage of
skin samples was assessed using freshly excised pig skin and skin samples that were stored
at −80 °C for up to 28 days.
Intact skin samples showed a water release between 4 − 15 g/m2/h, which lies within the
range of TEWL values observed on humans. Besides skin hydration and environmental
conditions, the water release measured on human skin was shown to be mainly dependent
on the site of the body and the circadian rhythm [70, 71]. Lower values between 3 −
14 g/m2/h have been measured on the forearm, whereas palms, soles, or the forehead
release higher amounts of water with TEWL values of up to 48 g/m2/h [70, 71]. The
TEWL of excised, intact pig skin samples was comparable to the TEWL measured on
human forearms, indicating that a comparable micropore formation with similar depths
and RTD should be possible at this site of the body. Moreover, intact skin samples, freshly
excised or stored, showed consistent TEWL values at the time of laser microporation and
in the Franz cell setup, indicating that optimum conditions were reached for the laser
microporation treatment. Certain variations of the TEWL between fresh and stored skin
samples were recognized but could not be linked to the storage duration. The differences
detected were in the range of variation observed on human skin with TEWL fluctuations
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of up to 14 g/m2/h [70, 71]. Based on these results, we assume that a storage of pig
skin samples for up to 28 days at −80 °C is suitable to maintain a water release behavior
comparable to in vivo human skin. To ensure comparability in the following delivery
studies, only pig skin from the dorsal region of 5 − 7 week old pigs was used.
Laser microporation using the P.L.E.A.S.E.® laser device induced a 4- to 5-fold increase
of the TEWL in vitro. A comparable impact by laser microporation has been reported
on human skin with an increase of the TEWL by factor 4.5 to 6.3 [29]. The enhanced
TEWL through the skin facilitated a fast dissolution of the polymer films for all tested
compositions. All film formulations disintegrated within a similar time period, thereby
providing at least 18 h during which the model substance could diffuse into the micropore
tissue before the pores would close. On the other hand, the low water transport through
intact skin was insufficient to dissolve the polymer films within a total incubation time
of 24 h. We therefore conclude that a fast dissolution of the polymer films is ensured
with a TEWL above 40 g/m2/h and should further improve with elevating TEWL values.
Besides that, it should be considered that an efficient film dissolution requires the use of
occlusive backings that entrap the transpired water and maximize the water contact with
the polymer films.
4.2 Influence of the polymer film formulation on the RD70 de-
livery
Histological images and the quantification of RD70 in horizontal skin sections revealed
that macromolecules were successfully delivered into laser microporated skin. Although
most significant deposition of RD70 was visible in the epidermis, extracts from deeper
skin sections showed that RD70 also penetrated into the dermal skin layer. Due to the
high density of LCs and dDCs in the epidermis and dermis, an antigen-specific immune
response is supposedly enhanced when the antigen deposition in these layers is maximized.
It has been reported that both, the vehicle formulation and the molecular structure of the
applied substance, influence the drug delivery and hence also the APC targeting [63, 72].
The amount of RD70 delivered into the skin was comparable to results of previous in vitro
studies using macromolecules [34]. In vivo a delivery efficiency of up to 80 % has been
reported for OVA-loaded dry patches [62].
We have shown that RD70 did not penetrate into intact skin, but was exclusively delivered
into laser microporated skin. The intradermal deposition of RD70 was slightly higher
using PVA polymer films compared to PVA-CMC and PVA-carbomer blends. Although
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this trend was not supported by microscopic imaging, the absolute quantification of RD70
by fluorescence spectroscopy suggested superior delivery properties using pure PVA films.
This effect could be attributed to the increased film thicknesses of the PVA blend for-
mulations, which led to slightly slower dissolution during incubation. Although a smaller
casting knife was used for the manufacturing of the PVA blend films, the final film thick-
ness of PVA-CMC and PVA-carbomer films was up to two times higher compared to the
pure PVA formulation. The addition of the gelling agents CMC and carbomer improved
the film casting properties of the polymer solutions by increasing the viscosity but reduced
the diffusion of RD70 into the skin.
The in vitro release study could simulate the restricted liquid contact through the micro-
pores. The drug release in the diffusion chamber was comparable for all film formulations
due to a simultaneous solubilization and release of model substance and film forming poly-
mer. Slightly inferior release was observed for polymer films with a higher content of model
drug. However, these differences were negligible with a generally high total release after
12 h incubation despite limited contact to the release medium. Generally, no differences
in the dissolution and release behavior were detected for pure PVA, PVA-CMC, and PVA-
carbomer films. Also, no difference in complete film dissolution in different aqueous media
with direct liquid contact at pH 6−9 was observed in preliminary studies (data nor shown).
The pore diameter of 12 µm used in the experimental setup was suitable to simulate the
limited access to the tissue fluid. Although this pore size is smaller compared to the diam-
eter of laser-generated micropores of 100− 200 µm, both diameters are significantly larger
than the molecules that pass through the pores into the release medium or skin tissue upon
dissolution.
The diffusion into the skin tissue was assessed using the Franz cell setup and showed a
formulation-dependent penetration and permeation behavior. Although a non-physiological
pH of 9 was used as Franz cell receptor medium, the short exposure ≤ 24 h of the skin
tissue to the elevated pH was not expected to induce major changes to the tissue during
incubation time. Moreover, dextrane molecules are expected to exhibit a neutral surface
charge. The low pKa of the attached rhodamine dye of ∼3 would induce a deprotonation of
carboxylic functional groups at slightly elevated as well as physiological pH. We therefore
expect comparable diffusion behavior of the model substance RD70 in the present study
setup using aqueous receptor media at pH 9 as well as physiological pH.
The total RD70 delivery results suggest that the film composition and film thickness were
the main factors to influence the RD70 penetration and permeation. Upon hydration
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and dissolution of the films on the skin surface, the model substance could diffuse into
the accessible micropore tissue. Compared to pure PVA films, the addition of CMC and
carbomer increased the formulation viscosity upon dissolution on the skin. The viscous gel
matrix could not diffuse into the micropores but remained on the skin surface, lowering the
diffusivity of the model substance. Lower values for the total delivery of RD70 into and
through the skin for PVA-CMC and PVA-carbomer films indicate that the release from the
gel matrix upon dissolution was reduced due to increased viscosity. Moreover, the higher
polymer content for PVA blend films further reduced the diffusion of RD70 into the tissue.
Besides film thickness, the relative composition of pure PVA and PVA blend formulations
could influence the RD70 penetration behavior. In comparison to the blend formulations,
pure PVA films provided a higher relative sucrose and trehalose content, enhancing the
initial film dissolution due to osmotic effects. With respect to the total amount of sucrose
and trehalose, PVA-CMC and PVA-carbomer films had higher contents per cm2 related to
loading of the model substance. Upon film dissolution, the resulting osmotic gel could have
induced a draining of water from the tissue, thereby reducing the penetration of RD70 into
the skin in opposite direction. Furthermore, the addition of plasticizers, e.g. propylene
glycol, can affect the release behavior from films. Higher contents of propylene glycol
were used for PVA blend formulations in order to reduce the film brittleness, which was
increased by CMC and carbomer polymers. Due to its hygroscopic properties, propylene
glycol can improve the wetting and dissolution behavior of the polymer films. Although the
relative propylene glycol content was higher in the PVA blend formulations, the dissolution
behavior of PVA-CMC and PVA-carbomer films was comparable to pure PVA films with
lower amounts of the plasticizer. Our findings indicate that the major rate limiting step in
this study was the diffusion of model substance into the skin. The film dissolution played
a minor role and was comparably fast for all tested formulations. The experimentally
determined flux indicated a relatively slow diffusion of the macromolecule through the
tissue which was further decreased by addition of the gelling agents CMC and carbomer to
the film composition (Tab. IV.4). The intuitive model resulted in well-matching fluxes for
the PVA-CMC and PVA-carbomer films whereas the proposed new model [69] generally
overestimated the flux for all formulations. It has to be noted that generally higher fluxes
were predicted for the CMC and carbomer blend formulation, although experimental data
revealed a reduced diffusion for these formulations. This observation, likely due to increased
viscosity compared to the pure PVA films, highlights the need to include the formulation
viscosity into predictive models of flux predictions. Furthermore, we conclude that the
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formulation viscosity and the polymer content per cm2 are important parameters affecting
dissolution time and, more importantly, the RD70 penetration into the skin. Moreover,
films with increasing thickness with even slower dissolution may potentially provide limited
capability to deliver macromolecules and other drug substances into laser microporated
skin.
Considering the micropore filling in vitro, we expected a filling behavior of the solubilized
polymer films comparable to liquid solutions or gels, for which good filling properties
have been demonstrated before [63]. Under in vivo conditions, topically applied liquid
is absorbed by laser microporated skin tissue within approximately 10 min [51, 53, 54].
These findings suggest similar behavior for the present patch delivery system when tested
under in vivo conditions. Upon dissolution on laser microporated skin, the solubilized film
formulation could be absorbed by the viable tissue, thereby delivering the drug substance as
well as film forming polymers with lower molecular weight. Although the ratio of delivered
to applied RD70 remained relatively low in the present Franz diffusion cell study, we assume
that the delivery efficiency might be improved under in vivo conditions. Particularly the
application of unblended PVA polymer film patches on laser microporated skin provides
the chance of low viscosity PVA formulation to be absorbed by the viable tissue.
4.3 RD70 delivery using soft laser microporation parameters
The efficient delivery into laser microporated skin depends not only on the vehicle for-
mulation, but also on drug substance properties like molecular weight, hydrophilicity and
lipophilicity, and their interplay with micropore characteristics. It has been shown that
small hydrophilic molecules diffuse easier through the tissue upon laser microporation com-
pared to larger molecules [31, 72]. Furthermore, the drug transport of small, hydrophilic
molecules can be enhanced by increasing not only the number of pores per cm2 (pore
density) but also the micropore depth [11, 31, 55, 72, 73]. Notably, increasing laser pulse
durations from 50 µs (super short pulse) up to 1000 µs (very long pulse) do not substantially
increase the micropore dimensions but mainly influence the extent of RTD, which com-
promises the molecule permeation at the tissue interface [72]. The transdermal delivery of
small molecules could be significantly increased by optimizing the laser microporation treat-
ment, in some cases leading to systemic side effects [74, 75]. Considering other molecule
types, the influence of laser settings on the delivery efficiency is less pronounced. Small,
lipophilic substances mainly penetrate into the skin via passive diffusion, whereas the dif-
fusion capabilities of macromolecules are highly dependent on their molecular structure
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and charge [31].
In the present study, we used RD70 as a stable, hydrophilic model macromolecule that
cannot diffuse through intact skin [31]. Our results prove that a substantial amount of
the macromolecule with a size of 70 kDa was delivered into laser microporated skin using
’cold ablation’ laser parameters. The P.L.E.A.S.E.® fractional laser poration device was
used to create shallow micropores that reached the epidermal and superficial dermal layer,
employing two pulses per pore with a low laser fluence of 17.8 J/cm2 and a pore density
of 15 %. In previous studies, laser fluences of up to 13.59 J/cm2 and about 22.65 J/cm2
have resulted in micropores with a diameter between 150− 200 µm, reaching depths of up
to 30 µm and 100 µm, respectively [26]. With the parameters used in this study, we were
able to generate micropores with equal diameter and a pore depth well comparable to the
expected nominal value provided by the laser poration device (Fig. IV.4). The application
of two pulses with a laser fluence of 17.8 J/cm2 facilitated the creation of micropores with
relatively small diameter but reaching deeper into the tissue compared to a one pulse
application. We assume that similar depths could be achieved at higher laser fluences,
however this would likely result in larger pore diameters and increased RTD, which would
affect penetration negatively. The laser poration treatment in the presented study resulted
in a distinct coagulation zone (RTD), which was observed around the micropore and most
likely attributed to a medium short pulse duration of 125 µs. Considering previous studies,
we expect that the delivery efficiency of RD70 could be further improved by optimizing the
micropore dimensions (laser fluence, number of pulses per pore), increasing the number of
pores per cm2 (pore density), and reducing the RTD-related tissue barrier (laser fluence,
pulse duration) [55, 72].
4.4 Nanoparticle delivery facilitated by fractional laser microp-
oration
To evaluate the intradermal delivery of particles as model vaccine vehicles, PS-nano- and
microparticles with a diameter of 0.5 µm and 5 µm were incorporated into the polymer films.
Fluorescence microscopy revealed that a substantial deposition of PS-nanoparticles over
the entire micropore surface was achieved. On the other hand, PS-microparticles did not
attach to the micropore surface or penetrate into the tissue. Unlike the PS-microparticles,
the smaller nanoparticles of 0.5 µm exhibited suitable properties to diffuse into the skin
upon tissue ablation. The differences in the deposition behavior can be attributed to a
smaller diffusivity for larger particles. We assume that an intermediate deposition of PS-
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microparticles was most likely mediated by sedimentation in the solubilized polymer films.
In contrast to PS-nanoparticles, larger microparticles could not enter the skin tissue and
were easily removed together with residual film in a post application cleaning treatment.
Just as described for RD70, the polymer formulation influenced the particle delivery sig-
nificantly. Histological images show that PVA films provided a superior deposition of
PS-nanoparticles compared to PVA films blended with CMC or cross-linked carbomer.
This effect was even more pronounced for the PS-nanoparticles which suggests a partic-
ularly strong sustaining effect on the particulate vehicles induced by the gelling agents.
Moreover, the gelling polymers might have interacted with the PS-nanoparticle surface as
observed with other polymers [76], thereby increasing the hydrodynamic radius and com-
promising the diffusion into the tissue. Therefore, a minimized content of film forming
polymer that maintains sufficient mechanical stability might be beneficial for the delivery
of nanoparticles from film patches into laser microporated skin.
Due to their immunostimulatory properties, nanoparticles are considered as a particularly
attractive adjuvant for vaccination [77]. Regarding the intradermal delivery of nanoparti-
cles, recent advances have shed more light on the delivery characteristics via the transfol-
licular route [78, 79]. Although a diameter between 0.4− 0.7 µm has been identified as the
optimum particle size [80], transfollicular delivery fails to provide an efficient deposition of
substantial particle amounts in close vicinity to cutaneous APCs. Moreover, a penetration
of nanoparticles larger than 10 nm into the viable skin is unlikely without further disrup-
tion of the skin barrier [81]. Furthermore, it has been reported that the particle uptake by
dendritic cells increases with decreasing particle diameters below 0.5µm [82].
5 Conclusion
We successfully demonstrated that PVA-based polymer films are easily water-soluble and
facilitate the delivery of macromolecules and nanoparticles into laser microporated skin.
The utilized film casting technique is easily scalable and would allow for a cost-effective
mass production of the film patches. Moreover, the good mechanical stability after direct
loading of different hydrophilic model substances into the formulations at varying concen-
trations suggests a good formulation compatibility with a wide range of molecules and
vehicles, e.g. vaccine antigens, allergens, nanoparticles, and adjuvants. However, the influ-
ence of different molecule types on the mechanical properties and storage stability of the
polymer films still requires an all-embracing investigation and shall be subject to future
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studies.
The patch delivery system, which is composed of a water-soluble polymer film and occlusive
backing, facilitates effective skin hydration, thereby promoting the antigen processing by
skin-resident APCs. Although immune responses have been observed upon prolonged anti-
gen contact with intact skin [83–85], the active delivery of vaccines into the viable tissue is
necessary to substantially boost the delivery efficiency and thus the immune response [4].
Reduced film thicknesses combined with higher loadings or the manufacturing of drug-
loaded droplet arrays are two further approaches to improve the delivery efficiency. Besides
that, the patch system allows to cover the impaired skin barrier during re-epithelialization,
thus rendering the application of plasters after microporation unnecessary.
In connection with fractional laser microporation, the presented PVA-based polymer film
patches offer a safe, minimally invasive route for cutaneous immunization and reduce sharp
waste and biohazard disposal, which are major disadvantages of intramuscular (i.m.) or
subcutaneous (s.c.) injections. The utilized P.L.E.A.S.E.® fractional laser poration system
provides the possibility to ablate the skin tissue with minimal RTD, offers a favorable side
effect profile, and provides the opportunity to safely and reproducibly increase the TEWL
through the skin. The development of a hand-held device might further increase the patient
compliance and particularly the commercial appeal.
The presented concept combines the advantages of both systems providing a minimally-
invasive access to viable layers of the skin and exploiting dry polymer films as vaccine
delivery formulations. The combination of the physical stimulus with the potency of
nanoparticle carriers as vaccines is consequently another appealing idea to maximize im-
mune responses upon cutaneous immunization. Good functionality, easy applicability, and
the readily available manufacturing technology makes the microporation-patch combina-
tion an attractive concept which is worth further investigation.
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SUMMARY OF THIS THESIS
1 Summary
The aim of this thesis was to evaluate the i.d. delivery of model vaccines using selected
needle-free, minimally invasive delivery techniques and to assess their potential application
for cutaneous vaccination.
Chapter II is focused on the i.d. delivery of vaccine microparticles using a hand-held pow-
der injector. A highly concentrated sugar-based vaccine using ovalbumin (OVA) as model
antigen was manufactured using a two-step process combining collapse lyophilization and
cryogenic milling. The resulting vaccine with a loading of 200 µg/mg OVA showed good
stability for up to 12 months at ambient conditions. The vaccine powder, which was loaded
into the powder injector using an oily mixture of the components of the adjuvant system 03
(AS03), namely squalene, D/L-α-tocopherol, and polysorbate 80, exhibited good adhesion
on the device membrane. The powder adhesion increased with the viscosity for a range
of different oily liquids tested. The stability of the oily adhesive composed of AS03 adju-
vant components was shown to provide a superior persistence against UV/Vis light and
improved long-term stability when stored in direct contact with the highly concentrated
OVA vaccine powder. Qualitatively, the successful i.d. delivery of vaccine microparti-
cles into the epidermal and upper dermal skin layers by needle-free powder injection was
demonstrated. However, the in vivo immunization study in piglets showed no detectable
immune response within 28 days upon two applications of the highly concentrated OVA
vaccine by powder injection on day 0 and 14.
In chapter III, micro- and nanoparticles were delivered into the skin using different types of
solid microneedles (MN). In this study the maximum penetration depths and quantitative
i.d. deposition depending on the particle size ranging from 0.1 − 7.0 µm and the type of
MN was evaluated, comparing a flat MN array and a MN roller. It was shown that the
MN tip geometry and application mode influence the maximum penetration depth as well
as the quantitative deposition. On the other hand, the particle size affects the quantitative
deposition only. Moreover, manual massage can improve the i.d. delivery significantly. In
summary, MN roller pretreatment and a particle size of 0.5 µm were identified to provide
maximum delivery depth and i.d. particle deposition.
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Another concept for the delivery of macromolecules and nanoparticles using water-soluble
polyvinyl alcohol (PVA)-based polymer films was presented in chapter IV. Pure PVA films
and blends with carboxymethyl cellulose (CMC) or cross-linked carbomer were prepared
using an easily scalable film casting technique. Fluorescein isothiocyanate (FITC) and
rhodamine B-labeled dextrane 70 kDa (RD70), used as small and macromolecular model
substances, or nano- and microparticles with diameters of 0.5 µm and 5 µm were directly
incorporated into the polymer formulations at varying concentrations. Fractional laser
microporation using a pulsed Er:YAG laser (λ = 2.94 µm) was applied to provide access
to the viable skin inducing a 4- to 5-fold increase of water transport (TEWL) through the
porated skin compared to intact skin. Within 6 h, the polymer films dissolved on laser
microporated skin only and facilitated a considerable intradermal delivery of RD70 and
nanoparticles over 24 h. The quantitative RD70 deposition was superior for pure PVA
films compared to PVA-CMC or PVA-carbomer blend formulations.
2 Conclusion and outlook
Cutaneous vaccination is a promising alternative to conventional i.m. immunization and
has been extensively studied during the past decade. The potential for dose sparing due
to the high abundance of professional antigen presenting cells (APCs) in the skin tissue
and the effective initiation of adaptive and innate immune responses have put i.d. vaccine
delivery into the focus of research. Despite the advantages of i.d. vaccination, its practical
realization still poses many challenges, some of which are addressed in this thesis. Although
several studies have shown increased cost-efficiency of fractional dose vaccination by i.d.
injection [1–4], many needle-free i.d. delivery techniques are lacking sufficient delivery
efficiency and reproducibility of delivery. The inefficient use of the vaccine by many needle-
free approaches attenuates the key benefit of i.d. vaccine delivery and thus increases the
overall costs per vaccination. Nevertheless, to date, an impressive variety of different i.d.
delivery approaches have been developed and tested in preclinical and clinical trails aiming
to tackle poor vaccine delivery and to challenge conventional i.m. immunization.
In this thesis, three different active i.d. delivery techniques were presented: Needle-free
powder injection, microneedling using solid MNs, and fractional laser microporation. Con-
sidering the key attributes of these techniques, each approach provides different advantages
and disadvantages. Figure V.1 highlights the characteristics of the delivery techniques pre-
sented in this thesis and allows for a direct comparison. Each technique was subjectively
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rated (0=poor, 4=good) with respect to a set of key attributes previously discussed else-
where [5], and additional aspects related to efficiency and reproducibility of delivery and
vaccine stability.
Needle-free powder injection using a single-use, hand-held injector is a highly attractive
approach for cutaneous vaccination. It facilitates the administration of a vaccine in one
step, is pain-free and minimally invasive, avoids sharps and is expected to yield a high
patient acceptability. The device design potentially allows for self-administration and the
dry formulation provides a superior storage stability over liquid vaccines. However, an-
other study and the results presented in this thesis show that the reproducibility of i.d.
delivery by powder injection depends on the skin condition [6]. The limited reproducibility
of delivery is a major concern for the efficacy of vaccination. Furthermore, needle-free
powder injection requires advanced technological devices, which further increases the costs
per vaccination. In the context of this work, the pyrotechnical accelerator requires elab-
orated engineering to ensure effectiveness and safety, in particular, to receive regulatory
approval. Different approaches can be taken to further improve the performance of powder
immunization in future studies. Regarding the powder injector, further optimization can
include the design of a customized nozzle, which could create a directional particle flow at
high speed towards the skin surface compared to the relatively large area of particle admin-
istration in the presented design. Considering the vaccine formulation, vaccine powders
with increased density, achieved for example by incorporation of crystalline nanoparticles,
can be used to enhance the i.d. particle deposition. Moreover, the potency of the vaccine
can be improved using chemical adjuvants, which are either directly incorporated into the
vaccine formulation or obtained by mixing of vaccine and adjuvant powder. Further results
associated to chapter II indicate that potent vaccines, e.g. influenza antigens, can increase
the immune response upon powder immunization [7].
Compared to the powder injector, solid MNs are an established tool for intra- and trans-
dermal drug delivery for cosmetic or research applications. Various designs of MNs are
commercially available and cost-efficient to produce in large scale. In this thesis, solid
MNs were used for the i.d. delivery of micro- and nanoparticles. Considering this approach
for cutaneous vaccination, the complex particle administration procedure represents a sig-
nificant drawback. Although microneedling is pain-free, widely accepted, and generally
improves the i.d. delivery compared to intact skin, the efficiency and reproducibility of
particle delivery by manual massage requires further improvement. Nevertheless, the high
flexibility of MN skin pretreatment makes it an attractive technique for the screening of
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Figure V.1: Key attributes considering the development and commercial use of the intra-
dermal delivery techniques discussed in this thesis. Approach was inspired by [5]. (0=poor,
4=good)
new types of antigens, adjuvants, and vaccine formulations. Considering this flexibility,
solid MNs are an ideal tool for a thorough screening of potential chemical and particulate
adjuvants to evaluate their potency and safety for cutaneous vaccination. Moreover, differ-
ent types of particles providing immediate or extended release of antigens and adjuvants
should be subject to future studies. A device facilitating reproducible MN insertion and
application of the formulation in one step would further increase the attractivity of this
rather easy i.d. delivery approach.
On the other hand, the combination of skin laser microporation with a model vaccine-
loaded film patch provides a more convenient approach for i.d. vaccine delivery. This work
demonstrates that fractional laser microporation reproducibly breaches the skin barrier.
Although the subsequent application of a vaccine-loaded water-soluble film patch for 24 h
provided insufficient delivery efficiency ex vivo, higher deposition can be expected under
in vivo conditions as discussed in chapter IV. The development of a hand-held device for
skin laser treatment would further enhance the commercial potential of this cutaneous
vaccination approach. Interestingly, tesa Labtec and Pantec Biosolutions are pursuing the
combination of laser poration and vaccine patches [8]. Future studies should focus on the
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in vivo testing using commercially available i.d. vaccines, e.g. influenza, and new types of
vaccines. Additionally, the optimization of the vaccine patch manufacturing, e.g. by 3D-
printing, and the up-scaling of conventional casting techniques should be subject to further
development. In addition to the potential compatibility of vaccine films with protein
antigens, attenuated or inactivated vaccines are further promising loads for cutaneous
vaccination. Similarly, different types of nanoparticles can be loaded into the films serving
as adjuvant or vaccine stabilizer and reservoir.
Despite the key attributes discussed, to date the most critical factor limiting the success
of most i.d. delivery techniques are the associated costs. Recent prices per vaccine dose
in low-income countries have been estimated below US$ 1 [9, 10]. On the other hand,
vaccine costs in a range of US$ 53− 271 (1.0BC ≈ US$ 1.2) per pathogen are expected for a
Western European citizen [11]. This dramatic difference in costs per vaccination underlines
the current ambivalence in the development of cutaneous vaccination approaches. The
administration of fractional doses of existing vaccines by i.d. injection by N&S allows
for a clear cost reduction with only minimal change in administration routine compared
to conventional i.m. injection. On the other hand, alternative needle-free i.d. delivery
techniques, e.g. jet injection, increase the costs per vaccination significantly [4]. In many
cases, this renders needle-free techniques unsuitable for low- to middle-income countries.
However, the high costs associated with new i.d. delivery techniques also makes them rather
unattractive for Western economies. In a recent example, the development a different hand-
held powder injector, acquired by Novartis and Pfizer in 2006, was discontinued supposedly
because of high development costs. Provided the cost of needle-free powder injectors can be
further reduced, e.g. by large-scale production, powder injection is a promising alternative
to conventional vaccination by N&S.
The success of low-dose i.d. vaccination and the fast progress in the design of large scale
manufacturing processes for certain delivery techniques, such as i.d. injectors, dissolving
MNs, and vaccine patches, provide a promising view on the implementation of cutaneous
vaccination in future. The greatest potential is the exploitation of cutaneous vaccination for
new therapeutic areas, e.g. cancer immunotherapy, prevention against infectious diseases,
which are not yet preventable, or neurodegenerative diseases. The use of fractional vaccine
doses by i.d. injection is most likely only the starting point for the growing success and
establishment of cutaneous vaccination in healthcare.
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